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Sponsor Information 
Study Monitors 
Cornelia Bevilacqua 
‘La Fédarié Haute’ 
81440 Vénès 
France 
Tel: + 33 563 75 92 66 
Fax: + 33 563 75 92 66 
Mobile phone: + 33 685 25 24 69 
e-mail: corneliabevilacqua@usa.net 
 
Valérie Marichal,  
Central Study Coordinator, 
GlaxoSmithKline Biologicals, 
89, Rue de l'Institut, 1330 Rixensart, 
Belgium 
Tel: + 32 2 656.9812 
Fax: + 32 2 656.8133 
e-mail: valerie.marichal@gskbio.com 
 
Study Monitor WHO 
Dr.Lawrence Kweku Yamuah 
Post-Doctoral Researcher / Data Manager 
Armauer Hansen Research Institute (AHRI) 
P.O. Box 1005 
Addis Ababa 
Ethiopia 
Tel: + 251 1 71 02 88 (work) 
Tel: + 251 1 71 17 04 (home) 
Fax: + 251 1 71 13 90 
Email: yamuahlawrence_kweku@hotmail.com 
 
Study Contact for Reporting of a Serious Adverse Event at GSK Biologicals 
Dr. Dominique Boutriau,  
Director, Clinical Research & Development, Meningitis vaccines  
GlaxoSmithKline Biologicals,  
Rue de l'Institut 89, 1330 Rixensart, Belgium 
Tel: +32.2.656. 9120  
Fax: +32.2.656. 8044 
e-mail: dominique.boutriau@gskbio.com 
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Study Contact for Reporting of a Serious Adverse Event for WHO 
Dr. Zarifah Reed 
WHO/IVR/POP  
WHO/IVB/IVR/POP  
20 Avenue Appia 
CH-1211 GENEVE 27 
Switzerland 
Tel.  +41 22 791 4760 
Fax. +41 22 791 4860 
Email: reedz@who.int 
 
Back-up Study Contact for Reporting of a Serious Adverse Event at GSK 
Biologicals  
GSK Biologicals Clinical Safety Physician 
Tel: +32-2-656 88 50 
Fax: +32-2-656 80 09/5116 
Mobile phone for 7/7 day availability: +32 477 404 713 or 32-(0) 474 53 48 68 
(Amendment 7: 12 April 2006) 
Study Contact for Emergency Code Break 
Local safety monitor i.e., 
Dr. John Williams (who will forward information to IDMC chairman)  
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: + 233 742 22310/ 22380 
Fax: + 233 742 22320 
e-mail: jwilliams@navrongo.mimcom.net 
Back-up Local Safety Monitor 
Dr. Frank Baiden 
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: + 233 742 22310/ 22380 
Fax: + 233 742 22320 
e-mail: fbaiden@navrongo.mimcom.net  
Study Center 
Navrongo Health Research Center  
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: + 233 742 22310/ 22380 
Fax: + 233 742 22320 
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Investigator Agreement 
eTrack study number 759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009)  
Title A phase II, double blind, randomized, controlled study to evaluate 
the immunogenicity, reactogenicity and safety of GlaxoSmithKline 
(GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously 
mixed with GSK Biologicals’ Tritanrix™-HepB, as compared to 
GSK Biologicals’ Hiberix™ vaccine, extemporaneously mixed 
with GSK Biologicals’ Tritanrix™-HepB, when administered 
intramuscularly in infants at 6, 10 and 14 weeks of age. 
I agree: 
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this protocol, any mutually agreed future 
protocol amendments, and with any other study conduct procedures provided by 
GlaxoSmithKline Biologicals (GSK Biologicals). 
• Not to implement any changes to the protocol without agreement from the sponsors 
and prior review and written approval from the Institutional Review Board (IRB) or 
Independent Ethics Committee (IEC), except where necessary to eliminate an 
immediate hazard to the subjects, or for administrative aspects of the study (where 
permitted by all applicable regulatory requirements). 
• That I am thoroughly familiar with the appropriate use of the vaccine, as described in 
this protocol, and any other information provided by the sponsors, including, but not 
limited to, the following: the current Investigator’s Brochure (IB) or equivalent 
document, IB supplement (if applicable), prescribing information (in the case of a 
marketed vaccine) and/or Master Data Sheet (if the Master Data Sheet exists and 
serves as reference document for the vaccine in the case of a marketed vaccine). 
• That I am aware of, and will comply with, “Good Clinical Practices” (GCP) and all 
applicable regulatory requirements. 
• That I have been informed that certain regulatory authorities require the sponsor 
(GSK Biologicals) to obtain and supply, as necessary, details about the investigator’s 
ownership interest in the sponsor or the investigational product, and more generally 
about his/her financial ties with the sponsor. GSK Biologicals will use and disclose 
the information solely for the purpose of complying with regulatory requirements.  
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Hence I: 
• Agree to supply GSK Biologicals with any necessary information regarding 
ownership interest and financial ties (including those of my spouse and dependent 
children). 
• Agree to promptly update this information if any relevant changes occur during the 
course of the study and for 1 year following completion of the study.  
• Agree that GSK Biologicals may disclose any information it has about such 
ownership interests and financial ties to regulatory authorities. 
• Agree to provide GSK Biologicals with an updated Curriculum Vitae and other FDA 
required documents. 
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Synopsis 
Title A phase II, double blind, randomized, controlled study to evaluate the 
immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) 
Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, as compared to GSK Biologicals’ Hiberix™ 
vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, 
when administered intramuscularly in infants at 6, 10 and 14 weeks of age. 
Indication/Study population Primary vaccination of healthy infants at 6, 10 and 14 
weeks of age.  
Rationale African countries, and more specifically the countries of the meningitis 
belt, face regular epidemics of meningococcal disease, including 
meningitis with an incidence as high as 1000/100,000. Except for an 
outbreak of serogroup W-135 that spread in Burkina Faso in 2002 and 
2003, serogroup A and to a lesser extent serogroup C are largely 
responsible for N. meningitidis epidemics in African countries. Children 
aged 5-14 years are the most affected. The existing meningococcal plain 
polysaccharide vaccines are less immunogenic in small children; also the 
duration of protection induced by these vaccines is short-lived, as 
polysaccharides vaccine do not induce immune memory. Therefore, there 
is a need to develop new generation meningococcal vaccines that protect 
against meningococcal disease in early childhood and induce immune 
memory. 
Recently, meningococcal serogroup C conjugate vaccines have been 
developed and have proven effective in small children and infants. 
In order to protect children from early childhood against N. meningitidis 
of the two most prevalent serogroups in Africa, and to facilitate the 
incorporation of such a vaccine in the immunization calendar, GSK 
Biologicals is developing a combined Hib-MenAC conjugate vaccine to 
be extemporaneously mixed with the Tritanrix™-HepB (DTPw-HBV) 
vaccine for administration as a 3-dose primary vaccination course in 
infants aged 6 weeks and over. 
The new Tritanrix™-HepB/Hib-MenAC vaccine has been evaluated in a 
feasibility trial in the Philippines. The combination using the Hib-MenAC 
formulation with a dosage of 2.5 µg of each of the MenA, MenC and Hib 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
10
conjugate antigens has been selected for further clinical development: the 
selected formulation was well tolerated; it induced similar antibody levels 
against the diphtheria, tetanus, pertussis, hepatitis B, Hib and 
meningococcal serogroup C antigens as the benchmark vaccines 
(Tritanrix™-HepB/Hiberix™ and Meningitec™) and 97.7 % subjects had 
meningococcal serogroup A serum bactericidal antibody titres of at least 
1:8. As feasibility of the new vaccine has now been shown, the present 
study plans to evaluate the use of GSK Biologicals’ Tritanrix™-
HepB/Hib-MenAC vaccine in a high endemicity region in Africa.  
The study will evaluate the immunogenicity induced by three doses of the 
vaccine given at 6, 10 and 14 weeks of age by measuring the immune 
response one month post-vaccination to ensure the vaccine is effective in 
the youngest children when the disease burden is highest. In order to 
assess whether the vaccine has induced long-term protection, the 
persistence of the immune response will be measured when the child is 
one year of age, and a small dose of plain polysaccharide (1/5th of a dose 
of Mencevax™ AC, i.e. 10µg/polysaccharide) will be given to evaluate 
whether immune memory was induced by priming.  
Objectives Co-primary 
One month after primary vaccination: 
• To demonstrate the immunogenicity of Tritanrix™-HepB/Hib-
MenAC with respect to SBA-MenA and SBA-MenC. 
• To demonstrate that Tritanrix™-HepB/Hib-MenAC is non-inferior to 
the control vaccine Tritanrix™-HepB/ Hiberix™ with respect to the 
immunogenicity of all common antigens (anti-PRP, anti-Diphtheria, 
anti-Tetanus, anti-BP, and anti-HBs). 
Criteria to achieve the co-primary objectives: 
• Immunogenicity of SBA-MenA and SBA-MenC: lower limit of the 
95% CI for the percentage of subjects with SBA-MenA titers 
(respectively SBA-MenC titers) ≥ 1:8 is greater than 80%. 
• Non-inferiority for all common antigens: upper limit of the 95% CI for 
the group difference in terms of the percentage of subjects with anti-
PRP concentration ≥ 1 µg/ml (respectively, anti-diphtheria 
concentration ≥ 0.1 IU/ml, anti-tetanus concentration ≥ 0.1 IU/ml, 
anti-HBs concentration ≥ 10 mIU/ml) is below 10% and upper limit of 
the 95% CI for the group GMC ratio in anti-BP is below 1.5. 
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 Secondary 
• At 12 months of age, to evaluate the antibody persistence induced by 
the primary vaccination with Tritanrix™-HepB/Hib-MenAC (new 
vaccine) and Tritanrix™-HepB/ HiberixTM (control vaccine) with 
respect to the immunogenicity of all antigens administered.  
• At 12 months of age, to evaluate the immune memory induced by the 
primary vaccination with Tritanrix™-HepB/Hib-MenAC vaccine by 
administering 10 µg of each meningococcal A and C polysaccharide 
(one fifth of a dose of Mencevax™ AC), using the unprimed subjects 
of the Tritanrix™-HepB/ Hiberix™ group as control.   
• To assess the reactogenicity and safety of the primary vaccination after 
each vaccine dose and overall in the two study groups. 
• At 12 months of age, to assess the reactogenicity and safety of the 
10 µg meningococcal A and C polysaccharides when given to subjects 
primed with either Tritanrix™-HepB/Hib-MenAC or with 
Tritanrix™-HepB/ Hiberix™. 
Study design • Experimental design: 2 parallel groups of 140 subjects each to 
receive either of the following vaccines: 
- Tritanrix™-HepB/Hib-MenAC 
- Tritanrix™-HepB/Hiberix™ 
• Active control group (Tritanrix™-HepB/Hiberix™) 
• Indication: primary vaccination of infants according to the 
Expanded Program of Immunization (EPI) schedule (6, 10, 14 
weeks of age). 
• BCG and OPV vaccines can be given at birth or up to at least 2 
weeks before study start. OPV can then be given concomitantly 
with the study vaccines at 6, 10 and 14 weeks of age or at any time 
during the study, whichever is more appropriate. At 9 months of 
age, all subjects will receive measles and yellow fever vaccines. 
• At 12 months of age, all subjects will be evaluated for antibody 
persistence and will be administered 10 µg of each plain 
meningococcal serogroup A and C polysaccharides (one fifth of a 
dose of Mencevax™ AC) to evaluate the immune memory induced 
by vaccination. 
• After study end, one dose of Mencevax™ ACWY will be offered to 
the Tritanrix™-HepB/Hiberix™ control group to protect them 
against meningococcal diseases of these serogroups: 
Mencevax™ ACWY will be given when the child is two years of 
age, or, if a meningitis epidemic occurs, earlier in the second year 
of life. 
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• Treatment allocation: randomized (1:1) 
• Blinding: Double-blind 
• Study duration per subject: approximately 22.5 months to include 
the retrospective follow-up of SAE(s) up to the time that subjects 
are at least 24 months of age. 
• Data collection: Hard copy Case Report Form (CRF) 
• For all subjects: 4 blood samples (3.5 ml):  
− immediately before the first dose of the primary vaccination 
course 
− one month after the third dose of the primary vaccination course 
− just prior to administration of the plain polysaccharides of 
serogroups A and C 
− one month after the administration of the plain polysaccharides 
of serogroups A and C. 
• 4-day follow-up of solicited local and general symptoms after each 
dose. 
• One month follow-up for unsolicited symptoms after each dose. 
• Reporting of serious adverse events during the entire study period. 
•  Retrospective follow-up of SAE(s). The parents/guardians of 
study subjects will be contacted by the local health staff when 
their child is at least 24 months of age for a follow-up of SAE(s) 
(i.e. any SAE(s) that occurred since the last study visit [Visit 7] up 
to the time that subjects are at least 24 months of age). 
(Amendment 7: 12 April 2006) 
 
Study Population • Healthy infants aged 6-8 weeks. 
• 280 in total (140/group) to allow 220 evaluable subjects 
for the co-primary endpoints. 
Co-primary endpoints 
 
Immunogenicity: post-primary vaccination: 
In all subjects, one month after the 3rd dose of the primary 
vaccination:  
• Serum bactericidal antibody titer (MenC) ≥1:8 
(seropositivity) 
• Serum bactericidal antibody titer (MenA) ≥1:8 
(seropositivity) 
• Anti-PRP concentration ≥ 1 µg/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-tetanus concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-diphtheria concentration ≥ 0.1 IU/ml by ELISA and, 
if negative, ≥ 0.016 IU/ml by Vero-cell (seroprotection) 
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• Concentration of anti-BP antibodies 
Secondary endpoints 
 
 
Immunogenicity 
Pre-primary vaccination 
In all subjects, just prior to the administration of the 1st dose 
of the primary vaccination 
• SBA-MenA titer ≥ 1:8 (seropositivity) 
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml 
• Anti-diphtheria concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-BP concentration ≥ 15 EL.U/ml (seropositivity) 
• Concentration/titers of SBA-MenA, SBA-MenC, anti-
PSA, anti-PSC, anti-HBs, anti-diphtheria and anti-BP 
antibodies 
Post-primary vaccination: 
In all subjects, one month after the 3rd dose of the primary 
vaccination: 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Anti-PRP concentration ≥ 0.15 µg/ml (seroprotection) 
• Anti-BP concentration ≥15 EL.U/ml  
• Titers/Concentrations of all antibodies except anti-BP (see 
co-primary endpoints) 
Antibody persistence:   
In all subjects, at twelve months of age, just prior to the 
administration of 1/5 of a dose of Mencevax AC:  
• SBA-MenA titer ≥ 1:8 (seropositivity)  
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Anti-PRP concentration ≥ 0.15 µg/ml (seroprotection) 
• Anti-PRP concentration ≥ 1 µg/ml (seroprotection) 
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• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-tetanus concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-diphtheria concentration ≥ 0.1 IU/ml by ELISA and, 
if negative, ≥ 0.016 IU/ml by Vero-cell (seroprotection) 
• Anti-BP concentration ≥15 EL.U/ml (seropositivity) 
• Concentration/titers of SBA-MenA, SBA-MenC, anti-
PSA, anti-PSC, anti-PRP, anti-HBs, anti-tetanus, anti-
diphtheria and anti-BP antibodies.  
Immune memory:  
In all subjects, one month after the administration of 1/5 of a 
dose of Mencevax AC: 
• SBA-MenA titer ≥ 1:8 (seropositivity)  
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Concentration/titers of SBA-MenA, SBA-MenC, anti-PSA 
and anti-PSC antibodies.  
Reactogenicity and safety: 
After each vaccine dose: 
• Occurrence of solicited symptoms (during the 4-day 
follow-up period) 
Local: Pain and swelling at the injection site 
General:  Drowsiness, Fever, Irritability/ Fussiness, Loss 
of appetite 
• Occurrence of unsolicited symptoms (during the 30-day 
follow-up period) 
Over the full course of the study: 
• Occurrence of serious adverse events 
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Glossary of Terms 
Adverse Event: Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical 
product and which does not necessarily have a causal 
relationship with the pharmaceutical product (as defined by 
ICH Guideline for Good Clinical Practice). 
Blinding: A procedure in which one or more parties to the trial are 
kept unaware of the treatment assignment in order to 
reduce the risk of biased study outcomes. In a single-blind 
trial, the investigator and/or his staff are aware of the 
treatment assignment but the subject is not. When the 
investigator and sponsor staff who are involved in the 
treatment or clinical evaluation of the subjects and 
review/analysis of data are also unaware of the treatment 
assignments, the study is double blind. This level of 
blinding is maintained throughout the conduct of the trial, 
and only when the data are cleaned to an acceptable level 
of quality will appropriate personnel be unblinded or when 
required in case of a serious adverse event. 
Eligible: Qualified for enrolment into the study based upon strict 
adherence to inclusion/exclusion criteria. 
Evaluable: Meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and, therefore, included 
in the according-to-protocol (ATP) analysis (see Sections 
4.4 and 10.4 for details on criteria for evaluability). 
eTrack GlaxoSmithKline’s clinical trials tracking tool  
Investigational Product: A pharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, 
including a product with a marketing authorization when 
used in a way different from the approved form, or when 
used for an unapproved indication, or when used to gain 
further information about an approved use.  
Protocol Amendment: Any change in a clinical protocol which affects the safety 
of subjects, the scope, design, assessments or scientific 
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validity of the clinical investigation, e.g., dose change, 
duration of treatment, number of subjects, control group(s), 
the assessments.  
Protocol Modification: Strictly, any change to a clinical protocol that is not 
considered to be a protocol amendment. In essence, 
changes to clarify (but not alter) existing design features of 
a clinical investigation or to encourage greater compliance 
with the intent of the clinical protocol may be issued as 
modifications rather than amendments. A protocol 
modification addresses logistical or administrative aspects 
of the study (e.g., change of monitor(s), telephone 
number(s).  
Site Monitor: An individual assigned by GSK Biologicals who is 
responsible for assuring proper conduct of a clinical study 
at one or more investigational sites. 
Local Safety Monitor: The overall role of the Local Safety Monitor, an 
experienced physician based in-country, will be to support 
the study investigators and to act as a link between the 
investigators and the Independent Data Monitoring 
Committee (IDMC) (see Section 5.1.3 for further details).  
Solicited Adverse Event: Adverse events (AEs) to be recorded as endpoints in the 
clinical study. The presence/occurrence/intensity of these 
events is actively solicited from the subject or an observer 
during a specified post-vaccination follow-up period. 
Study Monitor: An individual assigned by and centrally located at GSK 
Biologicals who is responsible for assuring proper conduct 
of a clinical study, i.e., Central Study Coordinator. 
Subject(s): Term used throughout the protocol to denote the enrolled 
individual(s). 
Unsolicited Adverse 
Event: 
Any adverse event (AE) reported in addition to those 
solicited during the clinical study. Also any “solicited” 
symptom with onset outside the specified period of follow-
up for solicited symptoms will be reported as an 
unsolicited adverse event. 
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1 Introduction 
Meningococcal disease, including meningitis and meningococcaemia (meningococcal 
septicaemia), usually follows invasive infection by Neisseria meningitidis 
(meningococcus) and is a major cause of death and morbidity throughout the world. 
Despite the availability of appropriate treatment, the mortality rate is still 7-19% 
1
. The 
risk of meningococcal disease is inversely related to age with 49% of cases occurring in 
children of four years and younger in Europe 
2
. However, older children, adolescents and 
adults are more often affected during epidemics 
3, 4. 
The disease is endemic in developed countries, such as the US and Europe, and 
developing countries 5. Epidemics occur regularly worldwide with highest attack rates in 
sub-Saharan countries. Serogroups A, B, C, W-135 and Y are the most common causes of 
invasive meningococcal disease worldwide; serogroups B and C account for most of the 
cases in Europe and Latin America, while B, C and Y are the 3 prevalent serogroups in 
the USA. In Asia, serogroups A and C are most common 2, 5, 6. 
 
African countries, and more specifically the countries of the meningitis belt, face regular 
epidemics of meningococcal disease, including meningitis with incidence as high as 
1000/100,000 and a case-fatality rate of 10 % but much higher death rates are reported in 
remote areas where the population have a poor access to health care services. Except for 
outbreaks of serogroup W-135 that spread in Burkina Faso in 2002 and 2003, serogroup 
A and to a less extent serogroup C are the major serogroups responsible for 
N. meningitidis epidemics in African countries. Outbreaks hit all age-groups, children 
aged 5-14 years being the most affected 7.  
The disease presentation may be fulminant with no time for antibiotics to be effective, 
and permanent neurological damage can occur in children after infection, despite 
antibiotic therapy. Meningococcal strains with relative or absolute resistance to penicillin 
have been reported in many countries. In Africa, oily chloramphenicol is the drug of 
choice and although no cases of resistance have been reported in Africa, some few cases 
have been reported in Vietnam. 
1.1 Background 
Currently available meningococcal vaccines consisting of pure capsular polysaccharides 
(serogroup A, C, W-135 and Y meningococcal vaccines) are safe and efficacious in adults 
and children over two years of age. However they do not induce a satisfactory response in 
infants and young children under two years of age, the age group most at risk of 
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meningococcal infections. Indeed in this age group, maturation of B-cells is incomplete 
which leads to a defective B-cell activation. In addition, polysaccharide vaccines do not 
reduce mucosal carriage and cannot consequently confer herd immunity; they do not 
induce immunological memory and the associated affinity/avidity maturation of 
antibodies. 
Polysaccharide antigens can however be made to induce a T-cell response and 
immunological memory, by their covalent coupling with proteins which, in association 
with Major Histocompatibility Complex (MHC) class II molecules, will be presented to 
T-helper cells on the surface of Antigen Presenting Cells. This principle was the key to 
the successful development of Haemophilus influenzae type b (Hib)-conjugate vaccines 
immunogenic in young children and able to induce immunological memory.
8, 9, 10, 11 
To date, vaccine manufacturers have been developing meningococcal conjugate vaccines 
using the same carrier proteins as the one they use for their Hib conjugate vaccine. Based 
on this principle, meningococcal serogroup C conjugate vaccines using a non-toxic 
mutant of diphtheria toxin (CRM197) or tetanus toxoid (TT) as carrier proteins have been 
recently licensed in Europe, Canada, Australia and Latin America. The first data available 
after the introduction of the meningococcal serogroup C conjugate vaccines in a mass 
vaccination campaign in the United Kingdom have proven the effectiveness of these 
vaccines in all age-groups including infants
 12, 13, 14. 
N. meningitidis of serogroup A being important in Africa, meningococcal serogroup A + 
C conjugate vaccines using carrier proteins derived from the diphtheria toxoid have been 
developed and evaluated in clinical trials in African countries such as Niger and The 
Gambia. They were found to be safe in these populations. 
15, 16. 
The immunogenicity of meningococcal conjugate vaccines in infants is best shown by 
measuring bactericidal antibodies one month after primary vaccination. Demonstrating 
that meningococcal serogroup A and C conjugate vaccines prime for immune memory is 
an important mechanism to support the long-term protection effect of these vaccines. 
Such priming for memory was shown for the meningococcal serogroup C conjugate 
vaccine 17and for a preliminary meningococcal serogroup A+C conjugate candidate 
vaccine evaluated in the United Kingdom 18. However, in another trial in the Gambia, 
strong memory to the C component was induced but evidence of memory induction for 
the A component was less convincing 15. Priming for memory was demonstrated by 
administering a small dose (10 µg) of unconjugated polysaccharide C six to twelve 
months after priming. The dose of 10 µg polysaccharide was selected after three adverse 
events (allergic reactions) had been reported in 10 subjects initially vaccinated with the 
full polysaccharide vaccine (50 µg/polysaccharide). No further allergic reactions were 
reported with the reduced dose of 10 µg 18.  
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1.2 GSK Biologicals’ combined H. influenzae type b - N. meningitidis 
polysaccharide A, C (Hib-MenAC) conjugated vaccine 
GSK Biologicals is developing a combined Hib-MenAC conjugate vaccine, where each 
polysaccharide (PRP, PSA, PSC) is covalently linked to the tetanus toxoid (-TT) carrier 
protein.  
In a previous set of studies, GSK Biologicals had evaluated a Hib-MenAC conjugate 
vaccine (the meningococcal serogroup A and C polysaccharides were conjugated to 
another carrier protein than tetanus toxoid) and this combination, given as such or 
extemporaneously mixed with the Tritanrix™-Hep B vaccine was found to be safe (total 
N: 259 infants). 
Recently, GSK Biologicals has developed a MenC and a Hib-MenC conjugate vaccine 
using also –TT as carrier protein. Both vaccines were shown to be safe and immunogenic 
in infants.  
In the first three-dose primary vaccination study performed in the Philippines, three 
formulations of the combined Hib-Men AC vaccine (using TT as carrier protein) each 
extemporaneously mixed with Tritanrix™-HepB were evaluated and the 
Tritanrix™-HepB/Hib-MenAC combination using the Hib-MenAC formulation with a 
dosage of 2.5 µg of each of the MenA, MenC and Hib conjugate antigens was selected for 
further clinical development: the selected formulation was well tolerated; it induced 
similar antibody levels against the diphtheria, tetanus, pertussis, hepatitis B, Hib and 
meningococcal serogroup C antigens as the benchmark vaccines 
(Tritanrix™-HepB/Hiberix™ and Meningitec™) and 97.7 % subjects had meningococcal 
serogroup A serum bactericidal antibody titres of at least 1:8.  
Pre-clinical and clinical data generated with GSK Biologicals’ Tritanrix™-HepB/Hib-
MenAC vaccine are available in the combined Diphtheria-Tetanus-whole cell Pertussis-
Hepatitis B, Haemophilus Influenzae type B and Neisseria meningitidis serogroup A and 
C-Tetanus toxoid conjugate vaccine Investigator Brochure (DTPw-HBV-Hib-MenAC, 1st 
Edition, January 2004).  
1.3 Rationale for the study 
African countries, and more specifically the countries of the meningitis belt, face regular 
epidemics of meningococcal disease, including meningitis with an incidence as high as 
1000/100,000. Except for an outbreak of serogroup W-135 that spread in Burkina Faso in 
2002 and 2003, serogroup A and to a lesser extent serogroup C are largely responsible for 
N. meningitidis epidemics in African countries. Children aged 5-14 years are the most 
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affected. The existing meningococcal plain polysaccharide vaccines are less 
immunogenic in small children; also the duration of protection induced by these vaccines 
is short-lived as polysaccharides vaccine do not induce immune memory. Therefore, there 
is a need to develop new generation meningococcal vaccines that protect against 
meningococcal disease in early childhood and induce immune memory.    
Recently, meningococcal serogroup C conjugate vaccines have been developed and have 
proven effective in small children and infants. 
In order to protect children from early childhood against N. meningitidis of the two most 
prevalent serogroups in Africa, and to facilitate the incorporation of such a vaccine in the 
immunization calendar, GSK Biologicals is developing a combined Hib-MenAC 
conjugate vaccine to be extemporaneously mixed with the Tritanrix™-HepB vaccine for 
administration as a 3-dose primary vaccination course in infants aged 6 weeks and over.  
The new Tritanrix™-HepB/Hib-MenAC vaccine has been evaluated in a feasibility trial in 
the Philippines. The combination using the Hib-MenAC formulation with a dosage of 2.5 
µg of each of the MenA, MenC and Hib conjugate antigens has been selected for further 
clinical development: the selected formulation was well tolerated; it induced similar 
antibody levels against the diphtheria, tetanus, pertussis, hepatitis B, Hib and 
meningococcal serogroup C antigens as the benchmark vaccines 
(Tritanrix™-HepB/Hiberix™ and Meningitec™) and 97.7 % subjects had meningococcal 
serogroup A serum bactericidal antibody titres of at least 1:8. As feasibility of the new 
vaccine is has now been shown, the present study plans to evaluate the use of GSK 
Biologicals’ Tritanrix™-HepB/Hib-MenAC vaccine in a high endemicity region in Africa.  
The study will evaluate the immunogenicity induced by three doses of the vaccine given 
at 6, 10 and 14 weeks of age by measuring the immune response one month post-
vaccination to ensure the vaccine is effective in the youngest children when the disease 
burden is highest. In order to assess whether the vaccine has induced long-term 
protection, the persistence of the immune response will be measured when the child is 
one year of age, and a small dose of plain polysaccharide (1/5th of a dose of Mencevax™ 
AC, i.e. 10µg/polysaccharide) will be given to evaluate whether immune memory was 
induced by priming.  
1.4 Study site  
The Kassena-Nankana district (KND) is within the guinea savannah area of northern 
Ghana bordering Burkina Faso. The entire district lies within the meningitis belt of sub-
Saharan Africa. The climate is that of the sub-Sahel with a short rainy season from May 
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to October (average annual rainfall 850-950 mm) and a long dry season from November 
to April. The district covers an area of 1,675 km2 with a population of about 140,000. The 
entire population of the district is included in a demographic surveillance system, the 
Navrongo Demographic Surveillance System (NDSS), in which births, deaths, in and out 
migrations and other demographic parameters are recorded in a database and updated 
every ninety days.
19  
 
There are four health centers in the district, one each in the northern, southern, eastern 
and western parts of the district. The district hospital, the War Memorial Hospital 
(WMH), is situated in the central part of the district. It is a 120-bed hospital. 
Immunization services are conducted in all the health facilities as well as outreach clinics. 
The Expanded Programme of Immunization (EPI) calendar is as follows: BCG and OPV 
are given at birth. Tritanrix-HepB/Hib (DTPw-HepB/Hib) and OPV vaccines are given 
as 3 doses at 6, 10 and 14 weeks of age. Measles and yellow fever vaccines are given at 9 
months.  
 
The Navrongo Health Research Center (NHRC) has the mandate to research into health 
problems facing the people of the Sahelian ecological belt with a view to informing 
policy decisions. Over the years, it has conducted research on Vitamin A 
supplementation, use of impregnated bednets, Community Health and Family planning 
services, malaria, diarrhoea and meningitis. The findings from many of these studies have 
been made into policies in the country.  
 
Ongoing work on meningitis in collaboration with the Swiss Tropical Institute, Basel, 
Switzerland has involved studies on carriage 
20, 
21
, risk factors
22
, survival and sequelae
23 
and aetiological agents of meningitis in the district 
24
. 
 
Coordination with the EPI 
 
The vaccine trial will be conducted at several EPI clinics in the Kassena-Nankana district 
where routine immunization is taking place.  
All vaccinees in the EPI system have the so-called “Growth Monitoring Cards” on which 
the vaccines they receive are recorded. The subjects will be recruited at the time they are 
to receive the routine DTP, Hib and HepB vaccines (at 6 weeks of age). The vaccines 
given will be recorded on a specific immunization card (yellow card) and also on the 
Growth Monitoring Cards, i.e. the name of the study vaccine will be recorded in the box 
where DTP, Hib and HepB vaccines are usually recorded. Therefore, a duplication of 
vaccination is prevented as the Growth Monitoring Cards are always brought to the EPI 
clinics by the parents/guardians.  
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Health indicators 
1. Infant Mortality Rate 95.5 per 1000 live births
25
  
  
2. Crude death rate  16.2 deaths per 1000 person years 
25
 
3. The three top causes of death in the WMH in 2000 were: 
i. Malaria 
ii. Anaemia 
iii. Pneumonia 
Malaria is the leading cause of both morbidity and mortality, accounting for 60% of 
hospital admissions and 41% of hospital deaths. 
Data from verbal autopsies coded between 1993 and 1999, document malaria as 
responsible for 35% of all deaths in children aged less than 5 years.  
 
4. The 1996/97 meningococcal disease epidemic in the district, resulted in 1,396 cases 
with 65 deaths 
26
.  
5. The EPI coverage for Diphtheria-Tetanus-Pertussis 3rd dose in the district is 70%.  
6. The HIV prevalence amongst antenatal attendants is 2.4% only.  
2 Objectives 
2.1 Co-primary objectives 
One month after primary vaccination: 
• To demonstrate the immunogenicity of Tritanrix™-HepB/Hib-MenAC with respect to 
SBA-MenA and SBA-MenC. 
• To demonstrate that Tritanrix™-HepB/Hib-MenAC is non-inferior to the control 
vaccine Tritanrix™-HepB/ Hiberix™ with respect to the immunogenicity of all 
common antigens (anti-PRP, anti-Diphtheria, anti-Tetanus, anti-BP, and anti-HBs). 
Criteria to achieve the co-primary objectives: 
• Immunogenicity of SBA-MenA and SBA-MenC: lower limit of the 95% CI for the 
percentage of subjects with SBA-MenA titers (respectively SBA-MenC titers) ≥ 1:8 is 
greater than 80%. 
• Non-inferiority for all common antigens: upper limit of the 95% CI for the group 
difference in terms of the percentage of subjects with anti-PRP concentration ≥ 1 
µg/ml (respectively, anti-diphtheria concentration ≥ 0.1 IU/ml, anti-tetanus 
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concentration ≥ 0.1 IU/ml, anti-HBs concentration ≥ 10 mIU/ml) is below 10% and 
upper limit of the 95% CI for the group GMC ratio in anti-BP is below 1.5. 
Refer to Section 10.1 for definition of the co-primary endpoints. 
2.2 Secondary objectives 
• At 12 months of age, to evaluate the antibody persistence induced by the primary 
vaccination with Tritanrix™-HepB/Hib-MenAC (new vaccine) and Tritanrix™-HepB/ 
Hiberix™ (control vaccine) with respect to the immunogenicity of all antigens 
administered.  
• At 12 months of age, to evaluate the immune memory induced by the primary 
vaccination with Tritanrix™-HepB/Hib-MenAC vaccine by administering 10 µg of 
each meningococcal A and C polysaccharide (one fifth of a dose of Mencevax™ AC), 
using the unprimed subjects of the Tritanrix™-HepB/ Hiberix™ group as control.   
• To assess the reactogenicity and safety of the primary vaccination after each vaccine 
dose and overall in the two study groups. 
• At 12 months of age, to assess the reactogenicity and safety of the 10 µg 
meningococcal A and C polysaccharides when given to subjects primed with either 
Tritanrix™-HepB/Hib-MenAC or with Tritanrix™-HepB/ Hiberix™. 
Refer to Section 10.2 for definitions of secondary endpoints.  
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3 Study Design Overview 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Amendment 7: 12 April 2006) 
Note: BCG and OPV vaccines can be given at birth (or up to at least 2 weeks before the 
subject’s first visit) according to the nationally recommended immunization schedule. 
OPV can also be given at 6, 10, 14 weeks of age concomitantly with the study vaccines or 
at any time during the study, whichever is more appropriate.  
• Experimental design: 2 parallel groups of 140 subjects each to receive either of the 
following vaccines: 
- Tritanrix™-HepB/Hib-MenAC 
- Tritanrix™-HepB/Hiberix™ 
Measles/Yellow 
Fever Vaccine 
- Tritanrix™-HepB/Hiberix™ @ 6, 10, 14 weeks of age 
- Measles & Yellow fever vaccines @ 9 months of age 
- 1/5th of dose of Mencevax™ AC @ 12 months of age 
N = 140 
Primary Vaccination Immune memory & Antibody 
Persistence 
Visit 5 
Month 7.5 
Measles/ Yellow 
Fever Vaccines 
Age ± 9 months 
- Tritanrix™-HepB/Hib-MenAC @ 6, 10, 14 weeks of age 
- Measles & Yellow fever vaccine @ 9 months of age 
- 1/5th of dose of Mencevax™ AC @ 12 months of age 
N = 140 
Visit 1 
Day 0/ Month 0 
Blood sampling 
Vaccination 
Age ≥6-8 weeks 
Visit 2 
Month 1 
Vaccination 
Age ± 10 weeks 
Visit 3 
Month 2 
Vaccination 
Age ± 14 weeks 
Visit 4 
Month 3 
Blood sampling 
Age ± 18 weeks 
Visit 6 
Month 10.5 
1/5th dose of 
Mencevax™ AC 
Blood sampling 
Age ± 12 months 
Visit 7 
Month 11.5 
Blood sampling 
Age ± 13 months 
Randomization (1:1) 
Extended 
Safety 
Follow-up 
phase: 
Retrospective 
SAEs 
reported  
since Visit 7 
up to at least 
24 months of 
age 
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• Indication: primary vaccination of infants according to the Expanded Program on 
Immunization (EPI) schedule (6, 10, 14 weeks of age). 
• To comply with the Ghanean Immunisation Calendar, at 9 months of age, all subjects 
will receive measles and yellow fever vaccines.  
• At 12 months of age, all subjects will be evaluated for antibody persistence and will 
be administered 10 µg of each plain meningococcal serogroup A and C 
polysaccharides (one fifth of a dose of Mencevax™ AC) to evaluate the immune 
memory induced by vaccination.  
• Active control group (Tritanrix™-HepB/Hiberix™) 
• As the control group will not be properly immunised with 1/5th of a dose of 
Mencevax™ AC, after study end, one dose of Mencevax™ ACWY will be offered to 
the Tritanrix™-HepB/Hiberix™ control group to protect them against meningococcal 
diseases of these serogroups: Mencevax™ ACWY will be given when the child is 
two years of age, or, if a meningitis epidemic occurs, earlier in the second year of life.  
• Treatment allocation: randomized (1:1). Refer to Section 6.3 for a detailed description 
of the randomization method. 
• Blinding: Double-blind. Refer to Section 6.4 for details of blinding procedure. 
• Study duration per subject: approximately 22.5 months to include the retrospective 
follow-up of SAE(s) up to the time that subjects are at least 24 months of age. 
• Data collection: Hard copy Case Report Form (CRF) 
• For all subjects: 4 blood samples (3.5 ml each):  
− immediately before the first dose of the primary vaccination course 
− one month after the third dose of the primary vaccination course 
− just prior to administration of the plain polysaccharides of serogroups A and C 
− one month after the administration of the plain polysaccharides of serogroups A and 
C.: 
• 4-day follow-up of solicited local and general symptoms after each dose. 
• One month follow-up for unsolicited symptoms after each dose. 
• Reporting of serious adverse events during the entire study period.  
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• Retrospective follow-up of SAE(s). The parents/guardians of study subjects will be 
contacted by the local health staff when their child is at least 24 months of age for 
a follow-up of SAE(s) (i.e. any SAE(s) that occurred since the last study visit [Visit 
7] up to the time that subjects are at least 24 months of age). 
(Amendment 7: 12 April 2006) 
4 Study Cohort 
4.1 Number of subjects  
Target enrolment will be 280 healthy male and female infants (140 subjects per group) to 
provide 220 evaluable subjects (110 per group) for the immunogenicity analysis. The 
study will be conducted at the Navrongo Health Research Center in Ghana (War 
Memorial Hospital and several health centres of Navrongo health district).  
Enrolment will be terminated when 280 subjects have been enrolled.  
Refer to Section 10.3 for a detailed description of the criteria used in the estimation of 
sample size.  
Details of recruitment at each health center (immunization point), including any criteria 
for termination of enrolment, will be discussed in the recruitment plan, which is 
summarized in Appendix C of this document. 
If at the time of the initiation of the booster phase any parent/guardian declines 
participation of his/her child, refusal will be documented as instructed in the “subject 
tracking document” provided by GSK Biologicals. A copy of the completed tracking 
document will be forwarded to GSK Biologicals’ Study Monitor. The information will be 
entered in the GSK Biologicals’ clinical database for use in identification of any safety 
issue that may have prevented a subject’s participation.  
4.2 Inclusion criteria 
All subjects must satisfy the following criteria at study entry: 
• Subjects for whom the investigator believes that their parents/guardians can and will 
comply with the requirements of the protocol (e.g., completion of the diary cards, 
return for follow-up visits) should be enrolled in the study. 
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• A male or female between, and including, 6 and 8 weeks of age at the time of the first 
vaccination.  
• Written informed consent obtained from the parent or guardian of the subject.  
• Free of obvious health problems as established by medical history and clinical 
examination before entering into the study. 
4.3 Exclusion criteria for enrolment 
The following criteria should be checked at the time of study entry. If any apply, the 
subject must not be included in the study: 
• Use of any investigational or non-registered drug or vaccine other than the study 
vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use 
during the study period. 
• Chronic administration (defined as more than 14 days) of immunosuppressants or 
other immune-modifying drugs since birth. (For corticosteroids, this will mean 
prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed.) 
• Planned administration/ administration of a vaccine not foreseen by the study protocol 
within 30 days before each dose of vaccine, with the exception of OPV. 
• Hepatitis B and BCG vaccine given within two weeks prior to vaccination. 
• Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae 
type b or meningococcal serogroup A or C diseases.  
• History of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b or 
meningococcal serogroup A or C diseases. 
• Known exposure to (direct contact) diphtheria, tetanus, pertussis, hepatitis B, 
Haemophilus influenzae type b and/or meningococcal disease since birth. 
• A diagnosis or clinical suspicion of an immune suppressive or immunodeficient 
condition of any cause based on full clinical history and medical examination. 
• A family history of congenital or hereditary immunodeficiency. 
• History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine. 
• Major congenital defects or serious chronic illness.  
• Babies for which birth weight is <2 kg (if known), and/or malnutrition at visit 1.  
• History of any neurologic disorders or seizures. 
• Acute disease at the time of enrolment. (Acute disease is defined as the presence of a 
moderate or severe illness with or without fever. All vaccines can be administered to 
persons with a minor illness such as diarrhea, mild upper respiratory infection with or 
without low-grade febrile illness, i.e., axillary temperature <37.5°C or rectal 
temperature <38.0°C).  
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Note: Subjects with fever at the time of first vaccination (i.e., axillary temperature ≥ 
37.5°C or rectal temperature ≥ 38.0°C) need not necessarily be excluded but can be 
vaccinated at a later date after the subject recovers and if the subject still meets all 
eligibility criteria. 
• Administration of immunoglobulins and/or any blood products since birth or planned 
administration during the study period.  
• Other conditions which in the opinion of the investigator may potentially interfere 
with interpretation of study outcomes. 
4.4 Elimination criteria during the study 
The following criteria should be checked at each visit subsequent to the first visit. If any 
become applicable during the study, it will not require withdrawal of the subject from the 
study but does determine a subject’s evaluability in the according-to-protocol (ATP) 
analysis. See Section 10.4 for definition of study cohorts to be evaluated. 
• Use of any investigational or non-registered drug or vaccine other than the study 
vaccine(s) during the study period. 
• Chronic administration (defined as more than 14 days) of immunosuppressants or 
other immune-modifying drugs during the study period. (For corticosteroids, this will 
mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are 
allowed). 
• Administration of a vaccine not foreseen by the study protocol during the period 
starting from 30 days before the first dose of vaccine(s) and ending 30 days after the 
last dose of vaccine(s) with the exception of OPV. 
• Administration of a meningococcal vaccine not foreseen by the study protocol during 
the entire study period. 
• Administration of immunoglobulins and/or any blood products during the study 
period.  
4.5 Contraindications to subsequent vaccination 
The following adverse events (AEs) constitute absolute contraindications to further 
administration of the study vaccines; if any of these AEs occur during the study, the 
subject must not receive additional doses of vaccine but may continue other study 
procedures at the discretion of the investigator (see Section 9). The subject must be 
followed until resolution of the event, as with any AE (see Section 8.7): 
• Anaphylactic reaction following the administration of vaccine(s). 
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• Known hypersensitivity to any component of the vaccine, or subjects having shown 
signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, 
HB, Hib or meningococcal vaccines. 
• Any confirmed or suspected immunosuppressive or immunodeficient condition, 
including human immunodeficiency virus (HIV) infection. 
The following AEs constitute contraindications to administration of the study vaccines at 
that point in time; if any one of these AEs occurs at the time scheduled for vaccination, 
the subject may be vaccinated at a later date, within the time window specified in the 
protocol (see Section 5.3) or withdrawn at the discretion of the investigator (see Section 
9). The subject must be followed until resolution of the event, as with any adverse event 
(see Section 8.7): 
• Acute disease at the time of vaccination. (Acute disease is defined as the presence of a 
moderate or severe illness with or without fever. All vaccines can be administered to 
persons with a minor illness such as diarrhoea, mild upper respiratory infection with 
or without low-grade febrile illness, i.e., axillary or oral temperature  
< 37.5°C/rectal temperature < 38°C). 
• Axillary or oral temperature ≥ 37.5°C/rectal temperature ≥ 38°C at the time of 
vaccination. 
DTPw-HBV (Tritanrix™-HepB) 
The following AEs associated with DTP vaccination constitute absolute contraindications 
to further administration of DTP. If any of these AEs occur during the study, the subject 
must be withdrawn and must be followed until resolution of the event, as with any 
adverse event (see Section 8.7). 
• Encephalopathy (not due to another identifiable cause). This is defined as an acute, 
severe central nervous system disorder occurring within 7 days following vaccination, 
and generally consisting of major alterations in consciousness, unresponsiveness, 
generalized or focal seizures that persist more than a few hours, with failure to 
recover within 24 hours. Even though causation by DTP vaccine cannot be 
established, no subsequent doses of pertussis vaccine should be given.  In these 
circumstances the vaccination course should be continued with DT and HB vaccines. 
Special warnings and special precautions for use 
If any of the following events occur in temporal relation to receipt of Tritanrix™- HepB, 
the decision to give subsequent doses of vaccine containing the pertussis component 
should be carefully considered. 
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• Axillary or oral temperature of ≥ 40.0°C/rectal temperature ≥ 40.5°C within 48 hours 
of vaccination, not due to another identifiable cause. 
• Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of 
vaccination. 
• Persistent crying lasting ≥ 3 hours, occurring within 48 hours of vaccination. 
• Convulsions with or without fever, occurring within 3 days of vaccination. 
There may be circumstances, such as a high incidence of pertussis, when the potential 
benefits outweigh possible risks.  
A history of febrile convulsions, a family history of convulsions, a family history of 
Sudden Infant Death Syndrome (SIDS) and a family history of an adverse event following 
Tritanrix™-HepB vaccination do not constitute contraindications. 
As with all injectable vaccines, appropriate medical treatment should always be readily 
available in case of anaphylactic reactions following the administration of the vaccine.  
For this reason, the vaccinee should remain under medical supervision for 30 minutes 
after vaccination. 
Tritanrix™-HepB should be administered with caution to subjects with thrombocytopenia 
or a bleeding disorder since bleeding may occur following an intramuscular 
administration to these subjects. 
Tritanrix™-HepB should under no circumstances be administered intravenously. 
Hiberix™ 
The Hiberix™ vaccine should not be administered to subjects with known 
hypersensitivity to any component of the vaccine, or to subjects having shown signs of 
hypersensitivity after previous administration of Hib vaccines.  
5 Conduct of Study 
5.1 Ethics and regulatory considerations 
The study will be conducted according to Good Clinical Practice (GCP), the 1996 version 
of the Declaration of Helsinki (Protocol Appendix  A), and local rules and regulations of 
the country. The study protocol will be submitted for ethical review to the Navrongo 
Health Center Ethics Committee, WHO Ethical Review Board, the Ethics Committee of 
the London School of Hygiene and Tropical Medicine. 
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5.1.1 Institutional Review Board/Independent Ethics Committee (IRB/IEC) 
The IRB/IEC must be constituted according to the local laws/customs of each 
participating country. The ICH Harmonized Tripartite Guideline for Good Clinical 
Practice recommends that the IRB/IEC should include: 
(a) At least five members. 
(b) At least one member whose primary area of interest is in a non-scientific area. 
(c) At least one member who is independent of the institution/ study site. 
Only those IRB/IEC members who are independent of the investigator and the sponsor of 
the study should vote/ provide opinion on a study-related matter. 
A list of IRB/IEC members and their qualifications should be obtained by the 
investigator.  
This protocol and any other documents that the IRB/IEC may need to fulfil its 
responsibilities, including subject recruitment procedures and information about 
payments and compensation available to subjects, will be submitted to the IRB/IEC by 
the investigator. Written unconditional approval of the IRB/IEC must be in the possession 
of the investigator and GSK Biologicals before commencement of the study. Relevant 
GSK Biologicals’ data will be supplied by the investigator to the hospital/ university/ 
independent IRB/IEC for review and approval of the protocol. Verification of IRB/IEC 
unconditional approval of the protocol and the written informed consent statement will be 
transmitted by the investigator to the Site Monitor using the standard notification form, 
prior to shipment of vaccine supplies and CRFs to the site. This approval must refer to the 
study by exact protocol title and number, and should identify the documents reviewed and 
state the date of review. 
No deviations from, or changes to, the protocol should be initiated without prior written 
IRB/IEC approval/ favourable opinion of an appropriate amendment, except when 
necessary to eliminate immediate hazards to the subjects or when the change(s) involves 
only logistical or administrative aspects of the study (e.g., change of monitor[s], 
telephone number[s].) Modifications are submitted to the IRB/IEC for information only. 
However, written verification that the modification was submitted should be obtained. 
Approvals/ verifications must be transmitted in writing to the Site Monitor, by the 
investigator. 
The IRB/IEC must be informed by the investigator of: 
• all subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review, 
• serious and/or unexpected adverse events occurring during the study, where required, 
• all subsequent protocol modifications (for information), 
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• new information that may affect adversely the safety of the subjects or the conduct of 
the study, 
• an annual update and/or request for re-approval, where required, 
• when the study has been completed, where required. 
5.1.2 Informed consent 
In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to GCP and to the ethical 
principles that have their origin in the 1996 version of the Declaration of Helsinki. Prior 
to the beginning of the trial, the investigator should have the IRB/IEC’s written 
approval/favourable opinion of the written informed consent form and any other written 
information to be provided to the subjects’ parents/guardians. 
Information should be given in both oral and written form whenever possible and as 
deemed appropriate by the IRB/IEC. 
An investigator or designate will describe the protocol to potential subjects’ 
parents/guardians face to face. The Subject Information and Consent Form may be read to 
the subjects’ parents/guardians, but, in any event, the investigator or designate shall give 
the subjects’ parents/guardians ample opportunity to inquire about details of the study and 
ask any questions before dating and signing the Consent Form.  
Subject information and consent forms must be in a language fully comprehensible to the 
prospective subjects’ parents/guardians. Informed consent shall be documented by the use 
of a written consent form approved by the IRB/IEC and signed/thumbprinted and dated 
by the parent/guardian, and by the person who conducted the informed consent 
discussion. The signature/thumbprint confirms the consent is based on information that 
has been understood. All illiterate individuals will have the study, the Subject Information 
and Consent Form explained to them point by point by the interviewer in the presence of 
an impartial witness. The witness will personally sign and date the consent form. Oral 
witnessed consent will replace written consent only in countries where the local custom is 
contrary or if the parents’/guardians’ illiteracy precludes this and provided that the local 
legal obligations are fulfilled.  
Each subject's signed/ thumb printed informed consent form must be kept on file by the 
investigator for possible inspection by Regulatory Authorities and/or GSK Biologicals’ 
professional and Regulatory Compliance persons. The parents/guardians should receive a 
copy of the signed/ thumb printed and dated written informed consent form and any other 
written information provided to the subjects’ parents/guardians, and should receive copies 
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of any signed and dated consent form updates. Any amendments to the written 
information will be provided to subjects’ parents/guardians.  
Both the informed consent discussion and the written informed consent form and any 
other written information to be provided to the subjects’ parents/guardians should include 
explanations of the following: 
(a) That the trial involves research. 
(b) The purpose of the trial. 
(c) The trial treatment(s) and the probability for random assignment to each treatment. 
(d) The trial procedures to be followed, including all invasive procedures. 
(e) The subject’s parents’/guardians’ responsibilities. 
(f) Those aspects of the trial that are experimental. 
(g) The reasonably foreseeable risks or inconveniences to the subjects and, when 
applicable, to an embryo, fetus or nursing infant. 
(h) The reasonable expected benefits. When there is no intended clinical benefit to 
subjects, the subjects and/or subjects’ parents/guardians should be made aware of this. 
(i) The alternative procedure(s) or course(s) of treatment/ methods of prevention that 
may be available to subjects, and their important potential benefits and risks. 
(j) The compensation and/or treatment available to subjects in the event of trial-related 
injury. 
(k) The anticipated prorated payment, if any, to subjects’ parents/guardians for 
participating in the trial. 
(l) The anticipated expenses, if any, to subjects’ parents/guardians for participating in the 
trial. 
(m) That the subjects’ participation in the trial is voluntary and subjects’ parents/guardians 
may refuse to participate or withdraw from the trial, at any time, without penalty or 
loss of benefits to which subjects are otherwise entitled. 
(n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will 
be granted direct access to the subject’s original medical records for verification of 
clinical trial procedures and/or data, without violating the confidentiality of subjects, 
to the extent permitted by the applicable laws and regulations and that, by signing a 
written informed consent, the subject’s parents/guardians is authorizing such access. 
(o) That records identifying subjects will be kept confidential and, to the extent permitted 
by the applicable laws and/or regulations, will not be made publicly available. If the 
results of the trial are published, subjects’ identity will remain confidential. 
(p) That the subjects’ parents/guardians will be informed in a timely manner if 
information becomes available that may be relevant to the subjects’ parents/guardians 
willingness for their continued participation in the trial. 
(q) The person(s) to contact for further information regarding the trial and the rights of 
trial subjects, and who to contact in the event of trial-related injury. 
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(r) The foreseeable circumstances and/or reasons under which a subject’s participation in 
the trial may be terminated. 
(s) The expected duration of a subject’s participation in the trial. 
(t) The approximate number of subjects involved in the trial. 
GSK Biologicals will prepare a representative subject information sheet/informed consent 
document which will embody all the elements described above. While it is strongly 
recommended that this representative document be followed as closely as possible, the 
informed consent requirements given in this document are not intended to pre-empt any 
local regulations which require additional information to be disclosed for informed 
consent to be legally effective. Clinical judgement, local regulations and requirements 
should guide the final structure and content of the document.  
The investigator has the final responsibility for the final presentation of the subject 
information sheet/informed consent document, respecting the mandatory requirements of 
local regulations. The consent form generated by the investigator with the assistance of 
the local sponsor’s representative, must be approved (along with the protocol, and any 
other necessary documentation) by the IRB/IEC and be acceptable to GSK Biologicals. 
5.1.3 Independent Data Monitoring Committee (IDMC)  
Composition of the IDMC 
An independent committee consisting of up to five experts in meningococcal diseases, 
paediatrics, vaccines, statistics and other appropriate disciplines will be appointed to 
oversee ethical and safety aspects of the study conduct. 
The Charter (terms of references) of the IDMC will be written after the first meeting of 
the IDMC members, prior to study start. 
Role of the IDMC 
The role of the IDMC includes the review of the implementation and progress of the 
study. It provides initial, regular, and closing advice on safety-related issues to GSK 
Biologicals.  Its advice is based on the interpretation of study data with reference to the 
study protocol. 
The IDMC will confer before the initiation of the study (pre-initiation review), during the 
study proper and at the close out of the study to review any relevant safety data; after 
study end, the IDMC will have a first assessment report. Other unscheduled meetings may 
be required. Meetings must be documented and minutes made available for the study files 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
40
on site and to the sponsors. The IDMC may, if deemed necessary, convene a meeting with 
or request further information from the Principal Investigators, the Local Safety Monitor, 
GSK Biologicals, WHO and designated project representatives at any stage of the study.  
The IDMC must be informed by the investigator of: 
• all subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review 
• systemic grade 3 adverse events (AEs) related to vaccination, serious adverse events 
and adverse events suggesting a lack of efficacy of the vaccine occurring during the 
study (transmitted through GSK Biologicals for SAEs and through the Local safety 
Monitor for the other adverse events)  
• all subsequent protocol modifications (for information) 
• new information that may affect adversely the safety of the subjects or the conduct of 
the study. 
The IDMC will be empowered to put the study on hold pending review of potential safety 
issues. All SAEs, including death, will be reported by the Principal Investigator to the 
local safety monitor, to the Manager of Clinical Safety Vaccines at GSK Biologicals, to 
WHO and to the WHO safety monitor. GSK Biologicals will be responsible to provide all 
information related to the SAEs to the IDMC according to the IDMC Charter.  
Reporting to IDMC – Role of Local Safety Monitor  
A Local Safety Monitor (LSM) will act independently from the investigational team. The 
overall role of the Local Safety Monitor (LSM), who will be an experienced clinician 
based in-country, will be to support the clinical investigators and to act as a link between 
the investigators and the IDMC. All systemic grade 3 AEs probably or suspected to be 
related to vaccination, all SAEs and all AEs suggesting a lack of efficacy of the vaccine 
will be reported to him/her. His/her involvement will be particularly important when 
decisions have to be made quickly. In exceptional circumstances, for example a death 
possibly related to vaccination, he/she will have the authority to suspend the whole or any 
specific aspect of the trial pending discussion with the IDMC.  
The LSM’s role will include: 
• acting as the study volunteer's advocate 
• provide the IDMC and the medical monitor of GSK Biologicals with a blinded listing 
of non-serious systemic grade 3 symptoms (solicited and unsolicited) that are related 
with vaccination, and of non-serious adverse events suggesting a lack of efficacy of the 
vaccine, this according to the IDMC Charter (note: GSK Biologicals will send all 
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information related to serious adverse events to the IDMC according to the IDMC 
Charter).  
• reviewing blinded reactogenicity data according to IDMC charter and discussing with 
IDMC if necessary  
• promptly communicating relevant safety information to the IDMC 
• providing advice to the investigators on whether a set of clinical circumstances in a 
study warrants formal notification to the IDMC 
• providing clinical advice on any illness in study subjects especially in circumstances in 
which treatment might influence the course of the trial 
• Unblinding a subject if deemed necessary, upon request of the investigator/physician 
in charge of the subject, to allow for adequate treatment. 
The LSM will liaise closely with the chair of the IDMC throughout the course of the trial. 
5.2 General study aspects 
The maximum distance between a subject’s compound and the nearest health facility will 
be 10 km. Each visit to the clinic for vaccination will last approximately 4 hours; each 
home visit by a field worker will last about 15 minutes.  
The dates of administration of a dose of hepatitis B vaccine and/or Bacille Calmette-
Guérin (BCG) and/or Oral Polio Vaccine (OPV) vaccine as well as any other vaccines 
other than the study vaccines that may be given to the subjects from birth until the end of 
the study will be documented in the concomitant vaccination section of the individual 
CRF.  
Any meningococcal vaccine given to the mother of the child from one year before the 
first study vaccine dose administration up to the first study vaccine administration will be 
documented in the concomitant vaccination section of the individual CRF (see section 6.8 
for details). 
One specific ancillary study will be done on the subjects participating in this study by 
Abraham Hodgson, Navrongo Health Research Center (NHRC), Navrongo, Ghana; Gerd 
Pluschke, Molecular Immunology, Swiss Tropical Institute (STI), Basel, Switzerland. 
GSK Biologicals is not sponsor of this ancillary study but the protocol of this ancillary 
study is attached as an Appendix to this protocol (refer Appendix  H for further details) 
for operational reasons (only one subject information sheet will be written and one 
informed consent will be submitted to the approval of the parents/guardians of the child, 
however, any parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will also have to sign an 
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Informed Consent prior to providing any throat swab). This ancillary study will be 
reported separately by the investigators of the ancillary study. This ancillary study 
requires collection of throat swabs from the parent/guardian and infant prior to the first 
dose (6-8 weeks) and at 10 weeks, 18 weeks, 9 months and 12 months of age. The 
collection of throat swab will be detailed in the study procedures (section 5. 3) and the 
subject information sheet.  
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5.3 Outline of study procedures 
Table 5-1: List of study procedures 
 Primary Phase (759346/009) Booster Phase (104430)  
Age ±6 w ±10 w ±14 w ±18 w ± 9 m ±12 m ±13 m 
Visit VISIT 1 VISIT 2 VISIT 3 VISIT 4 VISIT 5 VISIT 6 VISIT 7 
Timing Month 0 Month 1 Month 2 Month 3 Month 
7.5 
Month 10.5 Month 11.5
Sampling time point Pre vacc   Post vacc III  Pre booster Post booster
Informed consent# • (•)#  (•)# (•)# (•)#  
Check inclusion criteria •       
Check exclusion criteria •       
Check elimination criteria  • • • • • • 
Check contraindications  • •  °## •  
Medical history •       
Physical examination • • • • • • • 
Pre-vaccination body 
temperature 
• • •  • •  
Measure/record height and 
weight  
•       
Randomization •       
Blood sampling for antibody 
determination (3.5 ml) 
•*   •  • • 
Throat swab •** •**  •** •** •**  
Vaccination • • •  •*** •****  
Daily post-vaccination 
recording of solicited 
symptoms (days 0-3) by field 
workers 
• • •   •  
Recording of non serious 
adverse events occurring one 
month (minimum 30 days) 
post-vaccination, by 
investigator 
• • • •  • • 
Return of diary cards  • • •   • 
Diary card transcription  • • •   • 
Record any concomitant 
medication 
• • • • • • • 
Retrospective recording of 
relevant concomitant 
medication/vaccination since 
Visit 4### 
    •   
Reporting of Serious 
Adverse Events  
• • • • • • • 
Study Conclusion of 
Prirmary Phase 
   •    
Study Conclusion of Booster 
Phase 
      • 
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Footnotes to Table 5-1 
• denotes a procedure which must be recorded in the individual CRF. 
° denotes a procedure which need not be recorded in the individual CRF. 
# any parent/guardian accompanying the child at visits subsequent to the first visit who has not already signed an 
Informed Consent for this study will have to sign an Informed Consent prior to providing any throat swab  
.## Contraindications for measles and yellow fever vaccines. 
### Relevant medication/treatment will include meningococcal vaccine, any investigational or non-registered 
product (drug or vaccine), any immunosuppressant(s) or other immune-modifying drug(s), immunoglobulins 
and/or any blood product(s).  
* a minimum of 2 ml may be taken at prevaccination timepoint. See Section 5.5.2; ** from the subject and 
subject’s parents/guardians; ***Measles, yellow fever vaccine 
****1/5th of dose of Mencevax™ AC 
Note: BCG and OPV vaccines are given at birth (or at least 2 weeks before the subject’s first visit) according to 
the nationally recommended immunization schedule. 
OPV vaccine can be administered to the subjects at 6, 10 and 14 weeks of age concomitantly with the study 
vaccines or at any time during the study, whichever is more appropriate. 
  
Table 5-2: List of study procedures for the extended safety follow-up phase 
 EXTENDED SAFETY 
FOLLOW-UP PHASE 
Age ±24 m 
Visit  
Timing Month 22.5 
Informed consent • 
Retrospective recording of SAE(s) since Visit 7 
up to the time that subjects are aged at least 24 
months 
• 
Study conclusion  • 
 
(Amendment 7: 12 April 2006) 
It is the investigator’s responsibility to ensure that the intervals between visits/contacts 
are strictly followed. These intervals determine each subject’s evaluability in the 
according-to-protocol analyses (see Sections 4.4 and 10.4 for details of criteria for 
evaluability and cohorts to be analyzed).  
Table 5-3: Intervals between study visits 
Interval Size of interval 
1 (Visit 1→Visit 2)* 28−42 days 
2 (Visit 2→Visit 3)* 28−42 days 
3 (Visit 3→Visit 4)* 30−42 days 
4 (Visit 5) Approx 9 months of age (range 8-10 months) 
5 (Visit 6) Approx 12 months of age (range 11-13 months) 
6 (Visit 6→Visit 7)* 30−42 days 
* The date of the previous visit serves as reference date. 
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5.4 Detailed description of study stages/visits 
A description of each stage of the study, as summarized in the schedule of assessments 
(see Table 5-1) is given hereafter.  
Visit 1: 6 weeks of age: Study Day 0: Vaccination 
• Written informed consent from the subject’s parent/guardian.  
• Check of inclusion criteria for enrolment. 
• Check of exclusion criteria for enrolment. 
• Medical history taking. 
• Physical examination by the investigator including measurement and 
recording of pre-vaccination temperature. 
• Measurement and recording of height and weight. 
• Recording of any concomitant medication administered (See Section 6.8). 
This includes also the recording of any meningococcal vaccine given to the 
mother during the year preceding the visit 1. 
• Randomization (See Section 6.3). 
• Provision of temporary study identification card. 
• Collection of blood for serology: it is understood that collection of blood in 
infants aged 6 weeks may be technically difficult. Therefore a minimum of 
2.0 ml of whole blood, which is the minimum volume of blood that will allow 
the essential serology to be undertaken, has to be taken according to 
instructions in Appendix  D. However, whenever possible a 3.5 ml sample 
should be collected to provide the 1.5 ml sample of serum that is needed for 
full serological assessment of the response to the vaccine and for validation 
assays. See Section 5.5.2. 
Technically skilled and trained individuals will draw blood to avoid 
unnecessary pain and technical failure as much as possible.  
When materials are provided by GSK Biologicals, it is MANDATORY that all 
clinical samples (including serum samples) will be collected and stored using 
exclusively those materials in the appropriate manner. The use of other 
materials could result in the exclusion of the subject from the ATP analysis 
(See Section 10.4 for definition of study cohorts to be evaluated). The 
investigator must ensure that his/her personnel and the laboratory(ies) under 
his/her supervision comply with this requirement. However, when GSK 
Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. 
Refer to Appendix  D and Appendix  E. 
• Collection of throat swabs from the subject and subject’s parent/guardian  
• Vaccination: intramuscular administration of one dose of Tritanrix™-
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HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ according to the 
guidelines set out in Section 6.1.6. 
The vaccinees will be observed closely for at least 30 minutes, with 
appropriate medical treatment readily available in case of a rare 
anaphylactic reaction following the administration of vaccines. 
• The field worker will be given a diary card and will visit the subjects at their 
home to record, on the day of vaccine injection (day 0) and during the 3 
subsequent days (days 1-3) or up to resolution of the symptoms, whichever is 
longer, the subject’s body temperature and any local (at the injection site) or 
general adverse events (see section 8.5.1).  
• The field worker will visit the subjects’ parents/guardians one month after 
each vaccination to remind them to go for the next visit.  
• The subjects’ parents/guardians will be instructed to contact the 
investigator/study contact person at the health centre immediately should the 
subject manifest any signs or symptoms they perceive as serious.  
Visit 2: 10 weeks of age: Study Month 1 (28-42 days after Visit 1): 
Vaccination 
• Provision of definitive study ID card (plastified ID card including picture of 
parent/guardian and infant).  
• The investigator will verify the diary cards provided by the field workers. He 
will transcribe the information into the appropriate sections of the case report 
form (CRF), in English.  
• Check of elimination criteria (see Section 4.4). 
• Check of any contraindications (see Section 4.5). 
• Recording of any concomitant medication administered since the last visit 
(see Section 6.8). 
• Recording of any serious and any unsolicited adverse events which might 
have occurred since the last visit. 
• Physical examination by the investigator including measurement and 
recording of pre-vaccination temperature. 
• Collection of throat swabs from the subject and subject’s parent/guardian (any 
parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will have to 
sign an Informed Consent prior to providing any throat swab).  
• Vaccination: intramuscular administration of one dose of Tritanrix™-
HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ according to the 
guidelines set out in Section 6.1.6. 
The vaccinees will be observed closely for at least 30 minutes, with 
appropriate medical treatment readily available in case of a rare 
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anaphylactic reaction following the administration of vaccines. 
• The field worker will be given a diary card and will visit the subjects at their 
home to record, on the day of vaccine injection (day 0) and during the 3 
subsequent days (days 1-3) or up to resolution of the symptoms, whichever is 
longer, the subject’s body temperature and any local (at the injection site) or 
general adverse events (see section 8.5.1).  
• The field worker will visit the subjects’ parents/guardians one month after 
each vaccination to remind them to go for the next visit.  
• The subjects’ parents/guardians will be instructed to contact the investigator 
immediately should the subject manifest any signs or symptoms they perceive 
as serious.  
N.B. The parent/guardian of the study subject will be asked to present the study 
ID card every time they attend the hospital / health centers.  
Note: Any parent/guardian accompanying the child at visits subsequent to the 
first visit who has not already signed an Informed Consent for this study will 
have to sign an Informed Consent prior to providing a throat swab.  
Visit 3: 14 weeks of age: Study Month 2 (28-42 days after Visit 2): 
Vaccination 
• The investigator will verify the diary cards provided by the field workers. He 
will transcribe the information into the appropriate sections of the CRF, in 
English.  
• Check of elimination criteria (see Section 4.4). 
• Check of any contraindications (see Section 4.5). 
• Recording of any concomitant medication administered since the last visit 
(see Section 6.8). 
• Recording of any serious and any unsolicited adverse events which might 
have occurred since the last visit. 
• Physical examination by the investigator including measurement and 
recording of pre-vaccination temperature. 
• Vaccination: intramuscular administration of one dose of Tritanrix™-
HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ according to the 
guidelines set out in Section 6.1.6. 
The vaccinees will be observed closely for at least 30 minutes, with 
appropriate medical treatment readily available in case of a rare 
anaphylactic reaction following the administration of vaccines. 
• The field worker will be given a diary card and will visit the subjects at their 
home to record, on the day of vaccine injection (day 0) and during the 3 
subsequent days (days 1-3) or up to resolution of the symptoms, whichever is 
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longer, the subject’s body temperature and any local (at the injection site) or 
general adverse events (see section 8.5.1). 
• The field worker will visit the subjects’ parents/guardians one month after 
each vaccination to remind them to go for the next visit. 
• The subjects’ parents/guardians will be instructed to contact the 
investigator/study contact person at the health centre immediately should the 
subject manifest any signs or symptoms they perceive as serious.  
Visit 4: 18 weeks of age: Study Month 3 (30-42 days after Visit 3): Follow-
up visit 
• The investigator will verify the diary cards provided by the field workers. He 
will transcribe the information into the appropriate sections of the CRF, in 
English.  
• Recording of any unsolicited adverse events which might have occurred 
within one month (minimum 30 days) following the previous vaccination (see 
Section 8.7). 
• Recording of any serious adverse events which might have occurred since the 
last visit. 
• Check of elimination criteria (see Section 4.4). 
• Recording of any concomitant medication administered since the last visit 
(see Section 6.8). 
• Physical examination by the investigator. 
• Collection of throat swabs from the subject and subject’s parent/guardian (any 
parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will have to 
sign an Informed Consent prior to providing any throat swab). 
• Collection of blood for serology: a minimum of 3.5 ml of whole blood to 
provide a minimum of 1.5 ml of serum according to instructions in Appendix  
D. 
Technically skilled and trained individuals will draw blood to avoid 
unnecessary pain and technical failure as much as possible.  
When materials are provided by GSK Biologicals, it is MANDATORY that all 
clinical samples (including serum samples) will be collected and stored using 
exclusively those materials in the appropriate manner. The use of other 
materials could result in the exclusion of the subject from the ATP analysis 
(See Section 10.4 for definition of study cohorts to be evaluated). The 
investigator must ensure that his/her personnel and the laboratory(ies) under 
his/her supervision comply with this requirement. However, when GSK 
Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. 
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Refer to Appendix  D and Appendix  E.  
• The subjects’ parents/guardians will be instructed to contact the 
investigator/study contact person at the health centre immediately should the 
subject manifest any signs or symptoms they perceive as serious.  
Note: Any parent/guardian accompanying the child at visits subsequent to the 
first visit who has not already signed an Informed Consent for this study will 
have to sign an Informed Consent prior to providing a throat swab  
• Study conclusion of the primary phase 
Visit 5: 9 months of age (8-10 months) -Vaccination with Measles and 
Yellow Fever vaccine 
• If at the time of the initiation of the booster phase any parent/guardian 
declines participation of his/her child, refusal will be documented as 
instructed in the “subject tracking document” provided by GSK Biologicals. 
A copy of the completed tracking document will be forwarded to GSK 
Biologicals’ Study Monitor. The information will be entered in the GSK 
Biologicals’ clinical database for use in identification of any safety issue that 
may have prevented a subject’s participation.  
• Recording of any serious adverse events which might have occurred since the 
last visit. 
• Check of elimination criteria (see Section 4.4). 
• Recording of concomitant medication administered since the last visit (see 
Section 6.8).  
• Physical examination by the investigator including measurement and 
recording of pre-vaccination temperature. 
• Check of contraindications for measles and yellow fever vaccine (this will not 
be documented in the individual CRF) 
• Retrospective recording of any relevant concomitant medication/ vaccination 
since the last visit according to instructions provided in Section 6.8. Relevant 
vaccines will include meningococcal vaccines and investigational or non 
registered vaccines and will be recorded with trade name, route of 
administration and date(s) of administration. Relevant medications/treatments 
will include any investigational or non-registered product(s), any 
immunosuppressant(s) or other immun-modifying drug(s), immunoglobulins 
and/or any blood products. All such medication/treatment is to be recorded 
with generic name of the medication (trade names are allowed for 
combination drugs, i.e. multi-component drugs), medical indication, total 
daily dose, route of administration, start and end dates of treatment.  
• Collection of throat swabs from the subject and subject’s parent/guardian (any 
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parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will have to 
sign an Informed Consent prior to providing any throat swab).  
• Vaccination: intramuscular/subcutaneous administration of one dose of 
measles vaccine and intramuscular administration of one dose of yellow fever 
vaccine. 
The vaccinees will be observed closely for at least 30 minutes, with 
appropriate medical treatment readily available in case of a rare 
anaphylactic reaction following the administration of vaccines. 
• The subjects’ parents/guardians will be instructed to contact the 
investigator/study contact person at the health centre immediately should the 
subject manifest any signs or symptoms they perceive as serious.  
Note: Any parent/guardian accompanying the child at visits subsequent to the 
first visit who has not already signed an Informed Consent for this study will 
have to sign an Informed Consent prior to providing a throat swab  
Visit 6: 12 months of age (11-13 months) - Booster vaccination 
• Recording of any serious adverse events which might have occurred since the 
last visit. 
• Check of elimination criteria (see Section 4.4). 
• Recording of any concomitant medication administered since the last visit 
(see Section 6.8).  
• Physical examination by the investigator including measurement and 
recording of pre-vaccination temperature. 
• Collection of throat swabs from the subject and subject’s parent/guardian (any 
parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will have to 
sign an Informed Consent prior to providing any throat swab). 
• Collection of blood for serology: a minimum of 3.5 ml of whole blood to 
provide a minimum of 1.5 ml of serum according to instructions in Appendix  
D. 
Technically skilled and trained individuals will draw blood to avoid 
unnecessary pain and technical failure as much as possible.  
When materials are provided by GSK Biologicals, it is MANDATORY that all 
clinical samples (including serum samples) will be collected and stored using 
exclusively those materials in the appropriate manner. The use of other 
materials could result in the exclusion of the subject from the ATP analysis 
(See Section 10.4 for definition of study cohorts to be evaluated). The 
investigator must ensure that his/her personnel and the laboratory(ies) under 
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his/her supervision comply with this requirement. However, when GSK 
Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. 
Refer to Appendix  D and Appendix  E.  
• Check of any contraindications (see Section 4.5). 
• Vaccination: intramuscular administration of 1/5th of a dose of Mencevax™ 
AC according to the guidelines set out in Section 6.1.6. 
The vaccinees will be observed closely for at least 30 minutes, with 
appropriate medical treatment readily available in case of a rare 
anaphylactic reaction following the administration of vaccines. 
• The field worker will be given a diary card and will visit the subjects at their 
home to record, on the day of vaccine injection (day 0) and during the 3 
subsequent days (days 1-3) or up to resolution of the symptoms, whichever is 
longer, the subject’s body temperature and any local (at the injection site) or 
general adverse events (see section 8.5.1).  
• The field worker will visit the subjects’ parents/guardians one month after 
each vaccination to remind them to go for the next visit.  
• The subjects’ parents/guardians will be instructed to contact the 
investigator/study contact person at the health centre immediately should the 
subject manifest any signs or symptoms they perceive as serious.  
Note: Any parent/guardian accompanying the child at visits subsequent to the 
first visit who has not already signed an Informed Consent for this study will 
have to sign an Informed Consent prior to providing a throat swab.  
Visit 7: Study Month 11.5 (30-42 days after Visit 6): Blood Sampling and 
Follow-up visit 
• The investigator will verify the diary cards provided by the field workers. He 
will transcribe the information into the appropriate sections of the CRF, in 
English.  
• Recording of any serious adverse events which might have occurred since the 
last visit. 
• Check of elimination criteria (see Section 4.4). 
• Recording of any concomitant medication administered since the last visit 
(see Section 6.8). 
• Physical examination by the investigator. 
• Collection of blood for serology: a minimum of 3.5 ml of whole blood to 
provide a minimum of 1.5 ml of serum according to instructions in Appendix  
D. 
Technically skilled and trained individuals will draw blood to avoid 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
52
unnecessary pain and technical failure as much as possible.  
When materials are provided by GSK Biologicals, it is MANDATORY that all 
clinical samples (including serum samples) will be collected and stored using 
exclusively those materials in the appropriate manner. The use of other 
materials could result in the exclusion of the subject from the ATP analysis 
(See Section 10.4 for definition of study cohorts to be evaluated). The 
investigator must ensure that his/her personnel and the laboratory(ies) under 
his/her supervision comply with this requirement. However, when GSK 
Biologicals does not provide material for collecting and storing clinical 
samples, then appropriate materials from the investigator’s site are to be used. 
Refer to Appendix  D and Appendix  E.  
• Study conclusion of the booster phase  
• After study end, one dose Mencevax™ ACWY will be offered to the 
Tritanrix™-HepB/Hiberix™ control group to protect them against 
meningococcal diseases of these serogroups: Mencevax™ ACWY will be 
given when the child is two years of age or, if a meningitis epidemic occurs, 
earlier in the second year of life.  
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Extended Safety Follow-Up Phase: Retrospective recording of SAE(s) 
The parents/guardians of all study subjects will be contacted by the local 
health staff when their child is at least 24 months of age for a retrospective 
follow-up of SAE(s) (i.e. occurrence of any SAE(s) since the last study visit 
[Visit 7] up to the time that subjects are at least 24 months of age). Prior to 
initiating the study procedures for this safety follow-up phase, an informed 
consent will be obtained from the parents/guardians of the child after 
explaining the purpose of this contact. 
 
The study personnel will contact the parents/guardians of the subjects and 
will question them in a RETROSPECTIVE manner if the subject has 
suffered any unreported SAE(s) in the period between the last study visit 
(study conclusion of the booster phase) and this follow-up contact; the 
study personnel will also consult the child health card whenever available. 
If SAE(s) had occurred, further investigations will be performed on the 
subject’s hospital/health centre records (if available). Details of these 
SAE(s) will be reported on the SAE forms. If a death had occurred, a verbal 
autopsy report will be obtained whenever possible. 
 
As subjects will be at least two years of age at this safety follow-up visit, the 
study staff will also remind parents/guardians that the children part of the 
control group and those with sub-optimal response to the MenA and/or 
MenC component of the vaccines given to the DTPw-HepB/Hib-MenAC 
group, will be offered a dose of Mencevax™ ACWY vaccine to protect them 
against meningococcal diseases (serogroups A, C, W and Y). 
 
This will be the study conclusion for the extended safety follow-up phase. 
 
(Amendment 7: 12 April 2006) 
5.5 Sample handling and analysis 
5.5.1 Treatment and storage of biological samples 
See Appendix  D of the protocol for details of treatment and storage of biological 
samples. 
See Appendix  E for instructions for shipment of biological samples. 
See Appendix  H for instructions on collection and analysis of throat swabs.  
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5.5.2 Laboratory assays 
All serological assays will be performed at GlaxoSmithKline Biologicals' central 
laboratory or in a validated laboratory designated by GlaxoSmithKline Biologicals using 
standardized, validated procedures with adequate controls.  
For all subjects, a 3.5 ml sample of whole venous blood will be collected at visits 1, 4, 6 
and 7 using tubes with serum separator. Since the investigator has suggested that the 
collection of this amount of blood at Visit 1 may be technically difficult in such small 
infants, the quantity collected at this visit can be reduced to 2.0 ml, as a strict minimum, 
however this will not allow for any validation/retesting etc that may be required when the 
testing is performed. After blood centrifugation and serum separation, samples will be 
stored at −20°C until collection by the sponsor. The aliquots of serum (approximately 
1.5 ml) will be sent to GlaxoSmithKline Biologicals for the following tests according to 
the serology plan (refer to Section 5.5.3): 
1. Functional anti-meningococcal serogroups A and C activity (SBA-MenA and SBA-
MenC) will be determined by a serum bactericidal test according to the CDC 
protocol 
27
 using rabbit complement. The cut-off of the test is a dilution of 1:8. Titers 
will be expressed as the reciprocal of the dilution resulting in 50% inhibition. The use 
of 1:8 and 1:128 as SBA endpoints when using rabbit complement for SBA-MenC 
has been discussed at a recent WHO conference, they are now being used in the 
literature to report on the immunogenicity of meningococcal C conjugate vaccines 
28
 
More recently, efficacy data from postlicensure surveillance has been shown to 
validate the SBA-MenC 1:8 cut-off as a serological correlate of protection for 
meningococcal serogroup C conjugate vaccines
29
.  
2. Meningococcal polysaccharide C specific IgG will be measured by ELISA; the assay 
is based on the CDC protocol 
30
. The assay cut-off is 0.30 µg/ml. The use of the 
ELISA endpoint of 2 µg/ml is based on the correlate of protection proposed for the 
plain meningococcal C polysaccharide vaccine. The same cut-offs will be employed 
for meningococcal A polysaccharide. 
3. Total antibodies to the Hib polysaccharide PRP will be measured by ELISA using an 
in-house assay. The cut-off is 0.15 µg/ml. 
4. Specific antibodies against diphtheria and tetanus toxoid will be measured by ELISA 
techniques. The cut-off of the tests is 0.1 IU/ml 
31, 32. Post-vaccination serum samples 
with ELISA anti-D antibody concentrations <0.1 IU/ml will be re-tested using a 
VERO-cell neutralization assay 
33, 34
. The cut-off of the VERO-cell assay is 
0.016 IU/mL.  
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
55
5. Anti-B. pertussis antibody concentrations will be determined by ELISA using the IgG 
EIA test kit Lab Systems, and expressed in EL.U/ml with an assay cut-off of 
15 EL.U/ml. 
6. Antibodies to HBs antigen will be measured using a commercially available kit 
(AUSABEIA test, Abbott Laboratories or equivalent). Antibody concentrations 
= 10 mIU/ml are considered as protective. 
Note: Details of assays for throat swabs are available in Appendix  H.  
 
Table 5-4: Laboratory Assays 
Antigen Assay 
method 
Test Kit/ 
Manufacturer
Assay 
unit 
Assay
cut-off 
Laboratory 
SBA-MenA Bactericidal 
assay 
in house dilution for 
50% killing
1:8 Rixensart 
SBA-MenC Bactericidal 
assay 
in house dilution for 
50% killing
1:8 Rixensart 
PRP  ELISA in-house µg/ml 0.15 Rixensart* 
PSA ELISA in-house µg/ml 0.3 Rixensart 
PSC ELISA in-house µg/ml 0.3 Rixensart 
Diphtheria  ELISA in-house IU/ml 0.1 Rixensart* 
Tetanus ELISA in-house IU/ml 0.1 Rixensart* 
BP ELISA commercial EL.U/ml 15 Rixensart* 
HBs  ELISA commercial mIU/ml 10 Rixensart* 
Diphtheria Vero-cell in house IU/ml 0.016 Rixensart 
* or in a validated laboratory designated by GlaxoSmithKline Biologicals 
5.5.3 Serology plan 
Pre-vaccination (Day 0) serum samples will be tested in all subjects for antibodies against 
SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, diphtheria toxoid, pertussis antigen and 
recombinant DNA hepatitis B surface antigen (no pre-vaccination testing of anti-TT and 
anti-PRP is foreseen as immunogenicity results of the previous clinical study were highest 
for these two antibodies). 
Post-vaccination III and pre-booster serum samples will be tested in all subjects for 
antibodies against all vaccine antigens (SBA-MenA, SBA-MenC, anti-PRP, anti-PSA, 
anti-PSC, diphtheria and tetanus toxoids, pertussis antigen and recombinant DNA 
hepatitis B surface antigen). 
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The post-booster serum sample taken from all children will be tested for SBA-MenA and 
SBA MenC, anti-PSA and anti-PSC antibodies. 
In case of insufficient blood sample volume to perform assays for all antibodies, they will 
be analyzed according to the following priority ranking:  
• SBA-MenA 
• SBA-MenC 
• anti-PRP (only for Post vacc III and pre-booster) 
• anti-diphtheria (Vero-cell assay only when required for Post vacc III and Pre-booster) 
• anti-HBs 
• anti-tetanus, (only for Post vacc III and pre-booster) 
• anti-BP 
• anti-PSA 
• anti-PSC 
Any additional serology on antigens contained in the study vaccines may be performed if 
deemed necessary by GlaxoSmithKline Biologicals, or if any findings in the present study 
or in other studies necessitate investigation of the immunogenicity of the vaccine. In this 
case, the ranking above may also be changed. 
5.5.4 Endpoints for suboptimal response 
Suboptimal response will be defined as either of the following: 
SBA-MenA  < 1:8 
SBA-MenC  < 1:8 
anti-PRP concentration < 0.15 µg/ml 
anti-HBs concentration < 10 mIU/ml 
anti-BP concentration < 15 EL.U/ml 
anti-diphtheria concentration < 0.016 (Vero-cell assay) 
anti-tetanus concentration < 0.1 IU/ml 
Subjects who demonstrate a suboptimal response to one or more of the following 
antigen(s) – D, T, Pw, HBV or Hib one month after the primary series will receive a 
booster dose of licensed Tritanrix™-HepB/Hiberix™ vaccine in the second year of life.  
Subjects who demonstrate a suboptimal response to the MenA or MenC antigens will 
receive a dose of Mencevax™ ACWY to be provided by GSK Biologicals. Mencevax™ 
ACWY will be given when the child is two years of age or, if a meningitis epidemic 
occurs, earlier in the second year of life.  
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6 Investigational Products and Administration 
6.1 Study Vaccines 
All candidate vaccines to be used have been developed and manufactured by GSK 
Biologicals.  
The Quality Control Standards and Requirements for each candidate vaccine are 
described in separate release protocols and the required approvals have been obtained.  
Commercial vaccines are assumed to comply with the specifications given in the 
manufacturer's Summary of Product Characteristics. 
6.1.1 GSK Biologicals’ Haemophilus influenzae type b meningococcal AC-TT 
(Hib-MenAC) conjugate vaccine  
One lot of the vaccine will be used. The vaccine will be supplied as a white freeze dried 
pellet in monodose vials to be reconstituted with Tritanrix™-HepB before use. Each vial 
of the Hib-MenAC (5/5/5) vaccine needs to be reconstituted with 2 vials of the 
Tritanrix™-HepB before use (0.5 ml per vial). Only half of the dose (i.e. 0.5 ml will be 
administered. For details of the dose dilution see Section 6.1.7. One dose (0.5 ml) of the 
reconstituted vaccine contains the following components: 
Haemophilus influenzae type b capsular polysaccharide 
(PRP) conjugated to tetanus toxoid 
: 2.5 µg 
Neisseria meningitidis A capsular polysaccharide 
conjugated to tetanus toxoid 
: 2.5 µg 
Neisseria meningitidis C capsular polysaccharide 
conjugated to tetanus toxoid 
: 2.5 µg 
   
6.1.2 GSK Biologicals’ combined diphtheria-tetanus-whole cell Bordetella 
pertussis-hepatitis B (DTPw-HBV) vaccine: Tritanrix™-HepB 
The vaccine will be supplied as a whitish liquid in monodose vials. One dose (0.5 ml) 
contains the following components: 
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Diphtheria toxoid : not less than 30 IU (7.5 Lf) 
Tetanus toxoid : not less than 60 IU (3.25 Lf) 
Inactivated Bordetella pertussis (whole cell) : not less than 4 IU (15 OU) 
Recombinant HbsAg protein : 10 µg 
Aluminium (as salts) : 0.63 mg 
2-phenoxyethanol (as preservative) : 0.50 mg 
Thiomersal : 0.025 mg 
in a sterile saline solution  
 
6.1.3 GSK Biologicals’ Haemophilus influenzae type b conjugate vaccine: 
Hiberix  
The vaccine will be supplied as a white freeze-dried pellet in monodose vials to be 
reconstituted with one 0.5 ml vial of Tritanrix-HepB before use. One dose (0.5 ml) of 
the reconstituted vaccine contains the following components: 
Haemophilus influenzae type b capsular 
polysaccharide conjugated to tetanus toxoid 
: 10 µg  
 
Refer to Appendix G for details of vaccine supplies. 
6.1.4 GSK Biologicals’ Mencevax™ AC vaccine, used as booster vaccine 
Mencevax™ AC is a commercial vaccine which is manufactured by GSK Biologicals. 
The vaccine will be supplied as a freeze dried pellet to be reconstituted before use with 
1.0 ml of the appropriate diluent, supplied in 2 separate vials or ampoules each containing 
0.5 ml of diluent. One dose (1 ml) of the reconstituted vaccine will contain: 
Components Content 
Polysaccharide A 50 µg 
Polysaccharide C 50 µg 
 
Note: Only one fifth of a dose of Mencevax™ AC (0.2 ml) will be administered to each 
subject as detailed below: 
 
After reconstitution, 0.8 ml (four fifths) of a dose will be discarded and the remaining 
0.2 ml, i.e., one fifth (1/5) of a dose, will be administered. 
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6.1.5 Commercial Measles and Yellow Fever vaccines 
The Measles and Yellow Fever vaccines used will be those available commercially in 
Ghana at the time of the study.  
6.1.6 Dosage and administration 
An overview of the vaccines to be administered during the study is provided in Table 6-1. 
Table 6-1: Dosage and Administration 
Visit Vaccination Dose Study Group Vaccine Route Site Side Location
1, 2, 3 Diphtheria, 
Tetanus,  
Bordetella 
pertussis, 
hepatitis B, 
Hib  
N.meningitidis 
of serogroups 
A and C  
3 Tritanrix™-
HepB/ 
Hib-MenAC 
Tritanrix™-HepB/
Hib-MenAC 
IM T L U 
1, 2, 3 Diphtheria, 
Tetanus,  
Bordetella 
pertussis, 
hepatitis B, 
Hib 
 
3 Tritanrix™-
HepB/ 
Hiberix™ 
Tritanrix™-HepB/
Hiberix™ 
IM T L U 
5 Measles,  
Yellow fever  
1 All Subjects Commercially 
available vaccines 
IM/SC
IM 
D 
D 
L/R 
R 
U 
U 
6 Antibody 
persistence/ 
immune 
memory 
1 All Subjects 1/5th of dose of 
Mencevax™ AC 
IM T L U 
Intramuscular (IM) 
Thigh (T) 
Left (L) 
Right (R)   
Deltoid (D) 
Upper (U)  
Subcutaneous (SC) 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
60
Injection technique 
In order to ensure proper intramuscular injection of the study vaccines, a needle of at least 
1 inch (2.54 cm) length will be used. The following injection technique is 
recommended
35
: 
The needle should be inserted in the upper lateral quadrant of the thigh, directed inferiorly 
at an angle of 45 degrees with the long axis of the leg, and posteriorly at a 45-degree 
angle to the tabletop, with the subject supine. During the injection, the tissues of the 
injection site are compressed with the free hand, increasing the penetrable muscle mass 
and stabilising the extremity.  
The vaccinees will be observed closely for at least 30 minutes following the 
administration of vaccines, with appropriate medical treatment readily available in case of 
a rare anaphylactic reaction. 
6.1.7 Extemporaneous mixing of Tritanrix™-HepB and Hib-MenAC vaccines or 
Hiberix™  
Tritanrix™-HepB and Hiberix™ 
The liquid Tritanrix™-HepB vaccine should always be shaken before use. The full 
content of the Tritanrix™-HepB vaccine vial should be extracted and injected into the 
vial containing the lyophilized Hiberix™ vaccine. The vial should be agitated until the 
lyophilized vaccine pellet has completely dissolved. The mixed vaccines will appear 
white. The reconstituted mixed vaccines should be used promptly after reconstitution 
(within 30 minutes): 
 
• withdraw one dose of 0.5 ml of the mixed vaccines from the vial into the syringe; 
• a new needle should be used for injection; 
One dose (0.5 ml) of the mixed vaccines should be administered by intramuscular 
injection into the anterolateral quadrant of the left thigh. 
Tritanrix™-HepB and Hib-MenAC : dose dilution to provide Hib-MenAC (2.5/2.5/5.5) 
The Hib-MenAC (2.5/2.5/2.5) formulation containing 2.5 µg of each polysaccharide will 
be used in this study. This will be obtained by dilution of the supplied Hib-MenAC 
(5/5/5) vaccine that contains 5µg of each polysaccharide. Each vial of the Hib-MenAC 
(5/5/5) vaccine needs to be reconstituted with 2 vials of the Tritanrix™-HepB before use. 
The liquid Tritanrix™-HepB vaccine should always be shaken before use. The full 
content of two monodose vials of Tritanrix™-HepB vaccine should be extracted and 
injected into the vial containing the lyophilized Hib-MenAC (5/5/5) vaccine. The vial 
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should be agitated until the lyophilized vaccine pellet has completely dissolved. The 
mixed vaccines will appear white. The reconstituted mixed vaccines should be used 
promptly after reconstitution (within 30 minutes): 
 
• withdraw one dose of 0.5 ml of the mixed vaccines from the vial; 
• a new needle should be used for injection; 
One dose (0.5 ml) of the mixed vaccines should be administered by intramuscular 
injection into the anterolateral quadrant of the left thigh. 
Note: The reconstituted vaccine remaining in the vial after 1 dose (0.5 ml) has been 
withdrawn is to be retained by the investigator for purposes of vaccine accountability and 
should not be reused. See Appendix G for more details. 
6.2 Storage 
All vaccines must be stored in a safe and locked place with no access for unauthorized 
personnel. They must be kept in the refrigerator (+2°C to +8°C/ 36°F to 46°F) and must 
not be frozen. Storage temperature should be monitored and documented at least once 
per day. It is advisable to have a back-up refrigerator/ freezer in case of power failure/ 
breakdown. Procedures must be in place to ensure that the vaccine is kept at the indicated 
temperature range at all times. 
The study monitor must be contacted if the vaccines become frozen or if refrigeration 
fails. 
Storage conditions for transport of vaccines from country medical department or dispatch 
center to study sites or between sites are described in Appendix  G. 
6.3 Treatment allocation and randomization 
The target sample size is 280 enrolled subjects (220 evaluable for immunogenicity 
analysis, with 110 subjects in each group).  
The randomization will be performed in GlaxoSmithKline Biologicals, Rixensart, using a 
standard Statistical Analysis System (SAS) program. 
A randomization list will be generated using a randomization blocking scheme (1:1 ratio). 
This list will be used to ensure balance between treatments and will be used to number 
the vaccines: a randomization number will uniquely identify the vaccine doses to be 
administered to the same subject.  
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The vaccine doses will be distributed to the study center while respecting the 
randomization block size. On Day 0 (Month 0), subjects will be administered the vaccine 
dose with the lowest number still available at the study center. The vaccine number will 
also be used as subject identification for all data collected under the study. 
6.4 Method of blinding and breaking the study blind 
The study will be double blind. The study vaccine and the control vaccine will have the 
same whitish appearance after reconstitution. However, since the vaccines used in this 
study are different in their packaging volumes (Tritanrix™-HepB and Hiberix™ = 1 vial 
of 0.5ml of each vaccine, Tritanrix™-HepB and Hib-MenAC = 2 vials of 0.5 ml of 
Tritanrix™-HepB and 1 vial of 0.5 ml of Hib-MenAC), special precautions will be taken 
to ensure blinding. For each vaccination during the course of the study, a Syringe Filler 
and Vaccinator will work as a vaccination team: the Syringe Filler will prepare the 
vaccine for administration to a specific subject and the Vaccinator will administer the 
vaccine to each subject, according to the investigator’s SOP. To ensure blinding, a 
vaccination team will perform no other function in the study. The subject’s 
parent/guardian as well as those responsible for the evaluation of safety or 
immunogenicity study parameters will all be unaware which vaccine preparation was 
administered to a particular subject.  
A set of individual codes will be held at the GSK Biologicals’ Central Safety Office and 
by the Local Safety Monitor. The code will be broken by the GSK Clinical Safety 
physician or Local Safety Monitor only in the case of medical events that the 
investigator/physician in charge of the subject feels cannot be treated without knowing 
the identity of the study vaccine.  
GSK Biologicals’ policy (incorporating ICH E2A guidance, EU Clinical Trial Directive 
and Federal Regulations) is to unblind any serious adverse event (SAE) report associated 
with the use of the investigational product, which is unexpected and 
attributable/suspected, prior to regulatory reporting. The Clinical Safety physician is 
responsible for unblinding the treatment assignment in accordance with specified time 
frames for expedited reporting of SAEs (Refer to Section 8.9). 
6.5 Replacement of unusable vaccine doses 
Additional vaccine doses will be provided to replace those that are unusable (see 
Appendix  G for details of supplies). 
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In addition to the vaccine doses provided for the planned number of subjects, at least 5% 
additional doses of Tritanrix™-HepB and Hiberix™ will be supplied. In case a vaccine 
dose is broken or unusable, the investigator should replace it with a replacement vaccine 
dose. Although GlaxoSmithKline Biologicals need not be notified immediately in these 
cases, documentation of the use of the replacement vaccine must be recorded by the 
investigator on the vaccine administration page of the CRF and on the vaccine 
accountability form.  
6.6 Packaging 
See Appendix G. 
6.7 Vaccine accountability 
See Appendix G. 
6.8 Concomitant medication/treatment 
6.8.1 Recording of concomitant medication/treatment during the primary phase of 
the study  
At each study visit/contact, the investigator should question the subject's parents/guardian 
about any medication(s) taken. 
All concomitant medication, with the exception of vitamins and/or dietary supplements, 
administered at ANY time during the period starting with administration of each dose and 
ending one month (minimum 30 days) after each dose are to be recorded with generic 
name of the medication (trade names are allowed for combination drugs, i.e., multi-
component drugs), medical indication, total daily dose, route of administration, start and 
end dates of treatment. 
Any treatments and/or medications specifically contraindicated, e.g., any 
immunoglobulins, other blood products and any immune modifying drugs administered 
since birth or at any time during the study period are to be recorded with generic name of 
the medication (trade names are allowed for combination drugs only), medical indication, 
total daily dose, route of administration, start and end dates of treatment. Refer to 
Sections 4.3 and 4.4. 
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Any meningococcal vaccine given to the mother of the child during the year preceding 
the first vaccine dose given to the child should be recorded in the CRF with trade name, 
route of administration and date(s) of administration.  
Any vaccine not foreseen in the study protocol administered since birth and throughout 
the study period are to be recorded with trade name, route of administration and date(s) of 
administration, with the exception of OPV. Refer to Sections 4.3 and 4.4. 
Any concomitant medication administered prophylactically in anticipation of reaction to 
the vaccination must be recorded in the CRF with generic name of the medication (trade 
names are allowed for combination drugs only), total daily dose, route of administration, 
start and end dates of treatment and coded as ‘Prophylactic’. 
Concomitant medication administered for the treatment of an AE or SAE must be 
recorded in the CRF with generic name of the medication (trade names are allowed for 
combination drugs only), medical indication (including which AE/SAE), total daily dose, 
route of administration, start and end dates of treatment. Refer to Section 8.2 for 
definition of SAE. 
6.8.2 Recording of concomitant medication/treatment during the booster phase of 
the study  
At Visit 5, the investigator will question the parents/guardians in a RETROSPECTIVE 
manner if the subject received any relevant medication/treatment or vaccine in the time 
period since the last study visit of the primary phase of the study (Visit 4). Relevant 
vaccines will include meningococcal vaccines and investigational or non registered 
vaccines and will be recorded with trade name, route of administration and date(s) of 
administration. Relevant medications/ treatments will include any investigational or non-
registered product(s), any immunosuppressant(s) or other immune-modifying drug(s), 
immunoglobulins and/or any blood products. All such medication/treatment is to be 
recorded with generic name of the medication (trade named are allowed for combination 
drugs, i.e. multi-component drugs), medical indication, total daily dose, route of 
administration, start and end dates of treatment. 
In addition, all concomitant medication, with the exception of vitamins and/or dietary 
supplements, administered at ANY time during the period starting with administration of 
each dose and ending one month (minimum 30 days) after each dose are to be recorded 
with generic name of the medication (trade names are allowed for combination drugs, i.e., 
multi-component drugs), medical indication, total daily dose, route of administration, 
start and end dates of treatment. 
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Any treatments and/or medications specifically contraindicated, e.g., any 
immunoglobulins, other blood products and any immune modifying drugs administered at 
any time during the study period are to be recorded with generic name of the medication 
(trade names are allowed for combination drugs only), medical indication, total daily 
dose, route of administration, start and end dates of treatment. Refer to Section 4.4. 
Any vaccine not foreseen in the study protocol administered throughout the study period 
are to be recorded with trade name, route of administration and date(s) of administration, 
with the exception of OPV that can be given throughout the study. Refer to Section 4.4. 
Any concomitant medication administered prophylactically in anticipation of reaction to 
the vaccination must be recorded in the CRF with generic name of the medication (trade 
names are allowed for combination drugs only), total daily dose, route of administration, 
start and end dates of treatment and coded as ‘Prophylactic’. 
Concomitant medication administered for the treatment of an AE or SAE must be 
recorded in the CRF with generic name of the medication (trade names are allowed for 
combination drugs only), medical indication (including which AE/SAE), total daily dose, 
route of administration, start and end dates of treatment. Refer to Section 8.2 for 
definition of SAE. 
7 Health Economics 
Not applicable. 
8 Adverse Events, Serious Adverse Events and vaccine failure  
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an adverse event (AE) or serious adverse event (SAE) as 
provided in this protocol. During the study, when there is a safety evaluation, the 
investigator or site staff will be responsible for detecting AEs and SAEs, as detailed in 
this section of the protocol.  
Each subject’s parents/guardians will be instructed to contact the investigator 
immediately should the subject manifest any signs or symptoms they perceive as serious. 
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8.1 Definition of an adverse event 
An AE is any untoward medical occurrence in a clinical investigation subject, temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with 
the use of a medicinal product. For marketed medicinal products, this also includes 
failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.  
Examples of an AE include: 
• Significant or unexpected worsening or exacerbation of the condition/indication under 
study. See Section 8.3 ‘Lack of Efficacy’ for additional information.  
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
• New conditions detected or diagnosed after investigational product administration 
even though it may have been present prior to the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per se should not be 
reported as an AE/SAE). 
• Signs, symptoms temporally associated with vaccine administration. 
Examples of an AE DO NOT include: 
• Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that 
leads to the procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
• The disease/disorder being studied, or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition. 
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AEs may include pre- or post-treatment events that occur as a result of protocol-mandated 
procedures (i.e., invasive procedures, modification of subject’s previous therapeutic 
regimen). 
N.B. AEs to be recorded as endpoints (solicited events) are described in Section 8.5.1. All 
other AEs will be recorded as UNSOLICITED AES. 
Example of events to be recorded in the medical history section of the CRF: 
• Pre-existing conditions or signs and/or symptoms present in a subject prior to the start 
of the study (i.e. prior to the first study procedure) should be recorded in the medical 
history section of the subject’s CRF as instructed by the GSK Biologicals’ Study 
Monitor. 
8.2 Definition of a serious adverse event  
A serious adverse event (SAE) is any untoward medical occurrence that: 
a) results in death, 
b) is life-threatening, 
NOTE: The term 'life-threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe. 
c) requires hospitalization or prolongation of existing hospitalization, 
NOTE: In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or out-
patient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfils any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalization” occurred or was necessary, the 
AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE. 
d) results in disability/incapacity, 
NOTE: The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, 
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diarrhoea, influenza, and accidental trauma (e.g. sprained ankle) which may interfere or 
prevent everyday life functions but do not constitute a substantial disruption. 
e)  is a congenital anomaly/birth defect in the offspring of a study subject, 
f) medical or scientific judgement should be exercised in deciding whether reporting 
is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization but may 
jeopardize the subject or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These should also be 
considered serious. Examples of such events are invasive or malignant cancers, 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospitalization. 
8.3 Lack of efficacy 
“Lack of efficacy” per se will not be reported as an AE. The signs and symptoms or 
clinical sequelae resulting from lack of efficacy will be reported if they fulfil the AE or 
SAE definition (including clarifications). Any case of diphtheria, tetanus, pertussis, 
hepatitis B, invasive diseases due to Haemophilus influenzae type b, measles, yellow 
fever or Neisseria meningitidis of serogroup A and C will be reported to the Independent 
Data Monitoring Committee (IDMC).  
8.4 Clinical laboratory parameters and other abnormal assessments 
qualifying as adverse events and serious adverse events 
Abnormal laboratory findings (e.g., clinical chemistry, haematology, urinalysis) or other 
abnormal assessments (e.g., ECGs, X-rays, vital signs, etc.) that are judged by the 
investigator to be clinically significant will be recorded as AEs or SAEs if they meet the 
definition of an AE, as defined in Section 8.1 or SAE, as defined in Section 8.2. 
Clinically significant abnormal laboratory findings or other abnormal assessments that are 
detected during the study or are present at baseline and significantly worsen following the 
start of the study will be reported as AEs or SAEs. However, clinically significant 
abnormal laboratory findings or other abnormal assessments that are associated with the 
disease being studied, unless judged by the investigator as more severe than expected for 
the subject’s condition, or that are present or detected at the start of the study and do not 
worsen, will not be reported as AEs or SAEs. 
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The investigator will exercise his or her medical and scientific judgement in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
8.5 Time period, frequency, and method of detecting adverse events 
and serious adverse events 
All AEs occurring within one month (minimum 30 days) following administration of 
each dose of vaccine/ comparator must be recorded on the Adverse Event form in the 
subject's CRF, irrespective of severity or whether or not they are considered vaccination-
related. 
The standard time period for collecting and recording SAEs will begin at randomization 
or the first receipt of vaccine/ comparator and will end one month (minimum 30 days) 
following administration of the last dose of study vaccine/ comparator for each subject. 
See Section 8.8 for instructions for reporting and recording SAEs. 
Additionally, in order to fulfil international reporting obligations, SAEs that are related to 
study participation (e.g. procedures, invasive tests, a change from existing therapy) or are 
related to a concurrent medication will be collected and recorded from the time the 
subject consents to participate in the study until she/he is discharged. 
• The investigator will inquire about the occurrence of AEs/SAEs at every visit/contact 
during the study. 
All AEs either observed by the investigator or one of his clinical collaborators or reported 
by the subject’s parent/guardian spontaneously or in response to a direct question will be 
evaluated by the investigator. AEs not previously documented in the study will be 
recorded in the Adverse Event form within the subject's CRF. The nature of each event, 
date and time (where appropriate) of onset, outcome, intensity and relationship to 
vaccination should be established. Details of any corrective treatment should be recorded 
on the appropriate page of the CRF. Refer to Section 6.8. 
As a consistent method of soliciting AEs, the subject’s parent/guardian should be asked a 
non-leading question such as: 
"Has your child acted differently or felt different in any way since receiving the vaccine 
or since the last visit?"  
N.B. The investigator should record only those AEs having occurred within the time 
frame defined above. 
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AEs already documented in the CRF, i.e. at a previous assessment, and designated as 
‘ongoing’ should be reviewed at subsequent visits, as necessary. If these have resolved, 
the documentation in the CRF should be completed.  
N.B.  If an AE changes in frequency or intensity during the specified reporting period, a 
new record of the event will be entered. 
When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) relative 
to the event. The investigator will then record all relevant information regarding an 
AE/SAE on the CRF or SAE Report Form as applicable. It is not acceptable for the 
investigator to send photocopies of the subject’s medical records to GSK Biologicals in 
lieu of the appropriate completed AE/SAE pages. However, there may be instances when 
copies of medical records for certain cases are requested by GSK Biologicals. In this 
instance, all subject identifiers will be blinded on the copies of the medical records prior 
to submission to GSK Biologicals. 
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis should be 
documented as the AE/SAE and not the individual signs/symptoms. 
There will be a retrospective follow-up of SAE(s) (i.e. occurrence of any SAE(s) since 
the last study visit [Visit 7] up to the time that subjects are at least 24 months of age). 
(Amendment 7: 12 April 2006) 
8.5.1 Solicited adverse events 
Local (injection site) adverse events 
A four-day follow-up (day 0-3) of solicited local adverse events at each injection site will 
be performed after vaccination. Data concerning the following adverse events will be 
solicited using diary cards provided by the sponsor. 
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Table 8-1: Solicited local adverse events 
Pain at injection site 
Swelling at injection site 
General (systemic) adverse events 
A four-day follow-up (day 0-3) of solicited general adverse events will be performed after 
vaccination. Data concerning the following adverse events will be solicited using diary 
cards provided by the sponsor. 
Table 8-2: Solicited general adverse events 
Drowsiness 
Fever 
Irritability/ Fussiness 
Loss of appetite 
N.B.  Temperature will be recorded by axillary route by the field worker during the 
home visits. Should temperature measurement additionally be performed at another time 
of day, the highest temperature will be recorded. 
8.6 Evaluating adverse events and serious adverse events 
Field workers will be trained on the definition of adverse events including SAEs as per 
protocol definition, under the supervision of the principal investigator.  
8.6.1 Assessment of intensity 
Intensity of the following AEs will be assessed as described: 
Table 8-3: Intensity scales for solicited symptoms  
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Adverse Event Intensity grade Parameter 
Pain at injection site 0 Absent 
 1 Minor reaction to touch 
 2 Cries/protests on touch 
 3 Cries when limb is moved/spontaneously painful 
Swelling at injection site Record greatest surface diameter in mm 
Fever*  Record temperature in °C 
Irritability/Fussiness 0 Behavior as usual 
 1 Crying more than usual/ no effect on normal activity 
 2 Crying more than usual/ interferes with normal activity
 3 Crying that cannot be comforted/ prevents normal 
activity 
Drowsiness 0 Behavior as usual 
 1 Drowsiness easily tolerated 
 2 Drowsiness that interferes with normal activity 
 3 Drowsiness that prevents normal activity 
Loss of appetite 0 Normal 
 1 Eating less than usual/ no effect on normal activity 
 2 Eating less than usual/ interferes with normal activity 
 3 Not eating at all 
*Fever is defined as axillary temperature ≥ 37.5°C. 
The maximum intensity of local injection site swelling will be scored at GSK Biologicals 
as follows:  
0 : none 
1 : >0 - ≤ 10 mm 
2 : >10 - ≤ 30 mm 
3 : >30 mm 
The maximum intensity of fever* will be scored at GSK Biologicals as follows:  
  Axillary 
0 : <37.5°C 
1 : ≥37.5°C - ≤38.5°C 
2 : >38.5°C - ≤39.5°C 
3 : >39.5°C 
*  Temperature will be measured by the axillary route. 
For each solicited symptom, the subjects’ parents/guardians will be asked if they sought 
medical advice (i.e., contact with a member of medical personnel) for this symptom. 
The investigator will make an assessment of intensity for all other AEs, i.e. unsolicited 
symptoms, including SAEs reported during the study. The assessment will be based on 
the investigator’s clinical judgement. The intensity of each AE and SAE recorded in the 
CRF or SAE Report Form, as applicable, should be assigned to one of the following 
categories: 
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1 (mild) = An AE which is easily tolerated by the subject, causing 
minimal discomfort and not interfering with everyday 
activities. 
2 (moderate) = An AE which is sufficiently discomforting to interfere with 
normal everyday activities. 
3 (severe) = An AE which prevents normal, everyday activities. (In a 
young child, such an AE would, for example, prevent 
attendance at school/ kindergarten/ a day-care center and 
would cause the parents/ guardians to seek medical advice.) 
An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. 
Grade 3 is a category utilized for rating the intensity of an event; and both AEs 
and SAEs can be assessed as Grade 3. An event is defined as ‘serious’ when it 
meets one of the pre-defined outcomes as described in Section 8.2. 
8.6.2 Assessment of causality 
The investigator is obligated to assess the relationship between investigational product 
and the occurrence of each AE/SAE. The investigator will use clinical judgement to 
determine the relationship. Alternative causes, such as natural history of the underlying 
diseases, concomitant therapy, other risk factors and the temporal relationship of the 
event to the investigational product will be considered and investigated. The investigator 
will also consult the Investigator Brochure and/or Product Information, for marketed 
products, in the determination of his/her assessment. 
There may be situations when a SAE has occurred and the investigator has minimal 
information to include in the initial report to GSK Biologicals. However, it is very 
important that the investigator always makes an assessment of causality for every event 
prior to transmission of the SAE Report Form to GSK Biologicals. The investigator may 
change his/her opinion of causality in light of follow-up information, amending the SAE 
Report Form accordingly. The causality assessment is one of the criteria used when 
determining regulatory reporting requirements. 
In case of concomitant administration of multiple vaccines, it may not be possible to 
determine the causal relationship of general AEs to the individual vaccines administered. 
The investigator should, therefore, assess whether the AE could be causally related to 
vaccination rather than to the individual vaccines. 
All solicited local (injection site) reactions will be considered causally related to 
vaccination. Causality of all other AEs should be assessed by the investigator using the 
following question: 
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In your opinion, did the vaccine(s) possibly contribute to the adverse event? 
NO : The AE is not causally related to administration of the study 
vaccine(s). There are other, more likely causes and administration 
of the study vaccine(s) is not suspected to have contributed to the 
AE. 
YES : There is a reasonable possibility that the vaccine contributed to the 
AE.  
Non-serious and serious AEs will be evaluated as two distinct events. If an event meets 
the criteria to be determined “serious” (see Section 8.2 for definition of serious adverse 
event), it will be examined by the investigator to the extent to be able to determine ALL 
contributing factors applicable to each serious adverse event. 
Other possible contributors include: 
• Medical history 
• Other medication 
• Protocol required procedure 
• Other procedure not required by the protocol 
• Lack of efficacy of the vaccine 
• Erroneous administration 
• Other cause (specify) 
8.7 Follow-up of adverse events and serious adverse events and 
assessment of outcome 
After the initial AE/SAE report, the investigator is required to proactively follow each 
subject and provide further information to GSK Biologicals on the subject’s condition. 
All AEs and SAEs documented at a previous visit/contact and designated as not 
recovered/not resolved or recovering/resolving will be reviewed at subsequent 
visits/contacts. 
Investigators will follow-up subjects: 
(1) with SAEs or subjects withdrawn from the study as a result of an AE, until the event 
has resolved, subsided, stabilized, disappeared, the event is otherwise explained, or 
the subject is lost to follow-up;  
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(2) or, in the case of other non-serious AEs, until they complete the study or they are lost 
to follow-up.  
Clinically significant laboratory abnormalities will be followed up until they have 
returned to normal, or a satisfactory explanation has been provided. Reports relative to 
the subsequent course of an AE noted for any subject must be submitted to the Study 
Monitor. 
GSK Biologicals may request that the investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations to elucidate as fully as possible the nature 
and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies 
during participation in the study or during a recognized follow-up period, GSK 
Biologicals will be provided with a copy of any available post-mortem findings, including 
histopathology. In the case of a death, supplementary information will be gained using the 
verbal autopsy technique. This will be conducted according to previously published 
methods and detailed in the SOPs on file with the investigators. The Verbal Autopsy 
Questionnaire will be completed and transmitted by the investigator to GSK Biologicals, 
WHO and the Local Safety Monitor, in addition to the SAE report, irrespective of 
relationship to vaccination and whether a written autopsy was performed or not. The 
Standard Verbal Autopsy Questionnaire will not replace a written autopsy.  
New or updated information will be recorded on the originally completed SAE Report 
Form, with all changes signed and dated by the investigator. The updated SAE report 
form should be resent to GSK Biologicals within 24 hours of receipt of the follow-up 
information as outlined in Section 8.8.1. 
All SAEs will be reported within 24 hours by the investigator to GSK Biologicals safety 
department, to the local safety monitor and to the WHO study contact for SAE reporting. 
GSK Biologicals will transmit the information to the IDMC according to the operating 
procedures of the IDMC.  
In addition, the investigator will also provide a listing of all systemic grade 3 symptoms 
suspected to be related to vaccination and any case of diphtheria, tetanus, pertussis, 
hepatitis B, invasive diseases due to Haemophilus influenzae type b, measles, yellow 
fever or Neisseria meningitidis of serogroup A and C to the LSM. The Local Safety 
Monitor will send the listing and information related to the non-serious grade 3 systemic 
symptoms related with vaccination and non-serious adverse events suggesting a lack of 
efficacy of the vaccine to the IDMC and the GSK medical monitor (the GSK medical 
monitor will forward the information to the other members of the Steering Committee) 
according to the Charter for the IDMC.  
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Outcome of any non-serious AE occurring within 30 days post-vaccination (i.e. 
unsolicited AE) or any SAE reported during the entire study will be assessed as: 
1 : Recovered/resolved 
2 : Not recovered/not resolved 
3 : Recovering/resolving 
4 : Recovered/resolved with sequelae 
8.8 Prompt reporting of serious adverse events to GSK Biologicals, 
WHO and the local safety monitor  
8.8.1 Time frames for submitting serious adverse event reports to GSK Biologicals, 
WHO and the local safety monitor  
SAEs will be reported promptly to the LSM, GSK Biologicals and WHO once the 
investigator determines that the event meets the protocol definition of an SAE. The 
investigator or designate will transmit the SAE reports to GSK Biologicals’ Study 
Contact for Serious Adverse Event Reporting and to the WHO study contact for SAE 
reporting within 24 hours of his/her becoming aware of these events. Additional or 
follow-up information relating to the initial SAE report, including completed verbal 
autopsy questionnaire in case of death, is also to be reported to the GSK Biologicals’ 
Study Contact for Serious Adverse Event Reporting and to the WHO study contact for 
SAE reporting within 24 hours.  
GSK Biologicals will transmit the SAEs to the IDMC on a regular basis according to the 
Charter for the IDMC (see section 5.1.3).  
8.8.2 Completion and transmission of serious adverse event reports to GSK 
Biologicals, WHO and the local safety monitor  
Once an investigator becomes aware that a SAE has occurred in a study subject, she/he 
will report the information to GSK Biologicals and WHO within 24 hours and to the local 
safety monitor as outlined in Section 8.8.1. The SAE Report Form will always be 
completed as thoroughly as possible with all available details of the event, signed by the 
investigator (or designee), and forwarded to GSK Biologicals and WHO within the 
designated time frames. If the investigator does not have all information regarding an 
SAE, he/she will not wait to receive additional information before notifying GSK 
Biologicals and WHO of the event and completing the form. The form will be updated 
when additional information is received and forwarded to GSK Biologicals and WHO 
within 24 hours as outlined in Section 8.8.1.  
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The investigator will always provide an assessment of causality at the time of the initial 
report as described in Section 8.6.2. 
Facsimile (Fax) transmission of the SAE Report Form is the preferred method to transmit 
this information to the Study Contact for Reporting SAEs. In rare circumstances and in 
the absence of facsimile equipment, notification by telephone is acceptable, with a copy 
of the SAE Report Form sent by overnight mail. Initial notification via the telephone does 
not replace the need for the investigator to complete and sign the SAE Report Form 
within 24 hours as outlined in Section 8.8.1. 
In the event of a death determined by the investigator to be related to vaccination, sending 
of the fax must be accompanied by telephone call to the Study Contact for Reporting 
SAEs. 
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Study Contacts for Reporting SAEs 
Medical Monitor at GSK Biologicals 
Dr. Dominique Boutriau,  
Director, Clinical Research & Development, Meningitis vaccines 
GlaxoSmithKline Biologicals,  
Rue de l'Institut 89, 1330 Rixensart, Belgium 
Tel: +32.2.656.9120 
Fax: +32.2.656. 8044 
e-mail: dominique.boutriau@gskbio.com 
 
(Amendment 7: 12 April 2006) 
Local Safety Monitor 
Dr. John Williams, 
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: +233 742 22310/ 22380 
Fax: + 233 742 22320 
e-mail: jwilliams@navrongo.mimcom.net  
Local Safety Monitor Back-up 
Dr. Frank Baiden  
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: + 233 742 22310/ 22380 
Fax: + 233 742 22320 
e-mail: fbaiden@navrongo.mimcom.net  
 
Study Contact for SAE Reporting at WHO 
Dr. Zarifah Reed 
WHO/IVR/POP  
WHO/IVB/IVR/POP  
20 Avenue Appia 
CH-1211 GENEVE 27 
Switzerland 
Tel.  +41 22 791 4760 
Fax. +41 22 791 4860 
Email: reedz@who.int 
 
Continued on next page 
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Study Contacts for Reporting SAEs 
Back-up Study Contact for Reporting SAEs at GSK Biologicals 
GSK Biologicals Clinical Safety Physician 
Tel: +32-2-656 88 50 
Fax: +32-2-656 80 09/5116 
Mobile phone for 7/7 day availability: +32 477 404 713 or 32-(0) 474 53 48 68 
24/24 hour and 7/7 day availability 
 
(Amendment 7: 12 April 2006) 
8.9 Regulatory reporting requirements for serious adverse events 
The investigator will promptly report all SAEs to GSK Biologicals in accordance with the 
procedures detailed in Section 8.8. GSK Biologicals has a legal responsibility to promptly 
notify, as appropriate, both the local regulatory authority and other regulatory agencies 
about the safety of a product under clinical investigation. Prompt notification of SAEs by 
the investigator to the Study Contact for Reporting SAEs is essential so that legal 
obligations and ethical responsibilities towards the safety of other subjects are met. 
The investigator, or responsible person according to local requirements, will comply with 
the applicable local regulatory requirements related to the reporting of SAEs to regulatory 
authorities and the IRB/IEC. 
Expedited Investigator Safety Reports (EISR) are prepared according to GSK Biologicals 
policy and are forwarded to investigators as necessary. An EISR is prepared for a SAE 
that is both attributable to the investigational product and unexpected. The purpose of the 
EISR is to fulfil specific regulatory and Good Clinical Practice (GCP) requirements, 
regarding the product under investigation. 
An investigator who receives an EISR describing a SAE or other specific safety 
information from GSK Biologicals will file it with the Investigator Brochure and will 
notify the IRB/IEC, if appropriate according to local requirements.  
8.10 Post study adverse events and serious adverse events 
A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE 
detection period defined in Section 8.5. Investigators are not obligated to actively seek 
AEs or SAEs in former study participants. 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
80
However, if the investigator learns of any SAE, including a death, at any time after a 
subject has been discharged from the study, and he/she considers the event reasonably 
related to the investigational product, the investigator will promptly notify the Study 
Contact for Reporting SAEs. 
8.11 Treatment of adverse events 
Treatment of any adverse event is at the sole discretion of the investigator. Any AE will 
be treated for free according to good medical practice and standard of care in Ghana. 
Standard treatment of the common diseases in the study sites will be available in each 
facility (hospital, health centres) where the study will take place. Any medication 
administered for the treatment of an AE should be recorded in the subject’s CRF. Refer to 
Section 6.8. 
9 Subject Completion and Withdrawal 
9.1 Subject completion 
A subject who returns for the concluding visit/is available for the concluding contact 
foreseen in the protocol is considered to have completed the study. 
9.2 Subject withdrawal 
Subjects who are withdrawn for AEs must be clearly distinguished from subjects who are 
withdrawn for other reasons. Investigators will follow subjects who are withdrawn as 
result of a SAE/AE until resolution of the event (see Section 8.7). 
Withdrawals will not be replaced. 
9.2.1 Subject withdrawal from the study 
From an analysis perspective, a ‘withdrawal’ from the study is any subject who did not 
come back for the concluding visit foreseen in the protocol.  
A subject qualifies as a ‘withdrawal’ from the study when no study procedure has 
occurred, no follow-up has been performed and no further information has been collected 
for this subject from the date of withdrawal/last contact. 
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Investigators will make an attempt to contact those subjects who do not return for 
scheduled visits or follow-up.  
Information relative to the withdrawal will be documented on the Study Conclusion page 
of the CRF. It will be specified which of the following possible reasons were responsible 
for withdrawal: 
• serious adverse event 
• non-serious adverse event 
• protocol violation (specify) 
• consent withdrawal, not due to an adverse event 
• moved from the study area 
• lost to follow-up 
• other (specify) 
9.2.2 Subject withdrawal from investigational product 
A ‘withdrawal’ from the investigational product is any subject who does not receive the 
complete treatment, i.e. when no further planned dose is administered from the date of 
withdrawal. A subject withdrawn from the investigational product may not necessarily be 
withdrawn from the study as further study procedures or follow-up may be performed 
(safety or immunogenicity) if planned in the study protocol.  
Information relative to premature discontinuation of the investigational product will be 
documented on the Vaccine Administration page of the CRF. The investigator will 
document whether the decision to discontinue further vaccination was made by the the 
subject’s parent or guardian or the investigator and which of the following possible 
reasons was responsible for withdrawal: 
• serious adverse event, 
• non-serious adverse event, 
• other (specify). 
9.3 Extension study 
There will be a retrospective follow-up of SAE(s) that occurred since the last study visit 
[Visit 7] up to the time that subjects are at least 24 months of age. 
(Amendment 7: 12 April 2006) 
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9.4 Screen and baseline failures 
Not applicable. 
10 Data Evaluation: Criteria for Evaluation of Objectives 
Note: Data collected for the ancillary study will be provided to the investigators of the 
ancillary study for evaluation (refer to Appendix H and Section 5.2). 
10.1 Co-primary endpoints 
Immunogenicity: post-primary vaccination 
In all subjects, one month after the 3rd dose of the primary vaccination:  
• Serum bactericidal antibody titer (MenC) ≥1:8 (seropositivity) 
• Serum bactericidal antibody titer (MenA) ≥1:8 (seropositivity) 
• Anti-PRP concentration ≥ 1 µg/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-tetanus concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-diphtheria concentration ≥ 0.1 IU/ml by ELISA and, if negative, ≥ 0.016 IU/ml 
by Vero-cell (seroprotection) 
• Concentration of anti-BP antibodies 
10.2 Secondary endpoints 
Immunogenicity  
Pre-primary vaccination 
In all subjects, just prior to the administration of the 1st dose of the primary vaccination 
• SBA-MenA titer ≥ 1:8 (seropositivity) 
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml 
• Anti-diphtheria concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-BP concentration ≥ 15 EL.U/ml (seropositivity) 
• Concentration/titers of SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, anti-HBs, anti-
diphtheria and anti-BP antibodies 
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Post-primary vaccination: 
In all subjects, one month after the 3rd dose of the primary vaccination: 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Anti-PRP concentration ≥ 0.15 µg/ml (seroprotection) 
• Anti-BP concentration ≥15 EL.U/ml  
Titers/Concentrations of all antibodies but anti-BP (see co-primary endpoints) 
Antibody persistence:   
In all subjects, at twelve months of age, just prior to the administration of 1/5 of a dose of 
Mencevax AC:  
• SBA-MenA titer ≥ 1:8 (seropositivity)  
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Anti-PRP concentration ≥ 0.15 µg/ml (seroprotection) 
• Anti-PRP concentration ≥ 1 µg/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-tetanus concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-diphtheria concentration ≥ 0.1 IU/ml by ELISA and, if negative, ≥ 0.016 IU/ml 
by Vero-cell (seroprotection) 
• Anti-BP concentration ≥ 15 EL.U/ml (seropositivity) 
• Concentration/titers of SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, anti-PRP, anti-
HBs, anti-tetanus, anti-diphtheria and anti-BP antibodies.  
Immune memory:  
In all subjects, one month after the administration of 1/5 of a dose of Mencevax AC: 
• SBA-MenA titer ≥ 1:8 (seropositivity)  
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml  
• Concentration/titers of SBA-MenA, SBA-MenC, anti-PSA and anti-PSC antibodies.  
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Reactogenicity and safety: 
After each vaccine dose: 
• Occurrence of solicited symptoms (during the 4-day follow-up period) 
Local: Pain and swelling at the injection site 
General:  Drowsiness, Fever, Irritability/ Fussiness, Loss of appetite 
• Occurrence of unsolicited symptoms (during the 30-day follow-up period) 
Over the full course of the study: 
• Occurrence of serious adverse events 
10.3 Estimated sample size 
The target sample size is 280 enrolled subjects to reach 220 evaluable subjects in the ATP 
cohort for immunogenicity (110 evaluable subjects in each group). Refer to Section 10.4 
for definition of study cohorts.  
The co-primary objectives of the study are: 
One month after primary vaccination: 
• To demonstrate the immunogenicity of Tritanrix™-HepB/Hib-MenAC with respect to 
SBA-MenA and SBA-MenC. 
• To demonstrate that Tritanrix™-HepB/Hib-MenAC is non-inferior to the control 
vaccine Tritanrix™-HepB/ Hiberix™ with respect to the immunogenicity of all 
common antigens (anti-PRP, anti-Diphtheria, anti-Tetanus, anti-BP, and anti-HBs). 
Criteria to achieve the co-primary objectives: 
1. Immunogenicity of SBA-MenA and SBA-MenC: lower limit of the 95% CI for the 
percentage of subjects with SBA-MenA titers (respectively SBA-MenC titers) ≥ 1:8 is 
greater than 80%. 
2. Non-inferiority for all common antigens: upper limit of the 95% CI for the group 
difference in terms of the percentage of subjects with anti-PRP concentration 
≥ 1 µg/ml (respectively, anti-diphtheria concentration ≥ 0.1 IU/ml, anti-tetanus 
concentration ≥ 0.1 IU/ml, anti-HBs concentration ≥ 10 mIU/ml) is below 10% and 
upper limit of the 95% CI for the group GMC ratio in anti-BP is below 1.5. 
In order to cope with the multiplicity of the objectives, the criteria of the objectives will 
be assessed sequentially and will lead to a conclusion only if all previous primary criteria 
have been met (refer to Section 10.6.2). Table 10-1 and Table 10-2 present the order in 
which the criteria will be assessed (see Rank), the power to meet each criterion and the 
power to meet all previous criteria (see cumulative power). For instance, the power to 
meet the first primary objective and non-inferiority for anti-PRP will be 78.6% assuming 
that the 2 vaccine groups are identical with respect to the primary endpoints. 
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Table 10-1: Power for criterion 1 (one-sided test on one proportion, alpha=0.025, 
N=110/group, power for H0: p = 80% under the alternative hypothesis Ha: p = 94%, 
power calculated using PASS 2000) 
Rank Endpoint Reference Individual Power Cumulative power 
1 SBA Men C = 1:8 94% 99.4% 99.4% 
2 SBA Men A = 1:8 94% 99.4% 98.8% 
Reference: MenAC-Hib-001 
 
Table 10-2: Power for criterion 2 (For all antigens except anti-BP: one-sided test of 
equivalence of two proportions, alpha=0.025, N=110/group, power calculated using 
PASS 2000, assuming identical seroprotection rates for the two groups; for anti-BP: one-
sided t-test of equivalence of two means, alpha = 0.025, N = 110/group, power 
calculated using nQuery 4 and assuming identical GMCs for the two groups.) 
 
Rank Endpoint Reference Individual 
Power 
Cumulative 
power 
3 Anti-PRP = 1 µg/ml 94% 79.8% 78.6% 
4 Anti-tetanus = 0.1 IU/ml 98% 97.9% 76.5% 
5 Anti-Diphtheria = 0.1 IU/ml by ELISA and,
if negative, ≥ 0.016 IU/ml by Vero-cell 
96% 89.1% 65.6% 
6 GMC of anti-BP 0.298* 99.0% 64.9% 
7 Anti-HBs = 10 mIU/ml 95% 84.4% 49.0% 
*standard deviation of log10 (concentration) 
References: MenAC-Hib-001 for % of anti-PRP, Hib-065 for % of anti-tetanus, anti-diphtheria (by ELISA 
only) and anti-HBs, DTPw-HBV-033 for s.d. of log10 (concentration) for anti-BP.  
It is acknowledged that the power to meet all primary objectives is low (at worst 49.0%). 
However, considering this is a Phase II feasibility study, the low power is deemed 
acceptable. 
10.4 Study cohorts to be evaluated 
A total of 6 cohorts are defined for the purpose of analysis.  
• Three cohorts that will be used for the analysis of the primary vaccination course: 
! the Total vaccinated cohort  
! the ATP cohort for safety 
! the ATP cohort for immunogenicity (used for the analysis of the co-primary 
objectives of immunogenicity) 
 
• Three cohorts that will be used for the analysis of the booster phase: 
! the Total vaccinated cohort  
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! the ATP cohort for safety 
! the ATP cohort for immune memory 
 
The Total vaccinated cohort (Primary vaccination)  
The Total vaccinated cohort will include all subjects vaccinated in the primary phase of 
the study. For the Total analysis of safety, this will include all subjects vaccinated in the 
primary phase of the study with at least one vaccine administration documented in the 
primary phase. For the Total analysis of immunogenicity / efficacy, this will include 
subjects vaccinated in the primary phase of the study for whom data concerning 
immunogenicity/efficacy endpoint measures are available. The Total vaccinated cohort 
analysis will be performed per treatment actually administered.  
According to protocol (ATP) cohort for safety (Primary vaccination)  
The According to protocol (ATP) cohort for safety will include all subjects:  
• who have received at least one dose of study vaccine/control according to their 
random assignment, 
• with sufficient data to perform an analysis of safety, 
• for whom the administration route of study vaccine/control is known and correct, 
• who have not received a vaccine not specified or forbidden in the protocol, 
• who did not receive a replacement vaccine, 
during the primary vaccination course. 
According to protocol (ATP) cohort for immunogenicity (Primary vaccination)  
The According to protocol (ATP) cohort for immunogenicity will include all evaluable 
subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined 
in the protocol, and with no elimination criteria during the study) from the ATP cohort for 
safety for whom assay results are available for antibodies against at least one study 
vaccine antigen component at Visit 4.  
The Total vaccinated cohort (Booster vaccination)  
The Total vaccinated cohort will include all subjects vaccinated in the booster phase of 
the study. For the Total analysis of safety, this will include all subjects vaccinated in the 
booster phase of the study with at least one vaccine administration documented in the 
booster phase. For the Total analysis of immunogenicity/efficacity, this will include 
subjects vaccinated in the booster phase of the study for whom data concerning 
immunogenicity / efficacy endpoint measures are available. The Total vaccinated cohort 
analysis will be performed per treatment actually administered.  
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According To Protocol (ATP) cohort for safety (Booster vaccination)  
The ATP cohort for safety will include all subjects from the ATP cohort (Primary 
vaccination) for safety  
• who have received the 3 doses in the primary vaccination course, 
• who have received the booster dose, 
• with documented safety follow-up, 
• for whom administration route of Mencevax™ AC is known, 
• who have not received a vaccine not specified or forbidden in the protocol. 
This cohort will also be used for the analysis of persistence of the immune response.  
According To Protocol (ATP) cohort for immune memory 
 
The ATP cohort for immune memory will include all evaluable subjects (i.e., those 
meeting all eligibility criteria, complying with the procedures defined in the protocol, 
with no elimination criteria during the study) from the Booster ATP cohort for safety for 
whom assay results are available for antibodies against at least one study vaccine antigen 
component at Visit 7. 
10.5 Derived and transformed data 
Immunogenicity 
For a given subject cohort and the analysis of a given measurement, missing or 
unevaluable measurements will not be replaced. Therefore an analysis will exclude 
subjects with missing or unevaluable measurements. 
• The cut-off value is defined by the laboratory before the analysis and is described in 
Section 5.5.2. 
• A seronegative subject is a subject whose titer or concentration is below the cut-off 
value. 
• A seropositive subject is a subject whose titer or concentration is greater than or equal 
to the cut-off value. 
• Antibody concentrations or titers below the cut-off of the assay will be given an 
arbitrary value of half the cut-off for the purpose of GMC or GMT calculation.  
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Other 
Subjects who missed reporting symptoms (solicited or unsolicited or concomitant 
medications) will be treated as subjects without symptoms (solicited or unsolicited or 
concomitant medications, respectively). 
10.6 Final analyses for the primary vaccination course 
10.6.1 Analysis of demographics/baseline characteristics 
Demographic characteristics (age in weeks, gender, race) of each study cohort will be 
tabulated. 
The mean age (plus range and standard deviation) by gender of the enrolled subjects, as a 
whole, and per group, will be calculated. 
The distribution of subjects enrolled among the study sites will be tabulated as a whole 
and per group. 
10.6.2 Analysis of Immunogenicity 
The analysis of immunogenicity will be based on the ATP cohort for immunogenicity. If, 
for any vaccine group, the percentage of enrolled subjects with serological results 
excluded from this ATP cohort is more than 5%, a second analysis based on the Total 
vaccinated cohort will be performed to complement the ATP analysis.  
Analysis of immunogenicity will be as follows: 
Descriptive analysis 
 
For each treatment group, one month after the third dose of the primary vaccination 
course, and in the mother prior to her child’s vaccination, for each serological assay done: 
• Geometric Mean antibody Concentrations/Titers (GMCs/GMTs) with 95% 
confidence intervals (CIs) will be tabulated for each antibody. Calculation of the 
GMCs/GMTs is performed by taking the anti-log of the mean of the log 
concentration/titer transformations.  
• Seropositivity / seroprotection rates with exact 95% CIs will be calculated. 
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• Antibody concentrations/titers post-vaccination will also be investigated using reverse 
cumulative curves for each antigen and serogroup. 
Inferential analysis   
The inferential analysis will be done sequentially. 
1. If the lower limit of the 95% CI for the percentage of subjects with SBA-MenC is 
above 80%, one will conclude that Tritanrix™-HepB/Hib-MenAC is immunogenic 
for MenC. 
2. If, in addition, the lower limit of the 95% CI of subjects with SBA-MenA is above 
80%, one will conclude that Tritanrix™-HepB/Hib-MenAC is immunogenic for 
MenA. 
3. If, in addition, the upper limit of the 95% CI for the group difference for anti-PRP is 
below 10% one will conclude non-inferiority with respect to anti-PRP. 
4. If, in addition, the upper limit of the 95% CI for the group difference for anti-Tetanus 
is below 10% one will conclude non-inferiority with respect to anti-Tetanus. 
5. If, in addition, the upper limit of the 95% CI for the group difference for anti-
Diphtheria is below 10% one will conclude non-inferiority with respect to anti-
Diphtheria. 
6. If, in addition, the upper limit of the 95% CI for the anti-BP GMC ratio (control 
vaccine / new vaccine) is below 1.5 one will conclude non-inferiority with respect to 
anti-BP. 
7. If, in addition, the upper limit of the 95% CI for the group difference for anti-HBs is 
below 10% one will conclude non-inferiority with respect to anti-HBs. 
10.6.3 Analysis of Safety 
The primary analysis will be based on the Total vaccinated cohort. If the percentage of 
enrolled subjects excluded from the ATP cohort for safety is more than 5%, a second 
analysis based on this ATP cohort will be performed to complement the Total vaccinated 
cohort analysis.  
The percentage of subjects with at least one local adverse event (solicited and 
unsolicited), with at least one general adverse event (solicited and unsolicited) and with 
any adverse event during the 4-day solicited follow-up period will be tabulated with exact 
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95% CI after each vaccine dose and overall. The percentage of doses followed by at least 
one local adverse event (solicited and unsolicited), by at least one general adverse event 
(solicited and unsolicited) and by any adverse event will be tabulated, overall vaccination 
course, with exact 95% CI. 
The percentage of subjects reporting each individual solicited local and general adverse 
event during the 4-day solicited follow-up period will be tabulated with exact 95% CI. 
The percentage of doses followed by each individual solicited local and general adverse 
event will be tabulated, overall vaccination course, with exact 95% CI. 
The same tabulation will be performed for grade 3 adverse events and for adverse events 
with relationship to vaccination. 
The proportion of subjects with at least one report of unsolicited adverse event classified 
by the Medical Dictionary for Regulatory Activities (MedDRA), and reported up to 30 
days after vaccination will be tabulated with exact 95% CI. The same tabulation will be 
performed for grade 3 unsolicited adverse events and for unsolicited adverse events with 
a relationship to vaccination. 
Serious adverse events and withdrawal due to adverse event(s) will be described in detail. 
10.7 Final Analyses for the booster vaccination 
10.7.1 Analysis of immunogenicity 
The analysis of antibody persistence and the analysis of immune memory will be 
respectively based on the ATP cohort for safety and the ATP cohort for immune memory. 
If, for any vaccine group, the percentage of enrolled subjects with serological results 
excluded from an ATP cohort is more than 5%, a second analysis based on the Total 
vaccinated cohort will be performed to complement the ATP analysis.  
The analysis of immunogenicity will be as follows: 
Analysis of antibody persistence  
For each treatment group, one month after the third dose of the primary vaccination 
course and just before the administration of one fifth of a dose of Mencevax™ AC: 
• Geometric Mean antibody Concentrations/Titers (GMCs/GMTs) with 95% 
confidence intervals (CIs) will be tabulated for each antibody. Calculation of the 
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GMCs/GMTs is performed by taking the anti-log of the mean of the log 
concentration/titer transformations.  
• Seropositivity / seroprotection rates with exact 95% CIs will be calculated. 
• Antibody concentrations/titers pre-booster will also be investigated using reverse 
cumulative curves for each antigen and serotype. 
Analysis of immune memory 
For each treatment group, just before and one month after the administration of one fifth 
of a dose of Mencevax™ AC: 
• Geometric Mean antibody Concentrations/Titers (GMCs/GMTs) with 95% 
confidence intervals (CIs) will be tabulated for each antibody. Calculation of the 
GMCs/GMTs is performed by taking the anti-log of the mean of the log 
concentration/titer transformations. 
• Seropositivity / seroprotection rates with exact 95% CIs will be calculated. 
• Antibody concentrations/titers post-booster will also be investigated using reverse 
cumulative curves for each antigen and serotype. 
The ratio of the GMCs/GMTs between the TritanrixTM-HepB/Hib-MenAC group and the 
TritanrixTM-HepB/HiberixTM group one month after the administration of one fifth of a 
dose of Mencevax™ AC, will be computed with its 95% CI. The ratio and its 95% CI will 
be computed using an ANOVA model on the log-transformed concentration/titer with 
group effect as regressor. 
10.7.2 Analysis of safety 
All analyses will be based on the Total vaccinated cohort. If the percentage of enrolled 
subjects excluded from the ATP cohort for safety is more than 5%, a second analysis 
based on this ATP cohort will be performed to complement the Total vaccinated cohort 
analysis.  
The percentage of subjects with at least one local adverse event (solicited and 
unsolicited), with at least one general adverse event (solicited and unsolicited) and with 
any adverse event during the 4-day solicited follow-up period will be tabulated with exact 
95% CI after each vaccine dose and overall. 
759346/009 (DTPwHB/HIBMenACTT009)  GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
92
The percentage of subjects reporting each individual solicited local and general adverse 
event during the 4-day solicited follow-up period will be tabulated with exact 95% CI. 
The same tabulation will be performed for grade 3 adverse events and for adverse events 
with relationship to vaccination. 
The proportion of subjects with at least one report of unsolicited adverse event classified 
by the Medical Dictionary for Regulatory Activities (MedDRA), and reported up to 30 
days after vaccination will be tabulated with exact 95% CI. The same tabulation will be 
performed for grade 3 unsolicited adverse events and for unsolicited adverse events with 
a relationship to vaccination. 
Serious adverse events and withdrawal due to adverse event(s) will be described in detail. 
10.8 Reporting of final analyses 
A final analysis for the primary vaccination course will be carried out as soon as all data 
up to Visit 4 have been collected in order to analyse the immunogenicity endpoints 
(including the co-primary endpoints) and the analysis of safety/reactogenicity for the 
primary vaccination course (refer to Section 10.6 for details about this analysis). A report 
based on this analysis will be written and will be made available to the Principal 
Investigator and the sponsors involved in this study. The access to the individual 
treatment code will be limited to the statistician in charge of this analysis. 
A final analysis for the booster vaccination will be carried out based on all data collected 
up to one month after the administration of one fifth of a dose of Mencevax™ AC. An 
annex report based on the final analysis for the booster vaccination will be provided.  
Serious adverse events reported during the extended follow-up period (i.e. from visit 7 
up to 24 months of age) will be reported in a separate annex report. 
 
(Amendment 7: 12 April 2006) 
10.9 Planned interim analysis 
No interim analysis is planned. 
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11 Administrative Matters 
To comply with Good Clinical Practice important administrative obligations relating to 
investigator responsibilities, monitoring, archiving data, audits, confidentiality and 
publications must be fulfilled. See Appendix B for details. 
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Appendix  A: World Medical Association Declaration of Helsinki 
Recommendations guiding physicians 
in biomedical research involving human subjects 
Adopted by the 18th World Medical Assembly 
Helsinki, Finland, June 1964 
and amended by the  
29th World Medical Assembly 
Tokyo, Japan, October 1975 
35th World Medical Assembly 
Venice, Italy, October 1983 
41st World Medical Assembly 
Hong Kong, September 1989 
and the 
48th General Assembly 
Somerset West, Republic of South Africa, October 1996 
INTRODUCTION 
It is the mission of the physician to safeguard the health of the people. His or her 
knowledge and conscience are dedicated to the fulfilment of this mission. 
The Declaration of Geneva of the World Medical Association binds the physician with 
the words, "The health of my patient will be my first consideration," and the International 
Code of Medical Ethics declares that, "A physician shall act only in the patient's interest 
when providing medical care which might have the effect of weakening the physical and 
mental condition of the patient." 
The purpose of biomedical research involving human subjects must be to improve 
diagnostic, therapeutic and prophylactic procedures and the understanding of the etiology 
and pathogenesis of disease. 
In current medical practice most diagnostic, therapeutic or prophylactic procedures 
involve hazards. This applies especially to biomedical research. 
Medical progress is based on research which ultimately must rest in part on 
experimentation involving human subjects. 
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In the field of biomedical research a fundamental distinction must be recognized between 
medical research in which the aim is essentially diagnostic or therapeutic for a patient, 
and medical research, the essential object of which is purely scientific and without 
implying direct diagnostic or therapeutic value to the person subjected to the research. 
Special caution must be exercised in the conduct of research which may affect the 
environment, and the welfare of animals used for research must be respected. 
Because it is essential that the results of laboratory experiments be applied to human 
beings to further scientific knowledge and to help suffering humanity, the World Medical 
Association has prepared the following recommendations as a guide to every physician in 
biomedical research involving human subjects. They should be kept under review in the 
future. It must be stressed that the standards as drafted are only a guide to physicians all 
over the world. Physicians are not relieved from criminal, civil and ethical responsibilities 
under the laws of their own countries. 
I. BASIC PRINCIPLES 
1. Biomedical research involving human subjects must conform to generally accepted 
scientific principles and should be based on adequately performed laboratory and 
animal experimentation and on a thorough knowledge of the scientific literature. 
2. The design and performance of each experimental procedure involving human 
subjects should be clearly formulated in an experimental protocol which should be 
transmitted for consideration, comment and guidance to a specially appointed 
committee independent of the investigator and the sponsor provided that this 
independent committee is in conformity with the laws and regulations of the country 
in which the research experiment is performed. 
3. Biomedical research involving human subjects should be conducted only by 
scientifically qualified persons and under the supervision of a clinically competent 
medical person. The responsibility for the human subject must always rest with a 
medically qualified person and never rest on the subject of research, even though the 
subject has given his or her consent. 
4. Biomedical research involving human subjects cannot legitimately be carried out 
unless the importance of the objective is in proportion to the inherent risk to the 
subject. 
5. Every biomedical research project involving human subjects should be preceded by 
careful assessment of predictable risks in comparison with foreseeable benefits to the 
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subject or to others. Concern for the interests of the subject must always prevail over 
the interests of science and society. 
6. The right of the research subject to safeguard his or her integrity must always be 
respected. Every precaution should be taken to respect the privacy of the subject and 
to minimize the impact of the study on the subject's physical and mental integrity and 
on the personality of the subject. 
7. Physicians should abstain from engaging in research projects involving human 
subjects unless they are satisfied that the hazards involved are believed to be 
predictable. Physicians should cease any investigation if the hazards are found to 
outweigh the potential benefits. 
8. In publication of the results of his or her research, the physician is obliged to preserve 
the accuracy of the results. Reports of experimentation not in accordance with the 
principles laid down in this Declaration should not be accepted for publication. 
9. In any research on human beings, each potential subject must be adequately informed 
of the aims, methods, anticipated benefits and potential hazards of the study and the 
discomfort it may entail. He or she should be informed that he or she is at liberty to 
abstain from participation in the study and that he or she is free to withdraw his or her 
consent to participation at any time. The physician should then obtain the subject's 
freely-given informed consent, preferably in writing. 
10. When obtaining informed consent for the research project the physician should be 
particularly cautious if the subject is in a dependent relationship to him or her or may 
consent under duress. In that case the informed consent should be obtained by a 
physician who is not engaged in the investigation and who is completely independent 
of this official relationship. 
11. In case of legal incompetence, informed consent should be obtained from the legal 
guardian in accordance with national legislation. Where physical or mental incapacity 
makes it impossible to obtain informed consent, or when the subject is a minor, 
permission from the responsible relative replaces that of the subject in accordance 
with national legislation. 
Whenever the minor child is in fact able to give a consent, the minor's consent must 
be obtained in addition to the consent of the minor's legal guardian. 
12. The research protocol should always contain a statement of the ethical considerations 
involved and should indicate that the principles enunciated in the present Declaration 
are complied with. 
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II. MEDICAL RESEARCH COMBINED WITH PROFESSIONAL CARE 
(Clinical research) 
1. In the treatment of the sick person, the physician must be free to use a new diagnostic 
and therapeutic measure, if in his or her judgement it offers hope of saving life, re-
establishing health or alleviating suffering. 
2. The potential benefits, hazards and discomfort of a new method should be weighed 
against the advantages of the best current diagnostic and therapeutic methods. 
3. In any medical study, every patient - including those of a control group, if any - 
should be assured of the best proven diagnostic and therapeutic method. This does not 
exclude the use of inert placebo in studies where no proven diagnostic or therapeutic 
method exists. 
4. The refusal of the patient to participate in a study must never interfere with the 
physician–patient relationship. 
5. If the physician considers it essential not to obtain informed consent, the specific 
reasons for this proposal should be stated in the experimental protocol for 
transmission to the independent committee (I, 2). 
6. The Physician can combine medical research with professional care, the objective 
being the acquisition of new medical knowledge, only to the extent that medical 
research is justified by its potential diagnostic or therapeutic value for the patient. 
III. NON-THERAPEUTIC BIOMEDICAL RESEARCH INVOLVING HUMAN 
SUBJECTS 
(Non-clinical biomedical research) 
1. In the purely scientific application of medical research carried out on a human being, 
it is the duty of the physician to remain the protector of the life and health of that 
person on whom biomedical research is being carried out. 
2. The subjects should be volunteers - either healthy persons or patients for whom the 
experimental design is not related to the patient's illness. 
3. The investigator or the investigating team should discontinue the research if in his/her 
or their judgement it may, if continued, be harmful to the individual. 
4. In research on man, the interest of science and society should never take precedence 
over considerations related to the well being of the subject.
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Appendix  B: Administrative Matters 
I. Responsibilities of the Investigator 
• To ensure that he/she has sufficient time to conduct and complete the study and has 
adequate staff and appropriate facilities and equipment which are available for the 
duration of the study and to ensure that other studies do not divert essential subjects or 
facilities away from the study at hand. 
• To submit an up-to-date curriculum vitae and other credentials (e.g., medical license 
number in the United States) to GSK Biologicals and—where required—to relevant 
authorities. 
• To acquire the normal ranges for laboratory tests performed locally and, if required by 
local regulations, obtain the Laboratory License or Certification. 
• To ensure that no clinical samples (including serum samples) are retained on site or 
elsewhere without the approval of GSK Biologicals and the express written informed 
consent of the subject and/or the subject’s legally authorized representative. 
• To perform no other biological assays at the investigator site except those described in 
the protocol or its amendment(s). 
• To prepare and maintain adequate case histories designed to record observations and 
other data pertinent to the study. 
• To conduct the study in compliance with the protocol and appendices. 
• To co-operate with a representative of GSK Biologicals in the monitoring process of 
the study and in resolution of queries about the data. 
II. Protocol Amendments and Modifications 
• No changes to the study protocol will be allowed unless discussed in detail with GSK 
Biologicals' Clinical Development Manager/Medical Monitor and filed as an 
amendment/modification to this protocol. 
• Any amendment/modification to the protocol will be adhered to by the participating 
center(s) and will apply to all subjects. Written IRB/IEC approval of protocol 
amendments is required prior to implementation; modifications are submitted to 
IRBs/IECs for information only. 
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III. Sponsor’s Termination of Study 
GSK Biologicals reserves the right to discontinue the clinical study at any time for 
medical or administrative reasons. When feasible, a 30-day written notification will be 
tendered. 
IV. Case Report Form Instructions  
Prior to screening the first potential participant, the investigator will provide the Site 
Monitor with a list (Site Staff Signature Sheet) showing the signature and hand-written 
initials of all individuals authorized to make or change entries on CRFs (already defined). 
If the authorized individuals should change during the study, the investigator is to inform 
GSK Biologicals of the specific change(s). 
CRFs (and subject diary cards, if applicable), will be supplied by GSK Biologicals for 
recording all data. It is the responsibility of the investigator or co-investigator to ensure 
that CRFs (and subject diary cards) are legible and completely filled in with a black ink 
fountain or ballpoint pen. 
Errors must be corrected by drawing a single line through the incorrect entry and writing 
in the new value/data positioned as close to the original as possible. The correction must 
then be initialled, dated and justified, where necessary, by the authorized individual 
making the change. The original entry must not be obliterated, overwritten or erased 
when a correction is made. 
When a subject completes a visit, it is anticipated that relevant sections of the CRF will 
be completed by the investigator (or designated staff as documented in the Site Staff 
Signature Sheet) as soon as possible after the last data becoming available. Similarly, 
when a subject completes a study, it is anticipated that all relevant CRF pages will be 
completed promptly after the last data becoming available. This also applies to forms for 
potential study participants who were screened but not randomized to a study group. 
As soon as the subject has completed/withdrawn from the study and the CRF is 
completed, the principal investigator or designated physician(s) under his/her supervision 
will sign the study conclusion pages of the CRF to confirm that they have reviewed the 
data and that the data are complete and accurate. In all cases the investigator remains 
accountable for the study data collected. 
An original (top copy) CRF or log sheets must be submitted for all subjects who have 
undergone protocol specific procedures, whether or not the subject completed the study. 
While completed CRFs are reviewed by a GSK Biologicals professional monitor at the 
study site, errors detected by subsequent in-house CRF review may necessitate 
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clarification or correction of errors with documentation and approval by the investigator 
or appropriately qualified staff as documented on the Site Staff Signature Sheet. In all 
cases, the investigator remains accountable for the study data. Wherever possible the 
investigator should assist in the clarification or correction of errors detected after study 
finalization promptly after being brought to the attention of the investigator (preferably 
within 48 hours). 
Any questions or comments related to the CRF should be directed to the assigned Site 
Monitor. 
V. Monitoring by GSK Biologicals 
Monitoring visits by a professional representative of GSK Biologicals will be scheduled 
to take place as close as possible to entry of the first subject, during the study at 
appropriate intervals and after the last subject has completed the study. It is anticipated 
that monitoring visits will occur at a frequency defined before study start.  
These visits are for the purpose of confirming that GSK Biologicals’ sponsored studies 
are being conducted in compliance with the relevant Good Clinical Practice regulations/ 
guidelines, verifying adherence to the protocol and the completeness and accuracy of data 
entered on the CRF pages and Vaccine Inventory Forms. The monitor will verify CRF 
entries by comparing them with the source data/documents that will be made available by 
the investigator for this purpose. Data to be recorded directly into the CRF pages will be 
specified in writing preferably in the source documentation agreement form that is 
contained in both the monitor’s and investigator’s study file. The investigator must ensure 
provision of reasonable time, space and adequate qualified personnel for monitoring 
visits. 
Monitoring by WHO 
Independent WHO monitors will visit the study site to monitor procedures/data. 
VI. Archiving of Data 
A study report will be written after the statistical analysis. This report, including all 
individual data, will be given to the sponsors of the study and to the principal 
investigator. 
Following closure of the study, the investigator must maintain all site study records in a 
safe and secure location.  The records must be maintained to allow easy and timely 
retrieval, when needed (e.g., audit or inspection), and, whenever feasible, to allow any 
subsequent review of data in conjunction with assessment of the facility, supporting 
systems, and staff.  Where permitted by applicable laws/regulations or institutional 
policy, some or all of these records can be maintained in a validated format other than 
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hard copy (e.g., microfiche, scanned, electronic for studies with an eCRF, for example); 
however, caution needs to be exercised before such action is taken. The investigator must 
assure that all reproductions are legible and are a true and accurate copy of the original, 
and meet accessibility and retrieval standards, including re-generating a hard copy, if 
required.  Furthermore, the investigator must ensure there is an acceptable back-up of 
these reproductions and that an acceptable quality control process exists for making these 
reproductions. 
GSK will inform the investigator/ institution of the time period for retaining these records 
to comply with all applicable regulatory requirements. However, the investigator/ 
institution should seek the written approval of the sponsors before proceeding with the 
disposal of these records. The minimum retention time will meet the strictest standard 
applicable to that site for the study, as dictated by ICH GCP E6 Section 4.9, any 
institutional requirements or applicable laws or regulations, or GSK Biologicals 
standards/procedures; otherwise, the minimum retention period will default to 15 years.  
The investigator/ institution must notify GSK Biologicals of any changes in the archival 
arrangements, including, but not limited to, the following: archival at an off-site facility, 
transfer of ownership of the records in the event the investigator leaves the site.  
VII. Audits 
For the purpose of compliance with Good Clinical Practice and Regulatory Agency 
Guidelines it may be necessary for GSK Biologicals or a Drug Regulatory Agency to 
conduct a site audit. This may occur at any time from start to after conclusion of the 
study. 
When an investigator signs the protocol, he/she agrees to permit drug regulatory agencies 
and GSK Biologicals audits, providing direct access to source data/ documents. 
Furthermore, if an investigator refuses an inspection, his/her data will not be accepted in 
support of a New Drug Registration and/or Application, Biologics Licensing Application. 
GSK Biologicals has made and is making a substantial investment in clinical studies. 
Having the highest quality data and studies are essential aspects of vaccine development. 
GSK Biologicals has a Regulatory Compliance staff who audit investigational sites. 
Regulatory Compliance assesses the quality of data with regard to accuracy, adequacy and 
consistency. In addition, Regulatory Compliance assures that GSK Biologicals sponsored 
studies are in accordance with GCP and that relevant regulations/guidelines are being 
followed. 
To accomplish these functions, Regulatory Compliance selects investigational sites to 
audit. These audits usually take 1 to 2 days. The GSK Biologicals’ audits entail review of 
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source documents supporting the adequacy and accuracy of CRFs, review of 
documentation required to be maintained, and checks on vaccine accountability. The 
GSK Biologicals’ audit therefore helps prepare an investigator for a possible regulatory 
agency inspection as well as assuring GSK Biologicals of the validity of the database 
across investigational sites. 
The Inspector will be especially interested in the following items: 
• Log of visits from the sponsors’ representatives 
• IRB/IEC approval 
• Vaccine accountability 
• Approved study protocol and amendments 
• Informed consent of the subjects (written consent [or witnessed oral if applicable] ) 
• Medical records and other source documents supportive of CRF data 
• Reports to the IRB/IEC and the sponsor 
• Record retention 
GSK Biologicals will gladly help investigators prepare for an inspection. 
VIII. Confidentiality and Publication 
You, the investigator, agree that all information communicated to you by GSK 
Biologicals is the exclusive property of GSK Biologicals.You agree to keep such 
information strictly confidential and to restrict access to such information to the minimum 
number of persons connected with the work performed under this protocol on a need-to-
know basis and you will ensure that such persons shall be made aware that the 
information is confidential and shall be bound by confidentiality obligations at least as 
strict as those contained herein. You will be responsible for any breach of the 
confidentiality by any of those persons to whom such information has been furnished. 
You and any such person agree that said information shall not be disclosed, either orally 
or in written form, by you or such person to any third party without the prior written 
consent of GSK Biologicals. You shall communicate the results of the work promptly to 
GSK Biologicals. Such results shall be the property of GSK Biologicals and shall be 
subject to the confidentiality obligations contained herein except that you shall be 
authorised to publish the results pursuant to the provisions below.  
The results of the study covered by this protocol shall be the subject of a joint publication 
by the sponsors and you within six (6) months from the conclusion of the study and 
availability of a final study report. You and the sponsors will be expected to treat matters 
of authorship in a proper collaborative spirit, giving credit where it is due and proceeding 
in a manner that fosters cooperation and communication, but will not do anything in this 
regard that will jeopardize the issuance of a valid patent. 
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Besides and after such joint publication, GSK Biologicals agrees that you shall have the 
right to publish or permit the publication of any information or material relating to or 
arising out of the work performed under the study protocol after submission to GSK 
Biologicals at least forty-five (45) days prior to the intended publication provided that if 
GSK Biologicals shall so request, you will delete any confidential information of GSK 
Biologicals and/or delay publication for  a further sixty (60) days to enable GSK 
Biologicals to protect  its rights in such information or material. Any proposed 
publication or presentation (e.g. manuscript, abstract or poster) for submission to a 
journal or scientific meeting, should also be sent to the Clinical Development Manager 
(CDM) at GSK Biologicals forty-five (45) days prior to submission, together with 
confirmation that any other author(s) has seen and agreed to the proposed 
publication/presentation. GSK Biologicals will undertake to comment on such documents 
within said forty-five (45) days.  
GSK Biologicals will be acknowledged in all such publications or presentations by co-
authorship or acknowledgement whichever is appropriate.  
All rights and interests worldwide in any inventions, know-how or other intellectual or 
industrial property rights which arise during the course of and/or as a result of the clinical 
study which is the subject of this protocol or which otherwise arise from the information 
or materials supplied under this protocol, shall be assigned to, vest in and remain the 
property of GSK Biologicals.Only GSK Biologicals shall be authorised to utilise the 
results of the study for regulatory and commercial purposes. 
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Appendix  C: Overview of the Recruitment Plan 
The study will be conducted in the Kassena-Nankana district by the Navrongo Health 
Research Center in Ghana.  
 
A series of meetings inviting regional and district leaders, compound heads and parents is 
organized by the NHRC, where the aim of the study is explained and questions can be 
answered. 
Mothers delivering at the Navrongo War Memorial Hospital will be informed about the 
study and asked permission to contact them in the future about potential participation to 
the trial. 
One day before first immunization, trained field workers will perform visits to the 
villages of potential study participants to invite them to attend the hospital/health center 
the next day. 
On the day of immunization, prior to any study procedure, the parent information sheet 
and informed consent forms are read and explained to the subject’s parents/guardians in 
the local language and according to the local custom and questions can be answered. 
Literate parents/guardians are given the information sheet and IC form to read.  
When agreement is given by the parent/guardian, the IC is signed or thumbprinted 
(illiterates) by the parents/guardians of the subject, witnessed by an independent person.  
 
All subjects should be enrolled within a period of 5 months. 
Anticipated recruitment rate is approximately 56 subjects per month. Subjects will be 
recruited when they present themselves at the immunization clinics.  
• Enrolment will be terminated when 280 subjects are enrolled.  
• The recruitment will be monitored by weekly update through regular contacts with 
study monitors 
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Appendix  D: Handling of Biological Samples Collected by the Investigator 
Instructions for Handling of Serum Samples 
When materials are provided by GSK Biologicals, it is mandatory that all clinical samples 
(including serum samples) be collected and stored using exclusively those materials in the 
appropriate manner. The use of other materials could result in the exclusion of the subject 
from analysis. The investigator must ensure that his/her personnel and the laboratory(ies) 
under his/her supervision comply with this requirement. 
1. Collection 
The whole blood (by capillary or venous route) should be collected observing appropriate 
aseptic conditions. It is recommended that Vacutainer tubes WITH integrated serum 
separator (e.g. Becton-Dickinson Vacutainer SST or Corvac Sherwood Medical) be 
used to minimize the risk of haemolysis and to avoid blood cell contamination of the 
serum when transferring to standard serum tubes. 
2. Serum separation 
These guidelines aim to ensure high quality serum by minimizing the risk of haemolysis, 
blood cell contamination of the serum or serum adverse cell toxicity at testing. 
• For separation of serum using Vacutainer® tubes, the instructions provided by the 
manufacturer should be followed. Siliconized tubes should never be used (cell 
toxicity). Often the manufacturer’s instruction states that the relative centrifugal 
acceleration known also as “G” must be “between 1000 and 1300 G” with tubes 
spinning for ten minutes. Error in calculation of centrifuge speed can occur when 
laboratory personnel confuse “G” acceleration with “RPM” (revolutions per minute). 
The speed of centrifugation must be calculated using the “G” rate provided in the 
manufacturer’s instructions and the radius of the centrifuge head. After measuring the 
radius of the centrifuge machine, a speed/acceleration nomograph must be employed 
to determine the centrifuge speed in “RPM”. 
• Following separation, the serum should be aseptically transferred to the appropriate 
standard tubes using a sterile disposable pipette. The serum should be transferred as 
gently as possible to avoid blood cell contamination. 
• The tube should not be overfilled (max. 3/4 of the total volume) to allow room for 
expansion upon freezing. 
• The tube should be identified by the appropriate label provided by GSK Biologicals 
(see point 3). 
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3. Labelling 
• The standard labels provided by GSK Biologicals should be used to label each serum 
sample. 
• If necessary, any hand-written additions to the labels should be made using indelible 
ink. 
• The label should be attached to the tube as follows (see diagram): 
− first attach the paper part of the label to the tube 
− then wrap the label around the tube so that the transparent, plastic part of the 
label overlaps with the label text and bar code and shields them. 
This will ensure optimal label attachment. 
Plastic, transparent part
Paper, text part
Bar code
    Study N°.........
    Subject N° ......
  POST VACC. I
 STUDY MTH 1
For GlaxoSmithKline
 Biologicals
 
• Labels should not be attached to caps. 
4. Sorting and storage 
• Tubes should be placed in the GSK Biologicals’ carton in numerical order from left to 
right, starting from the lower left hand corner, beginning with the pre-vaccination 
samples series, then with the post-vaccination sample series. 
• The tubes of serum should be stored in a vertical position at -20°C (alternatively at -
70°/80°C is also acceptable) until shipment to GSK Biologicals. Wherever possible, a 
backup facility for storage of serum samples should be available. 
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• A standard Serum Listing Form, specifying the samples being shipped for individual 
subjects at each timepoint, should be prepared for each shipment. A copy of this list 
should be retained at the study site, while the original should be sealed in a plastic 
envelope and shipped with the serum samples.  
• Once flight details are known, a standard Specimen Transfer Form must be completed 
and faxed to GSK Biologicals to the number provided below. A copy of the Specimen 
Transfer Form must be in the parcel.1 
GLAXOSMITHKLINE BIOLOGICALS 
Attention: Biospecimen Reception 
R & D Department/Building 44 
Rue de l'Institut, 89 
B-1330 Rixensart – Belgium 
Telephone: +32-2-656 8949 or +32-2-656 6130  
or +32-2-656 8549 or +32-2-656 6108 
Fax: +32-2-656 6052 
E-mail: rix.ugbiospecimen-reception@gskbio.com  
 
 
Note: Handling of throat swabs are detailed in Appendix  H.  
 
                                                 
1 The Serum Listing Form and the Specimen Transfer Form are standard documents used in GSK 
Biologicals’ clinical trials. These documents are provided by GSK Biologicals’ Clinical Trials’ monitor at 
study initiation. 
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Appendix  E: Shipment of Biological Samples 
Instructions for Shipment of Serum Samples 
Serum samples should be sent to GSK Biologicals at regular intervals. The frequency of 
shipment of samples should be decided upon by the Site Monitor, Central Study 
Coordinator and the investigator prior to the study start. 
Serum samples should always be sent by air, preferably on a Monday, Tuesday or 
Wednesday, unless otherwise requested by the sponsor. 
Serum samples must be placed with dry ice (-20°C) in a container complying with 
International Air Transport Association (IATA) requirements. The completed standard 
serum listing form should always accompany the shipment. 
The container must be clearly identified with the labels provided by GSK Biologicals 
specifying the shipment address and the storage temperature (-20°C). 
The airway bill should contain the instruction for storage of samples at -20°C. 
A "proforma" invoice, stating a value for customs purposes only, should be prepared and 
attached to the container. This document should contain the instruction for storage of 
samples at -20°C. 
Details of the shipment, including: * number of samples 
 * airway bill 
 * flight number 
 * flight departure and arrival times 
should be sent by fax, two days before shipment, to: 
 
GLAXOSMITHKLINE BIOLOGICALS 
Attention: Biospecimen Reception 
R & D Department/Building 44 
Rue de l'Institut, 89 
B-1330 Rixensart – Belgium 
Telephone: +32-2-656 8949 or +32-2-656 6130  
or +32-2-656 8549 or +32-2-656 6108 
Fax: +32-2-656 6052 
E-mail: rix.ugbiospecimen-reception@gskbio.com  
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Appendix  F: Laboratory Assays 
Section 5.5.2 Laboratory assays.
759346/009 (DTPwHB/HIBMenACTT009) GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
Appendix G 1
Appendix  G: Vaccine supplies, packaging and accountability 
It is NOT permitted to use any of the supplies provided by GSK Biologicals for purposes 
other than those specified in the protocol. Unused supplies will be collected by GSK 
Biologicals on completion of the study. Used vaccine vials can be disposed on site 
according to local biosafety standard for disposal of biological waste material. 
1. Vaccine supplies 
GSK Biologicals will supply the following amounts of numbered doses of study vaccines, 
sufficient to administer 3 doses to all subjects as described in the present protocol. 
• 420 doses of Hib-MenAC vaccine in monodose vials  
• 420 doses of Hiberix™ vaccine in monodose vials  
• 1260 doses of Tritanrix™-HepB vaccine in monodose vials 
• 280 doses of Mencevax™ AC 
• 560 doses of 0.5 ml diluent for the Mencevax™ AC vaccine 
  
An additional quantity of at least 5% of Tritanrix™-HepB and Hiberix™ will be supplied 
for replacement in case of breakage, bad storage conditions or any other reason that 
would make the vaccine unusable (i.e., given by mistake to another subject).  
All monodose vials must be accounted for on the form provided. 
In case of suboptimal response to an antigen (refer to Section 5.5.4) GSK Biologicals will 
also supply doses of Mencevax™ ACWY or Tritanrix™-HepB/Hiberix™ vaccines on a 
case by case basis. 
2. Vaccine packaging 
The vaccines will be packed in labelled boxes. In order to ensure the double blind of the 
study, all vaccine boxes will be identical (size and appearance), despite the different 
number of vials needed for reconstitution of the vaccines. Only the vaccination team will 
open the boxes for reconstitution and administration of the vaccine so only the 
vaccination team will know which vaccine is contained in the individual boxes (see 
section 6.4). The box label will contain, as a minimum, the following information: study 
number, subject number, lot number (or numbers, when double-blind), instructions for 
vaccine administration.  
3. Vaccine accountability 
The investigator or pharmacist must sign a statement that he/she has received the clinical 
supplies for the study. At all times the figures on supplied, used and remaining vaccine 
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doses should match. All used vials should be placed in sealed envelopes by the 
vaccination team in order to maintain the blinding of the study. After the end of the study 
and unblinding, it must be possible to reconcile delivery records with those of used and 
unused stocks.  An explanation must be given of any discrepancies.  
After approval from GSK Biologicals, used vaccine vials should be destroyed at the study 
site using locally approved biosafety procedures and documentation unless otherwise 
described in the protocol. If no adequate biosafety procedures are available at the study 
site, the used vaccine vials are to be returned to an appropriate GSK Biologicals site for 
destruction in accordance with current GSK SOP NPD-112. Unused vaccine vials will be 
disposed at the local GSK Biologicals site in accordance with GSK SOP NPD-112. If no 
processes for destruction of unused vaccines are in place in the local GSK Biologicals 
site; the unused vials must be returned to GSK Biologicals in Rixensart, Belgium. 
4. Transfers of clinical vaccines or products from country medical department or dispatch 
center to study sites or between sites 
Storage temperatures must be maintained during transport and deviations must be 
reported to Logistics and Packaging for guidance. All transfers of clinical vaccines or 
products must be documented using the Clinical Supply Transfer Form. If the duration of 
the transfer is less than four hours, a transportable fridge or any suitable container (e.g. 
styrofoam container) with a maximum of eight refrigerated cold packs (cooling elements) 
must be used in order to maintain the vaccines at 2°-8°C during transport. If the duration 
is more than four hours, a transportable fridge or any suitable container (e.g. styrofoam 
container) with a minimum of eight cold packs (cooling elements) must be used as well 
as a temperature monitoring system that must be placed as close as possible to the doses 
and checked upon reception at the final destination. Never place frozen cold packs or dry 
ice inside vaccine/product boxes for vaccine that must be kept at +4°C in order to avoid 
cold-chain deviation (e.g. frozen vaccines). Exceptions to these instructions are detailed 
in product-specific transport guidelines. 
5. Labels for sample identification 
The investigator will receive labels from GSK Biologicals to identify samples taken from 
each subject at each timepoint. Each label will contain the following information: study 
number, subject number, sampling timepoint (e.g., post vacc 3), timing (e.g., study Month 
3).  
6. Other supplies provided by GSK Biologicals 
In addition to the vaccines, the study documentation and the sample labels, the 
investigator will receive the following supplies: 
• tubes for blood sampling, 
• tubes with screw caps for serum samples, 
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• racks for the tubes of serum 
• butterflies, needles for reconstitution and injection, thermometers, waste disposals for 
used materials 
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Appendix  H: Meningococcal carriage in the African meningitis belt  
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Meningococcal carriage in the African meningitis belt 
Date of 
Approval 
First Version: 14 January 2003 
Revised Version: Amended 27 January 2004 
Title Meningococcal carriage in the African meningitis belt, 
an ancillary study to  
A phase II, double blind, randomized, controlled study to evaluate the 
immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) 
Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, as compared to GSK Biologicals’ Hiberix™ 
vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, 
when administered intramuscularly in infants at 6, 10 and 14 weeks of age. 
Co-Sponsor, Swiss Tropical Institute (STI), Basel, Switzerland 
Co-investigator: Dr. Gerd Pluschke, Molecular Immunology 
Navrongo Health Research Center (NHRC), Navrongo, Ghana 
Principal Investigator: Dr. Abraham Victor Obeng Hodgson 
Co-investigator: Doctor Abudulai Adams Forgor 
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World Health Organization (WHO), Geneva, Switzerland 
Collaborating Person: Dr. Marie-Paule Kieny 
London School of Hygiene and Tropical Medicine 
Collaborating Person: Professor Brian Greenwood 
Collaborating Person: Dr. Daniel Chandramohan 
GlaxoSmithKline Biologicals 
Collaborating Person: Dominique Boutriau 
Medical Monitor  
GSK Biologicals: 
Dominique Boutriau,  
Director, Clinical Research & 
Development, Meningitis vaccines 
GlaxoSmithKline Biologicals, 
89, Rue de l'Institut, 1330 Rixensart, 
Belgium 
Tel: + 32 2 656.91.20  
Fax: + 32 2 656. 8044 
e-mail: dominique.boutriau@gskbio.com 
(Amendment 7: 12 April 2006) 
 
Study Monitors 
Cornelia Bevilacqua, 
Central Study Coordinator, 
‘La Fédarié Haute’ 
81440 Vénès 
France 
Tel: + 33 563 75 92 66 
Fax: + 33 563 75 92 66 
Mobile phone: + 33 685 25 24 69 
e-mail: corneliabevilacqua@usa.net 
 
 
Valérie Marichal,  
Central Study Coordinator, 
GlaxoSmithKline Biologicals, 
89, Rue de l'Institut, 1330 Rixensart, Belgium 
Tel: + 32 2 656.9812 
Fax: + 32 2 656.8133 
e-mail: valerie.marichal@gskbio.com 
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Local Safety Monitor Local Safety Monitor Back-up 
Dr. John Williams 
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, 
Ghana 
Tel: ++ 233 742 22310/ 22380 
Fax: ++ 233 742 22320 
e-mail: jwilliams@navrongo.mimcom.net 
Dr. Frank Baiden  
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, 
Ghana 
Tel: ++ 233 742 22310/ 22380 
Fax: ++ 233 742 22320 
e-mail: fbaiden@navrongo.mimcom.net  
WHO Monitor WHO Study Contact for Reporting SAEs 
Dr.Lawrence Kweku Yamuah 
Post-Doctoral Researcher / Data Manager 
Armauer Hansen Research Institute (AHRI) 
P.O. Box 1005 
Addis Ababa 
Ethiopia 
Tel: + 251 1 71 02 88 (work) 
Tel: + 251 1 71 17 04 (home) 
Fax: + 251 1 71 13 90 
yamuahlawrence_kweku@hotmail.com 
Dr. Zarifah Reed 
WHO/VAB/IVR/POP  
20 Avenue Appia 
CH-1211 GENEVE 27 
Switzerland 
Tel.  +41 22 791 4760 
Fax. +41 22 791 4860 
Email: reedz@who.int 
 
 
 
 
I PURPOSE OF THE ANCILLARY STUDY AND BACKGROUND 
 
1. Purpose of the ancillary study 
Aim of the ancillary colonization study is to investigate how frequently and for how long 
infants <1 year are colonized by N. meningitidis and N. lactamica in the study area. This 
will provide important baseline data allowing sample size calculations in later studies 
accompanying the introduction of a meningococcal conjugate vaccine and addressing the 
issue of potential serogroup replacement by mass vaccination. The proposed ancillary 
study will also address the question, whether colonization by A meningococci is reduced 
following meningococcal conjugate vaccination.  
 
2. Background 
African countries, and more specifically the countries of the meningitis belt, face regular 
epidemics of meningococcal disease, including meningitis with an incidence as high as 
1000/100,000. Except for an outbreak of serogroup W-135 that spread in Burkina Faso in 
2002, serogroup A and to a lesser extent serogroup C are largely responsible for N. 
meningitidis epidemics in African countries (1). Children aged 5-14 years are the most 
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affected. The existing meningococcal plain polysaccharide vaccines are less 
immunogenic in small children; also the duration of protection induced by these vaccines 
is short-lived, as polysaccharides vaccine do not induce immune memory. Therefore, 
there is a need to develop new generation meningococcal vaccines that protect against 
meningococcal disease in early childhood and induce immune memory (2, 3). Recently, 
meningococcal serogroup C conjugate vaccines have been developed and have proven 
effective in small children and infants (4). 
 
In order to protect children from early childhood against N. meningitidis of the two most 
prevalent serogroups in Africa, and to facilitate the incorporation of such a vaccine in the 
immunization calendar, GSK Biologicals is developing a combined Hib-MenAC 
conjugate vaccine to be extemporaneously mixed with the Tritanrix™-HepB (DTPw-
HBV) vaccine for administration as a 3-dose primary vaccination course in infants aged 6 
weeks and over. The new Tritanrix™-HepB/Hib-MenAC vaccine will first be evaluated in 
a feasibility trial outside Africa. Once feasibility of the new vaccine is shown, the obove 
mentioned core study plans to evaluate the use of GSK Biologicals’ Tritanrix™-
HepB/Hib-MenAC vaccine in a high endemicity region in Africa. 
In 1998 an ongoing longitudinal study of the dynamics of carriage of Neisseria 
meningitidis and N. lactamica was started by STI and NHRC in the Kassena-Nankana 
District of Northern Ghana (5-9). In 6-monthly field surveys (once in the dry season and 
once in the wet season of each year) 37 compounds randomly selected from a complete 
listing of the district population (Navrongo Demographic Surveillance System) are visited 
and Neisseria carriage of the total population of these compounds is monitored. The 
studies have provided information on longitudinal patterns of colonisation with multiple 
types of N. meningitidis and N. lactamica, and spatio-temporal patterns of colonisation 
and disease during and before a potential new epidemic. The data indicate that in contrast 
to Europe and the USA, carriage of non-encapsulated meningococci and other non-
pathogenic meningococci is infrequent in Africa. It is thought that carriage of non-
serogroupable meningococci protects against meningococcal disease by eliciting cross-
reactive immunity against pathogenic strains. Therefore, in Africa, low levels of carriage 
may result in inadequate levels of naturally acquired immunity and thus an  increased 
susceptibility of the population to meningococcal epidemics.  
After a N. meningitidis serogroup A epidemic in the Kassena-Nankana district in 1997 
serogroup A carriage decreased and for a period of about two years serogroup A 
meningococci were neither isolated from cases nor from carriers. However, after a period 
of only four years, a new serogroup A outbreak is now being observed, indicating that the 
decline in herd immunity may not be the crucial factor determining time intervals 
between epidemics. Molecular typing revealed that the current outbreak is caused by a 
different serogroup A clone (sequence type 7, a clone which was for the first time 
observed in 1995 in Africa) than the previous epidemic (sequence type 5, a clone which 
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caused epidemics first in Mecca (1987) and subsequently in several nations of the 
meningitis belt). Between the two outbreaks, a carriage epidemic of  serogroup X 
meningococci was observed, coinciding with a number of cases caused by serogroup X 
meningococci. Currently it is not clear whether X meningococci have an epidemic 
potential (like W-135 meningococci, which are the cause of a recent epidemic in Burkina 
Faso associated with an unusually high mortality). The recent increase in outbreaks 
caused by non-A non-C meningococci may reflect serogroup replacements caused by 
mass vaccination with serogroup A/C carbohydrate vaccine. Similarly, shifts in the 
serogroups of N. meningitidis causing disease could potentially arise as a result of 
immune selection resulting from mass-vaccination with conjugate vaccines. In view of 
recent outbreaks caused by W-135- and X meningococci this possibility is a real concern. 
Therefore, the database on longitudinal patterns of colonisation with multiple types of N. 
meningitidis, and the spatio-temporal patterns of colonisation and disease provides a 
unique baseline from which to carry out trials on the effects of vaccination on acquisition 
of meningococcal infection and on serogroup replacement. 
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II CHARACTERISTICS OF THE RESEARCH POPULATION 
1.  Number, gender, age, and race of subjects 
Target enrolment of the core vaccine study will be 280 healthy male and female infants 
(140 subjects per group) to provide 220 evaluable subjects (110 per group) for the core 
immunogenicity analysis.  
 
For the ancillary colonization study, throat swabbing of all infants and their consenting 
parents/guardians will be done. Samples will be taken from all children enrolled in the 
core study. 
 
The study will be conducted by the Navrongo Health Research Center in Ghana at the 
War Memorial Hospital (serving Navrongo central) and at other health centres in the 
Kassena-Nankana health district.  
 
Enrolment will be terminated when 280 infants have been enrolled for the core vaccine 
study.  
 
Currently there is hardly any information available on the frequency and duration of 
meningococcal colonization of infants <1 year in the study area. Since there is concern 
that mass vaccination with a meningococcal conjugate vaccine might result in serogroup 
replacement it is important to investigate this aspect in the target group of an EPI-
associated meningococcal conjugate vaccine. The ancillary study is expected to give first 
insight, thus providing important baseline data allowing sample size calculations in later 
studies accompanying the introduction of a meningococcal conjugate vaccine. Our long 
term colonization studies indicate that meningococci spread very fast within individual 
compounds. A colonization analysis of parents or guardians will provide insight into the 
frequency of this spread to infants.  
 
The intended racial and ethnic distribution is determined by the fact that the study should 
be performed in a population at high risk for epidemic meningococcal meningitis; i.e 
inhabitants of the African meningitis belt.     
         
 
2.  Inclusion criteria  
All subjects must satisfy the following criteria at study entry: 
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• Subjects for whom the investigator believes that their parents/guardians can and will 
comply with the requirements of the protocol (e.g., completion of the diary cards, 
return for follow-up visits) should be enrolled in the study. 
• A male or female between, and including, 6 and 8 weeks of age at the time of the first 
vaccination.  
• Written informed consent obtained from the parent or guardian of the subject for the 
participation of the subject and of the parent/guardian. 
• Free of obvious health problems as established by medical history and clinical 
examination before entering into the study. 
 
3.  Exclusion criteria for enrolment 
The following criteria should be checked at the time of study entry. If any apply, the 
subject must not be included in the study: 
• Use of any investigational or non-registered drug or vaccine other than the study 
vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use 
during the study period. 
• Chronic administration (defined as more than 14 days) of immunosuppressants or 
other immune-modifying drugs since birth. (For corticosteroids, this will mean 
prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed.) 
• Planned administration/ administration of a vaccine not foreseen by the study protocol 
within 30 days before each dose of vaccine, with the exception of OPV. 
• Hepatitis B and BCG vaccine given within two weeks prior to vaccination. 
• Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae 
type b or meningococcal serogroup A or C diseases.  
• History of diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b or 
meningococcal serogroup A or C diseases. 
• Known exposure to (direct contact) diphtheria, tetanus, pertussis, hepatitis B, 
Haemophilus influenzae type b and/or meningococcal disease since birth. 
• A diagnosis or clinical suspicion of an immune suppressive or immunodeficient 
condition of any cause based on full clinical history and medical examination. 
• A family history of congenital or hereditary immunodeficiency. 
• History of allergic disease or reactions likely to be exacerbated by any component of 
the vaccine. 
• Major congenital defects or serious chronic illness.  
• Babies for which birth weight is <2 kg (if known), and/or malnutrition at visit 1.  
• History of any neurologic disorders or seizures. 
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• Acute disease at the time of enrolment. (Acute disease is defined as the presence of a 
moderate or severe illness with or without fever. All vaccines can be administered to 
persons with a minor illness such as diarrhea, mild upper respiratory infection with or 
without low-grade febrile illness, i.e., axillary temperature <37.5°C or rectal 
temperature <38.0°C).  
Note: Subjects with fever at the time of first vaccination (i.e., axillary temperature ≥ 
37.5°C or rectal temperature ≥ 38.0°C) need not necessarily be excluded but can be 
vaccinated at a later date after the subject recovers and if the subject still meets all 
eligibility criteria. 
• Administration of immunoglobulins and/or any blood products since birth or planned 
administration during the study period.  
• Other conditions which in the opinion of the investigator may potentially interfere 
with interpretation of study outcomes. 
 
4.  Elimination criteria during the study 
The following criteria should be checked at each visit subsequent to the first visit. If any 
become applicable during the study, it will not require withdrawal of the subject from the 
study but does determine a subject’s evaluability in the according-to-protocol (ATP) 
analysis.  
• Use of any investigational or non-registered drug or vaccine other than the study 
vaccine(s) during the study period. 
• Chronic administration (defined as more than 14 days) of immunosuppressants or 
other immune-modifying drugs during the study period. (For corticosteroids, this will 
mean prednisone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are 
allowed). 
• Administration of a vaccine not foreseen by the study protocol during the period 
starting from 30 days before the first dose of vaccine(s) and ending 30 days after the 
last dose of vaccine(s) with the exception of OPV. 
• Administration of a meningococcal vaccine not foreseen by the study protocol during 
the entire study period. 
• Administration of immunoglobulins and/or any blood products during the study 
period.  
 
5.  Withdrawal of subject from core study 
If a study subject is withdrawn from the core study, that subject will also be withdrawn 
from the ancillary study. 
 
III  METHODS AND PROCEDURES 
1.  List of study procedures (core study) 
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Age ±6 w ±10 w ±14 w ±18 w ± 9 m ±12 m ±13 m 
Visit VISIT 1 VISIT 2 VISIT 3 VISIT 4 VISIT 5 VISIT 6 VISIT 7 
Timing Month 0 Month 1 Month 2 Month 3 Month 
7.5 
Month 10.5 Month 11.5
Sampling time point Pre vacc   Post vacc III  Pre booster Post booster
Informed consent# •       
Check inclusion criteria •       
Check exclusion criteria •       
Check elimination criteria  • • • • • • 
Check contraindications  • •  °## •  
Medical history •       
Physical examination • • • • • • • 
Pre-vaccination body 
temperature 
• • •  • •  
Measure/record height and 
weight  
•       
Randomization •       
Blood sampling for antibody 
determination (3.5 ml) 
•   •  • • 
Throat swab •** •**  •** •** •**  
Vaccination • • •  •*** •****  
Daily post-vaccination 
recording of solicited 
symptoms (days 0-3) by field 
workers 
• • •   •  
Recording of non serious 
adverse events occurring one 
month (minimum 30 days) 
post-vaccination, by 
investigator 
• • • •  • • 
Return of diary cards  • • •   • 
Diary card transcription  • • •   • 
Record any concomitant 
medication 
• • • • • • • 
Reporting of Serious 
Adverse Events  
• • • • • • • 
Study Conclusion        • 
• denotes a procedure which must be recorded in the individual CRF. 
° denotes a procedure which need not be recorded in the individual CRF. 
# any parent/guardian accompanying the child at visits subsequent to the first visit who has not already signed an 
Informed Consent for this study will have to sign an Informed Consent prior to providing any throat swab 
.## Contraindications for measles and yellow fever vaccines. 
** from the subject and subject’s parents/guardians; ***Measles, yellow fever vaccine 
****1/5th of dose of Mencevax™ AC 
Note: BCG and OPV vaccines are given at birth (or at least 2 weeks before the subject’s first visit) according to 
the nationally recommended immunization schedule. 
OPV vaccine can be administered to the subjects at 6, 10 and 14 weeks of age concomitantly with the study 
vaccines or at any time during the study, whichever is more appropriate. 
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2. Methods and procedures specific for the ancillary study 
Throat swabbing of consenting parents/guardians and infant subjects will also be done at 
age 6w, 10w, 18w, 9m and 12m.  
 
This non-invasive procedure is done using a sterile swab on stick. After consent is 
obtained from the subject (or his/her parent/guardian), the subject is asked to open the 
mouth as wide as possible and bend the head slightly backward. Children are assisted to 
bend their heads by an assistant. A trained investigator wearing disposable gloves 
depresses the tongue with a spatula in one hand. The subject is asked to say ah-ah (if an 
adult). The investigator picks the sterile swab with the other hand and passes it through 
the mouth gently rubs it against the posterior wall of the pharynx or behind the tonsils 
without touching the uvula and tongue. The swab stick is removed from the mouth and 
immediately inoculated directly on Thayer-Martin agar plates (Difco), which is labeled, 
and transported to the hospital laboratory within 2 hours for incubation in a candle jar at 
37ºC for 24 hours. 
 
 
 
Neisseria-like colonies will be picked and characterized by standard microbiological 
procedures in Navrongo. Isolates are then frozen and transported to Switzerland for 
detailed molecular characterization. N. meningitidis or N. lactamica are identified by 
Gram’s stain morphology, cytochrome oxidase test using N,N,N’,N’-tetramethyl-1,4-
phenylene-diammoniumdichloride as substrate, glucose, maltose and sucrose utilization 
THROAT SWAB BEING TAKEN FROM A SUBJECT
Ghanaian isolates.
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in cystine-trypticase agar, ONPG discs and gamma-glutamyltransferase activity. All 
isolated meningococci will be serogrouped by slide agglutination with serogroup specific 
antisera and serotyped/subtyped with monoclonal antibodies by whole cell ELISA. 
Further analysis is carried out using pulsed-field gel electrophoresis and for a sub-set of 
isolates representing the different PFGE variants multi locus sequence typing. N. 
meningitidis isolates are tested for sensitivity to penicillin G, cefotaxime, ciprofloxacin, 
rifampicin, chloramphenicol, tetracycline and sulfadiazine by the E-test method (AB 
Biodiscs, Solna, Sweden) according to the manufacturer’s instructions.  
 
 
3. Data analysis and data monitoring  
3.1 Safety monitoring 
An independent committee consisting of up to five experts in meningococcal diseases, 
paediatrics, vaccines, statistics and other appropriate disciplines will be appointed to 
oversee ethical and safety aspects of the study conduct. 
Terms of reference (operating procedures) of the IDMC will be written after the first 
meeting of the IDMC members, prior to study start. 
3.2 Role of the IDMC 
The role of the IDMC includes the review of the implementation and progress of the 
study. It provides initial, regular, and closing advice on safety-related issues to GSK 
Biologicals.  Its advice is based on the interpretation of study data with reference to the 
study protocol. 
The IDMC will confer before the initiation of the study (pre-initiation review), during the 
study proper and at the close out of the study to review any relevant safety data and to 
review and approve the Report and Analysis Plan (RAP), where applicable. Other 
unscheduled meetings may be required. Meetings must be documented and minutes made 
available for the study files on site and to the sponsors. The IDMC may, if deemed 
necessary, convene a meeting with or request further information from the Principal 
Investigators, the Local Safety Monitor, GSK Biologicals and designated project 
representatives at any stage of the study.  
The IDMC must be informed by the investigator of: 
• all subsequent protocol amendments, informed consent changes or revisions of other 
documents originally submitted for review 
• systemic grade 3 adverse events (AEs) related to vaccination, serious adverse events 
and adverse events suggesting a lack of efficacy of the vaccine occurring during the 
study (transmitted through GSK Biologicals for SAEs and through the Local safety 
Monitor for the other adverse events)  
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• all subsequent protocol modifications (for information) 
• new information that may affect adversely the safety of the subjects or the conduct of 
the study. 
The IDMC will be empowered to put the study on hold pending review of potential 
safety issues. All SAEs, including death, will be reported by the Principal Investigator to 
the local safety monitor, to the Manager of Clinical Safety Vaccines at GSK Biologicals, 
to WHO and to the WHO safety monitor. GSK Biologicals will be responsible to provide 
all information related to the SAEs to the IDMC according to the IDMC Charter.  
3.3 Reporting to IDMC – Role of Local Safety Monitor  
A Local Safety Monitor (LSM) will act independently from the investigational team. 
The overall role of the Local Safety Monitor (LSM), who will be an experienced clinician 
based in-country, will be to support the clinical investigators and to act as a link between 
the investigators and the IDMC. All systemic grade 3 AEs probably or suspected to be 
related to vaccination, all SAEs and all AEs suggesting a lack of efficacy of the vaccine 
will be reported to him/her. His/her involvement will be particularly important when 
decisions have to be made quickly. In exceptional circumstances, for example a death 
possibly related to vaccination, he/she will have the authority to suspend the whole or any 
specific aspect of the trial pending discussion with the IDMC.  
The LSM’s role will include: 
• acting as the study volunteer's advocate 
• provide the IDMC and the medical monitor of GSK Biologicals with a blinded listing 
of non-serious systemic grade 3 symptoms (solicited and unsolicited) that are related 
with vaccination, and of non-serious adverse events suggesting a lack of efficacy of the 
vaccine, this according to the IDMC Charter (note: GSK Biologicals will send all 
information related to serious adverse events to the IDMC according to the IDMC 
Charter).  
• reviewing blinded reactogenicity data according to IDMC charter after each dose and 
discussing with IDMC if necessary  
• promptly communicating relevant safety information to the IDMC 
• providing advice to the investigators on whether a set of clinical circumstances in a 
study warrants formal notification to the IDMC 
• providing clinical advice on any illness in study subjects especially in circumstances in 
which treatment might influence the course of the trial 
• Unblinding a subject if deemed necessary, upon request of the investigator/physician 
in charge of the subject, to allow for adequate treatment. 
The LSM will liaise closely with the chair of the IDMC throughout the course of the trial. 
3.4 Data analysis for ancillary study 
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The ancillary study represents a pilot exploratory analyses that will provide important 
baseline data for later more extended studies. Only rough estimates can therefore be made 
at this stage about outcomes and types of statistical data analyses required.  
 
It is expected that the proposed sampling of 280 infants at age 6w, 10w, 18w, 9m and 
12m will provide much more detailed insight in the relative level of colonization and the 
duration of colonization in this age group than previous research. Results gained in this 
pilot study would therefore strongly facilitate the design of a more extended carriage 
study accompanying the large scale introduction of a conjugate vaccine. Furthermore, the 
sample size of 130 in each group will already give >80% power to detect a conjugate 
vaccine-associated 90% reduction in the number of children carrying A meningococci, 
assuming that in the control group approximately 5% of children carry these bacteria in 
one or more of the sequential samplings.  
 
3.5 Data storage and confidentiality  
Samples will be coded with running numbers. Records that correlate these numbers with 
the name of the patient will remain with the investigators of the core study and will not be 
provided to the researchers responsible for the ancillary study. 
 
Electronic data will be stored in password-protected computers, and data in hardcopy 
form will be kept in a locked cabinet, accessible only to authorized study personnel.   
 
Data from the ancillary study will be provided to the trial monitors and sponsors of the 
core study, upon request.   
 
Publications of research results will not include any names or any personal information 
that could reasonably be associated with any research participant. 
 
IV  RISK/BENEFIT ASSESSMENT 
1. Risk category 
Risk associated with the throat swabbing procedure for the ancillary studiy is minimal. 
 
2. Potential risk and protection against risk 
Throat swabbing is considered a low risk procedure and is not known to produce 
substantial stress or discomfort. 
 
The risk of stress or discomfort from the procedures will be further reduced, through the 
training of the investigators performing these procedures, which have been clearly 
described in writing (see herein).  
 
In addition, there will be close monitoring for adverse events, largely because of potential 
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risks posed to participants by virtue of their participation in the vaccination clinical trial: 
Field workers will be trained on the definition of adverse events, including serious 
adverse events, under the supervision of the Principal Investigator. On the day of 
vaccination of any study vaccine and on each of the three subsequent days or up to 
resolution of symptoms, whichever is longer, field workers will visit each research 
participant at his/her home to record any adverse events. Field workers will also visit each 
research participants one month after the vaccination of any study vaccine and will 
observe the research participant for any adverse events. 
The Principal Investigator will report each serious adverse event within twenty-four (24) 
hours of becoming aware of such event. The Principal Investigator will report such event 
to the Local Safety Monitor, the WHO monitor and GSK Biologicals safety department. 
GSK Biologicals safety department will transmit the information to the IDMC according 
to the operating procedures of the IDMC. In addition, the investigator will also provide a 
listing of all systemic grade 3 symptoms suspected to be related to vaccination and any 
case of diphtheria, tetanus, pertussis, hepatitis B, invasive diseases due to Haemophilus 
influenzae type b, measles, yellow fever or Neisseria meningitidis of serogroup A and C 
to the LSM. The Local Safety Monitor will send the listing and information related to the 
non-serious grade 3 systemic symptoms related with vaccination and non-serious adverse 
events suggesting a lack of efficacy of the vaccine to the IDMC and the GSK medical 
monitor (the GSK medical monitor will forward the information to the other members of 
the Steering Committee) according to the Charter for the IDMC.  
The Principal Investigator will proactively follow each subject (a) with a serious adverse 
event or who has withdrawn from the study as a result of an adverse event, until the event 
has resolved, subsided, stabilized, disappeared, the event is otherwise explained, or the 
subject is lost to follow-up; (b) with a non-serious adverse event who has not withdrawn 
from the study, until the subject completes the study or is lost to follow-up; or (c) with 
clinically significant laboratory abnormalities, until the subject’s conditions return to 
normal or a satisfactory explanation has been provided.  
Updated information, including completed verbal autopsy questionnaire in case of death, 
will be recorded on each serious adverse event Report Form, and the Form will be signed 
and dated by the Principal Investigator. Updated information will be reported in the same 
manner as the original serious adverse event information.  
After the study end, the Principal Investigator is not obliged to actively seek for adverse 
events or serious adverse events in former research participants. However, if the Principal 
Investigator learns of any serious adverse event, including a death, at any time after a 
research participant has been discharged from the study, and he considers the event 
759346/009 (DTPwHB/HIBMenACTT009) GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
Appendix H16
reasonably related to the study, the Principal Investigator will promptly notify the study 
contact for reporting serious adverse events. 
 
3. Potential benefits  
Individuals participating in the ancillary study will have no direct benefit. The data from 
the ancillary studies will, however, enable more precise sample size calculation in later 
studies which will follow the introduction of a meningococcal conjugate vaccine, 
addressing the potential for serogroup replacement. This is of considerable potential 
importance and benefit for the population of the African meningitis belt.  
 
4. Alternatives to participation 
After one parent/guardian has consented to participate in the ancillary study and core 
study, any other parent/guardian who accompanies the infant to a clinical trial site visit 
will have the option not to participate in the ancillary study. Subjects can withdraw from 
the core study and ancillary study at any time.  
 
V  SUBJECT IDENTIFICATION, RECRUITMENT AND 
CONSENT/ASSENT 
1.  Subject identification and recruitment 
1.1. General enrollment information 
The study will be conducted in the Kassena-Nankana district by the Navrongo Health 
Research Center in Ghana.  
 
• All subjects should be enrolled within a period of 5 months. 
• Anticipated recruitment rate is 56 subjects per month. Subjects will be recruited when 
they present themselves at the immunization clinics. 
• Enrolment will be terminated when 280 subjects are enrolled. 
• The recruitment will be monitored by weekly update through regular contacts with 
study monitors. 
 
1.2 A community information campaign will be conducted as detailed below: 
Prior to the start of the study, the Regional Director of Health Services will be briefed 
about the study and the start dates. The District Director of Health Services will be 
reminded of the start of the study and the use of the health facilities at the three sub 
districts during that period. The Medical Superintendent of the district hospital, War 
Memorial Hospital, will also be informed. 
 
Meetings will be arranged with the District Chief Executive as well as paramount chiefs, 
sub chiefs and elders of the three sub districts separately at their convenience to explain 
the study to them and seek their consent. 
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At Navrongo central, the Navropio, his sub chiefs and elders will be met at the Navropio's 
palace. The Kologo chief, his sub chiefs and elders will be met at Kologo whilst the Bui 
chief and his elders will be met at Bui. 
 
In the East sub district, separate meetings will be held with the chiefs and elders of Sirigu, 
Yua, Kandiga, Nabogo, Mirigu, Natugnia and Amontanga as in the table below. 
 
At these meetings, the study will be explained to them, questions related to the study 
answered and their consent solicited to start the study.  
 
1.3 Recruitment through the Navrongo War Memorial Hospital: 
Mothers delivering at the Navrongo War Memorial Hospital will be informed about the 
study and permission solicited to contact them in future about their potential participation 
in the trial.  
 
1.4 Recruitment through the NDSS 
Potential study participants will also be identified from the demographic surveillance 
system of the Kassena-Nankana health district, the Navrongo Demographic Surveillance 
System (NDSS). The NDSS was established by the Ghana Ministry of Health for the 
purpose of enhancing research in the Kassena-Nankana district. The NDSS serves as the 
platform from which studies draw potential research participants. At the start of the study, 
a request is made to the head of the NHRC for access to the NDSS data set; once he 
approves, the requested data can be accessed. The approval for this study is attached. 
 
1.5 Recruitment by field workers 
Routine childhood immunizations are provided on fixed days at the Navrongo War 
Memorial Hospital and health clinics. One day before first immunization, the field 
workers will visit the potential study participants to invite them to attend the 
hospital/health centre the next day. 
 
2. Process and documentation of consent 
On the day of immunization, prior to any study procedure, the Parent Information Sheet 
and Informed Consent forms will be read and explained to the subject’s parents/guardians 
in the local languages (Kassem and Nankam) and according to the local custom and 
questions will be answered. Literate parents/guardians will be given the Parent 
Information sheet and Informed Consent form to read.  
 
When agreement is given by the parent/guardian, the IC is signed or thumbprinted 
(illiterates) by the parents/guardians of the subject, witnessed by an independent person. 
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Consent documentation and records that correlate study numbers with the name of the 
patient will remain with the Principal Investigator of the core study and will not be 
provided to the researchers responsible for the ancillary study. Hardcopy documents will 
be kept in a locked cabinet, accessible only to authorized study personnel.   
 
3. Costs/inconvenience of participation 
In terms of the inconvenience the study poses to the participants, the maximum distance 
between a subject’s compound and the nearest health facility will be ten kilometers. Each 
visit to the clinic for vaccination and throat swabbing will last approximately four hours, 
though the throat swabbing procedure will last approximately one minute. 
 
4. Payment for participation 
Subjects will not receive reimbursements or payments for their participation.  
 
 
759346/009 (DTPwHB/HIBMenACTT009) GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009) Confidential and Proprietary Information 
Amendment 7: 12 April 2006 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
Appendix   1
Appendix  I Amendments and Modifications to the Protocol 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT-009) (Amended 05 June 2003) 
Protocol Title: A phase II, double blind, randomized, controlled study to evaluate 
the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) 
Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, as compared to GSK Biologicals’ Hiberix™ 
vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, 
when administered intramuscularly in infants at 6, 10 and 14 weeks of age. 
Amendment 1 
05 June 2003 
Coordinating Author: N. Bülow 
Rationale/background for changes: 
This amendment includes several changes / additional information as requested by 
several ethics committees who reviewed the protocol: 
Change in the nomenclature of study alias: DTPwHB/HIBMenACTT instead of 
Hib-MenAC-TT. Details for the WHO monitor and SAE contact were added.  
Information were added to 
• justify why 1/5 dose of Mencevax™ AC will be administered 
• further elaborate the study rationale and study site conditions 
• stress that any lack of efficacy needs to be reported to the DSMB 
• specify the distance between the subjects’ compounds and the health facilities 
and the duration of each study visit 
An additional informed consent is mentioned that has to be signed by any 
parent/guardian accompanying the child (instead of the mother, at visits 
subsequent to the first visit) prior to providing any saliva sample. Details of the 
timepoint of study start were removed and two references were added. A potential 
change of PATH’ corporate structure was taken into account. 
Appendix H (Meningococcal carriage and mucosal immunity to Neisseria 
meningitidis in the African meningitis belt) was restructured and additional 
information on e.g. sample size and the power of the ancillary study were 
included. A supplement to the ancillary study was added describing the procedure 
of taking throat swabs. 
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The following items were amended on 05 June 2003: 
1st page: Study Vaccine 
GlaxoSmithKline (GSK) Biologicals’Haemophilus influenzae type b-
meningococcal AC-tetanus toxoid (Hib-MenAC) vaccine (as a mixed 
combination with Tritanrix™-HepB) 
Throughout the protocol the study alias Hib-MenAC-TT has been replaced by 
DTPwHB/HIBMenACTT. 
On page 2 and in the abbreviation list a potential change of PATH’ corporate 
structure was taken into account by adding a footnote/Note: 
≠PATH currently expects to form a limited liability company (the "LLC") to 
pursue the mission of, and to hold all of PATH's interest in, the Meningitis 
Vaccine Project. PATH will be the sole member and the sole manager of the 
LLC. In such case, the LLC, rather than PATH, will act as the co-sponsor of 
this protocol. 
Details of the WHO monitor and Study Contact for Reporting SAEs were added 
on page 4 (prior to “Sponsors”): 
WHO Monitor WHO Study Contact for Reporting 
SAEs 
Dr.Lawrence Kweku Yamuah 
Centre for Measurement and 
Information in Medicine 
City University 
Northampton Square 
London, EC1V 0HB 
United Kingdom 
Tel: (+ 44) 20 7040 8371 
Fax: (+ 44) 20 7040 8371 
email: L.K.Yamuah@city.ac.uk 
yamuahlawrence_kweku@hotmail.com 
Yuppaporn Wattanagoon 
M121 WHO/HTP/IVR/POP 
Avenue Appia 20 
CH-1211 GENEVE 27 
Switzerland 
Tel. +41 22 791 15 01 
Email: wattanagoony@who.int 
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Sponsor Information 
Study Monitor WHO 
A WHO monitor will be identified prior to the start of the study. 
Dr.Lawrence Kweku Yamuah 
Centre for Measurement and Information in Medicine 
City University 
Northampton Square 
London, EC1V 0HB 
United Kingdom 
Tel: (+ 44) 20 7040 8371 
Fax: (+ 44) 20 7040 8371 
email: L.K.Yamuah@city.ac.uk 
yamuahlawrence_kweku@hotmail.com 
Study Contact for Reporting of a Serious Adverse Event for WHO 
TBD. The name, address, phone and fax numbers will be provided prior to study 
start. 
Yuppaporn Wattanagoon 
M121 WHO/HTP/IVR/POP 
Avenue Appia 20 
CH-1211 GENEVE 27 
Switzerland 
Tel. +41 22 791 15 01 
Email: wattanagoony@who.int 
Section 1.1 Background (One paragraph was added at the end of this section) 
The immunogenicity of meningococcal conjugate vaccines in infants is best 
shown by measuring bactericidal antibodies one month after primary 
vaccination. Demonstrating that meningococcal serogroup A and C conjugate 
vaccines prime for immune memory is an important mechanism to support the 
long-term protection effect of these vaccines. Such priming for memory was 
shown for the meningococcal serogroup C conjugate vaccine 17and for a 
preliminary meningococcal serogroup A+C conjugate candidate vaccine 
evaluated in the United Kingdom 18. However, in another trial in the Gambia, 
priming for memory of the A+C conjugate vaccine was less convincing 15. 
Priming for memory was demonstrated by administering a small dose (10 µg) of 
unconjugated polysaccharide C six to twelve months after priming. The dose of 
10 µg polysaccharide was selected after three adverse events (allergic reactions) 
had been reported in 10 subjects initially vaccinated with the full 
polysaccharide vaccine (50 µg/polysaccharide). No further allergic reactions 
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were reported with the reduced dose of 10 µg 18. 
Synopsis and Section 1.3 Rationale for the study (one paragraph was added at the 
end of this section) 
The study will evaluate the immunogenicity induced by three doses of the 
vaccine given at 6, 10 and 14 weeks of age by measuring the immune response 
one month post-vaccination to ensure the vaccine is effective in the youngest 
children when the disease burden is highest. In order to assess whether the 
vaccine has induced long-term protection, the persistence of the immune 
response will be measured when the child is one year of age, and a small dose 
of plain polysaccharide (1/5th of a dose of Mencevax™ AC, i.e. 
10µg/polysaccharide) will be given to evaluate whether immune memory was 
induced by priming. 
Section 1.4 Study site 
The following paragraphs were added just before the sub-section “Health 
indicators”: 
 
Coordination with the EPI 
 
The vaccine trial will be conducted at three EPI clinics in the Kassena-
Nankana district where routine immunization is taking place:  
- KNE-Health Centre (serving the East sub district) 
- Biu Health Centre (serving the South sub district) 
- War Memorial Hospital (serving Navrongo central) 
All vaccinees in the EPI system have the so-called “Growth Monitoring Cards” 
on which the vaccines they receive are recorded. The subjects will be recruited 
at the time they are to receive the routine DTP, Hib and HepB vaccines (at 6 
weeks of age). The vaccines given will be recorded on a specific immunization 
card (yellow card) and also on the Growth Monitoring Cards, i.e. the name of 
the study vaccine will be recorded in the box where DTP, Hib and HepB 
vaccines are usually recorded. Therefore, a duplication of vaccination is 
prevented as the Growth Monitoring Cards are always brought to the EPI 
clinics by the parents/guardians. 
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Section 3 Study Design Overview 
In the flow chart and in the 3rd bullet point pluriel was used for measles and 
yellow fever vaccines. 
Flow chart: 
- Measles & Yellow fever vaccines @ 9 months of age 
- At Visit 5, Month 7.5 Measles/ Yellow Fever Vaccines 
• To comply with the Ghanean Immunisation Calendar, at 9 months of age, all 
subjects will receive measles and yellow fever vaccines. 
Synopsis and Section 3 Study Design Overview (one bullet point was deleted) 
• Study start: The enrolment will preferably start at the onset of the rainy season 
(June) and should be completed prior to the onset of the dry season (October). 
Section 5.1.3 Data Safety Monitoring Board (DSMB) (2nd bullet point and 2nd 
sentence in paragraph following “Role of Local Safety Monitor”) 
• systemic grade 3 adverse events (AEs) related to vaccination and, serious 
adverse events and adverse events suggesting a lack of efficacy of the 
vaccine occurring during the study (transmitted through the Local Safety 
Monitor) 
All systemic grade 3 AEs probably or suspected to be related to vaccination, and 
all SAEs and all AEs suggesting a lack of efficacy of the vaccine will be 
reported to him/her in his/her capacity as a liaison to the DSMB. 
Section 5.2 General study aspects (one paragraph was added at the beginning of 
this section) 
The maximum distance between a subject’s compound and the nearest health 
facility will be 1 km. Each visit to the clinic for vaccination will last 
approximately 4 hours; each home visit by a field worker will last about 15 
minutes. 
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Section 5.3 Outline of study procedures 
The following footnote was added to the informed consent row in the table: 
# any parent/guardian accompanying the child instead of the mother at visits 
subsequent to the first visit has to sign an Informed Consent prior to providing 
any saliva sample 
Section 5.4 Detailed description of study stages/visits 
The following note was added prior to the detailed description of Visits 3, 5, 6 and 
7: 
Note: Any parent/guardian accompanying the child instead of the mother at 
visits subsequent to the first visit has to sign an Informed Consent prior to 
providing any saliva sample. 
Section 6.5 Replacement of unusable vaccine doses (2nd paragraph) 
In addition to the vaccine doses provided for the planned number of subjects, at 
least 5% additional doses will be supplied… 
Section 8.3. Lack of efficacy (one sentence was added at the end of this section) 
Any case of diphtheria, tetanus, pertussis, hepatitis B, invasive diseases due to 
Haemophilus influenzae type b, measles, yellow fever or Neisseria meningitidis 
of serogroup A and C will be reported to the Data and Safety Monitoring Board 
(DSMB). 
In Section 8.7 Follow-up of adverse events and serious adverse events and 
assessment of outcome and Section 8.8.1 Time frames for submitting serious 
adverse event reports to GSK Biologicals and PATH the term “when appointed” 
was deleted for the WHO monitor as she is now appointed. 
Section 8.7 paragraph written in bold: All SAEs will be reported within 24 
hours by the investigator to GSK Biologicals, to the PATH Focal Point, to the 
local safety monitor and, when appointed, to the WHO monitor. 
Section 8.8.1, 2nd paragraph: In addition to the direct reporting of any SAE and 
any subsequent information by the investigator or its designate to GSK 
Biologicals and PATH, the investigator will also report the SAE and subsequent 
information to the local safety monitor for transmission to the DSMB (see section 
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5.1.3) and, when appointed, to the WHO monitor. 
Section 8.8.2 Completion and transmission of serious adverse event reports to 
GSK Biologicals and PATH 
Details for the WHO study monitor were added: 
TBD. The name, address, phone and fax numbers will be provided prior to study 
start. 
Study Contact for SAE Reporting at WHO 
Yuppaporn Wattanagoon 
M121 WHO/HTP/IVR/POP 
Avenue Appia 20 
CH-1211 GENEVE 27 
Switzerland 
Tel. +41 22 791 15 01 
Email: wattanagoony@who.int 
Section References (two references were added) 
17 Richmond P, Borrow R, Miller E, Clarck S, Sadler F, Fox A, Begg N, Morris 
R, Cartwright K. Meningococcal serogroup C conjugate vaccine is 
immunogenic in infancy and primes for memory. Journal Infectious 
Diseases 1999; 179: 1569-72. 
18 Borrow R, Fox AJ, Richmond PC, Clarck S, Sadler F, Findlow J, Morris R, 
Begg NT, Cartwright K. Induction of immunological memory in UK 
infants by a meningococcal A/C conjugate vaccine. Epidemiol. Infect 2000; 
124: 427-432. 
 
Appencix C: Overview of the Recruitment Plan 
The 1st bullet point of this section was amended: 
• All subjects should be enrolled within a period of 5 months (preferably June 
to October). 
Appendix  D: Handling of Biological Samples Collected by the Investigator and 
Appendix  E: Shipment of Biological Samples 
The Fax number at the end of each Appendix was corrected: 
Fax: +32-2-656 60529144 
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Appendix G: Vaccine supplies, packaging and accountability (paragraph after 
bullet point list) 
An additional quantity of at least 5% of Tritanrix™-HepB and Hiberix™ will be 
supplied for replacement in case of breakage, bad storage conditions or any other 
reason that would make the vaccine unusable (i.e., given by mistake to another 
subject). 
Appendix H: Meningococcal carriage and mucosal immunity to Neisseria 
meningitidis in the African meningitis belt 
The entire section was restructured and additional information on e.g. sample 
size and power were included. In addition, a supplement was added describing 
the procedure of taking throat swabs. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
Amended 5 June 2003 and 02 October 2003) 
Protocol Title: A phase II, double blind, randomized, controlled study to evaluate 
the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) 
Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, as compared to GSK Biologicals’ Hiberix™ 
vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, 
when administered intramuscularly in infants at 6, 10 and 14 weeks of age. 
Amendment 2 
02 October 2003 
Coordinating Author: Sheila Woods 
Rationale/background for changes: 
The formulation of the Tritanrix™-HepB/Hib-MenAC vaccine which will be used 
in this and other Phase II studies has now been selected following the analysis of 
data from the separate dose-range study which evaluated three different 
formulations of the Tritanrix™-HepB/Hib-MenAC vaccine administered in 
infants at 6, 10 and 14 weeks of age. 
As the presentation, and preparation, of the selected formulation of vaccine is 
different to the Tritanrix™-HepB/Hiberix™ control vaccine, information 
regarding the practical procedures to be implemented to ensure the blinding of the 
study (preparation and administration of the vaccines) as well as the details of the 
content and presentation of the vaccine have been added in this amendment. 
The immunogenicity analysis of the dose-range study has highlighted the 
importance of having an accurate picture of the pre-vaccination maternal antibody 
levels in the infants (especially hepatitis B, diphtheria, pertussis and 
meningococcal serogroup A and C antibodies) as it appears that the response to 
the vaccine (especially to the hepatitis B, diphtheria, pertussis and meningococcal 
serogroups A and C antigens) can be affected by these levels. It has therefore been 
decided to add an additional blood sampling from the infants in this study at the 
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pre-vaccination timepoint and to drop the planned blood sampling from the 
mother. The protocol has been amended accordingly, including changes to the 
objectives and endpoints where relevant. Furthermore since the mother is no 
longer required to accompany the child for the first visit, the protocol (and the 
informed consent) has been changed to allow another parent or guardian to 
provide informed consent. 
As it is possible that the collection of the additional blood sample from the infants 
in the study may lead to an increased rate of withdrawal/drop-out of subjects from 
the study, the sample size has been increased from 260(130/group) to 280 
(140/group) to ensure that the required number of evaluable subjects is reached. 
As the committee that will be set up to oversee the ethical and safety aspects of 
the study conduct will be an independent organisation, it will now be called the 
Independent Data Monitoring Committee (IDMC) rather than the Data Safety 
Monitoring Board (DSMB). 
Appendix H (Meningococcal carriage and mucosal immunity to Neisseria 
meningitidis in the African meningitis belt) has been restructured and additional 
information on the sample size included so that it complies with PATH’s 
guidelines for protocols. 
 
The following items were amended on 02 October 2003: 
GSK Biologicals has changed their monitoring system from CPMS to GSK’s 
clinical trials tracking tool, eTrack, with study identification by eTrack study 
number and abbreviated title. Therefore, throughout the protocol, the CPMS 
number and alias: 759346/009 (DTPwHB/HIBMenACTT-009) has been changed 
to the eTrack study number and abbreviated title: 759346/009 
(DTPwHB/HIBMenACTT009); eTrack has also been added to the Glossary of 
Terms. 
Sponsor Information and/or Title pages 
Study Monitors: Cornelia Bevilacqua’s contact details were amended, contact 
details for the WHO monitor Dr. Lawrence Kweku Yamuah amended, WHO 
Study Contact for Reporting SAEs was changed from Yuppaporn Wattanagoon to 
Dr. Zarifah Reed and an additional collaborator from the London School of 
Hygiene and Tropical Medicine (Dr. Daniel Chandramohan) was added: 
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London School of Hygiene and Tropical Medicine 
Collaborating persons: Prof. Brian Greenwood 
Dr. Daniel Chandramohan 
 
WHO Monitor 
Dr. Lawrence Kweku Yamuah  
Centre for Measurement and 
Information in Medicine 
City University 
Northampton Square 
London, EC1V 0HB 
United Kingdom 
Tel: (+ 44) 20 7040 8371 
Fax: (+ 44) 20 7040 8371 
Email: L.K.Yamuah@city.ac.uk 
yamuahlawrence_kweku@hotmail.co
m 
Dr. Lawrence Kweku Yamuah 
Post-Doctoral Researcher / Data 
Manager 
Armauer Hansen Research Institute 
(AHRI) 
P.O. Box 1005 
Addis Ababa 
Ethiopia 
Tel: + 251 1 71 02 88 (work) 
Tel: + 251 1 71 17 04 (home) 
Fax: + 251 1 71 13 90 
Email: 
yamuahlawrence_kweku@hotmail.com 
 
WHO Study Contact for Reporting SAEs 
Yuppaporn Wattanagoon 
M121 WHO/HTP/IVR/POP 
Avenue Appia 20 
CH-1211 GENEVE 27 
Switzerland 
Tel. +41 22 791 15 01 
Email: wattanagoony@who.int  
Dr. Zarifah Reed 
WHO/VAB I/IVR/POP  
20 Avenue Appia 
CH-1211 GENEVE 27 
Switzerland 
Tel.  +41 22 791 4760 
Fax. +41 22 791 4860 
Email: reedz@who.int 
Study Monitors  
Cornelia Bevilacqua 
Central Study Coordinator, 
GlaxoSmithKline Biologicals, 
89, Rue de l’Institut, 1330 Rixensart, 
Belgium 
Tel: + 32 2 656.77.70 
Fax: + 32 2 656.81.33 
Mobile: + 33 (0) 685 25 24 69 
e-mail: cornelia.bevilacqua@gskbio.com 
Cornelia Bevilacqua 
‘La Fédarié Haute’ 
81440 Vénès 
France 
Tel: + 33 563 75 92 66 
Fax: + 33 563 75 92 66 
Mobile phone: + 33 685 25 24 69 
e-mail: cornelia_bevilacqua@yahoo.fr 
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Sponsor Information 
Study contact for Emergency Code Break 
Dr. John Williams (who will forward information to DSMB IDMC chairman) 
Section 1 Introduction (3rd paragraph, 2nd sentence); Section 1.3 Study rationale 
and Synopsis (2nd sentence) 
Except for an outbreaks of serogroup W-135 that spread in Burkina Faso in 2002 
and 2003, serogroup A and to a lesser extent serogroup C are largely responsible 
for N. meningitidis epidemics in African countries. 
Section1.1 Background (5th paragraph, 4th sentence amended including addition of 
underlined text) 
However, in another trial in the Gambia, strong memory to the C component 
was induced but evidence of memory induction for the A component priming 
for memory of the A+C conjugate vaccine was less convincing. 
 
Section 1.2 GSK Biologicals’ combined… Hib MenAC) conjugated vaccine (4th 
paragraph amended to include results of the feasibility study) 
 
The new combined Hib-MenAC (using TT as carrier protein) extemporaneously 
mixed with Tritanrix™-HepB was shown to be safe and immunogenic in 
preclinical studies. A phase II dose-range study in infants is ongoing outside the 
African continent and preliminary data will be available prior to starting this 
study. 
In the first three-dose primary vaccination study performed in the Philippines, 
three formulations of the combined Hib-Men AC vaccine (using TT as carrier 
protein) each extemporaneously mixed with Tritanrix™-HepB were evaluated 
and the Tritanrix™-HepB/Hib-MenAC combination using the Hib-MenAC 
formulation with a dosage of 2.5 µg of each of the MenA, MenC and Hib 
conjugate antigens was selected for further clinical development: the selected 
formulation was well tolerated; it induced similar antibody levels against the 
diphtheria, tetanus, pertussis, hepatitis B, Hib and meningococcal serogroup C 
antigens as the benchmark vaccines (Tritanrix™-HepB/Hiberix™ and 
Meningitec™) and 97.7 % subjects had meningococcal serogroup A serum 
bactericidal antibody titres of at least 1:8. See Appendix I for a summary of 
clinical data of this study, including a preliminary report on the Serious 
Adverse Events reported during that study 
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(5th paragraph amended as follows) 
Pre-clinical and clinical data generated with GSK Biologicals’ meningococcal 
conjugate vaccines are available in the Neisseria meningitidis conjugate vaccines 
Investigator Brochure (Neisseria meningitidis A, C and Y conjugate vaccines, 3rd 
edition, September 2001). An updated edition of this Investigator Brochure 
(which will include the data presented in Appendix I) is under preparation. 
Section 1.3 Study Rationale and Synopsis (4th paragraph amended to include 
results of the feasibility study) 
The new Tritanrix™-HepB/Hib-MenAC vaccine is being has been evaluated in a 
feasibility trial outside Africa in the Philippines. The combination using the Hib-
MenAC formulation with a dosage of 2.5 µg of each of the MenA, MenC and 
Hib conjugate antigens has been selected for further clinical development: the 
selected formulation was well tolerated; it induced similar antibody levels 
against the diphtheria, tetanus, pertussis, hepatitis B, Hib and meningococcal 
serogroup C antigens as the benchmark vaccines (Tritanrix™-HepB/Hiberix™ 
and Meningitec™) and 97.7 % subjects had meningococcal serogroup A serum 
bactericidal antibody titres of at least 1:8. Once As feasibility of the new vaccine 
is has now been shown, the present study plans to evaluate the use of GSK 
Biologicals’ Tritanrix™-HepB/Hib-MenAC vaccine in a high endemicity region in 
Africa. 
Section 2.2 Secondary objectives and Synopsis (Deletion of the first bullet) 
Just prior to the administration of the first vaccine dose, to assess the serum 
bactericidal antibodies against N. meningitidis serogroups A and C in the 
mother of the child as an indirect measurement of the prevaccination status of 
her infant. 
Section 3 Study design overview 
In the flowchart, the number of subjects enrolled was amended from 130 per 
group to 140 per group and the Visit 1 “Pre blood sample in the child’s mother” 
was changed to Blood sampling [of the child]. 
Section 3 Study design overview and Synopsis (Note/bullet point regarding OPV 
amended and 3 further bullet points amended and one deleted) 
BCG and OPV vaccines can be given at birth (or up to at least 2 weeks before the 
subject’s first visit) according to the nationally recommended immunization 
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schedule. OPV can also be given at 6, 10, 14 weeks of age concomitantly with the 
study vaccines or at any time during the study, whichever is more appropriate. 
Experimental design: 2 parallel groups of 130 140 subjects each to receive either 
of the following vaccines: 
As the control group will not be properly immunised with 1/5th of a dose of 
Mencevax™ AC, at study end, the control group Tritanrix™-HepB/Hiberix™ 
will be offered one dose of Mencevax™-ACWY in order to protect the 
children against the meningococcal diseases after study end, one dose of 
Mencevax™ ACWY will be offered to the Tritanrix™-HepB/Hiberix™ control 
group to protect them against meningococcal diseases of these serogroups: 
Mencevax™ ACWY will be given when the child is two years of age, or, if a 
meningitis epidemic occurs, earlier in the second year of life. 
• For all subjects: 3 4 blood samples (3.5 ml each):  
− immediately before the first dose of the primary vaccination course 
− one month after the third dose of the primary vaccination course 
− just prior to administration of the plain polysaccharides of serogroups A 
and C 
− one month after the administration of the plain polysaccharides of 
serogroups A and C. 
For the mothers of all subjects, just prior to the administration of the first vaccine 
dose to their infants: one blood sample (3.5 ml). 
Section 4.1 Number of subjects and Synopsis (1st and 2nd paragraphs) 
Target enrolment will be 260 280 healthy male and female infants (130 140 
subjects per group) to provide 220 evaluable subjects (110 per group) for the 
immunogenicity analysis. The study will be conducted at the Navrongo Health 
Research Center in Ghana (War memorial Hospital and several 2 health centres of 
Navrongo health district). 
Enrolment will be terminated when 260 280 subjects have been enrolled 
Section 4.2 Inclusion criteria (One bullet point amended) 
Written informed consent obtained from the mother parent or guardian of the 
subject. 
Section 4.5 Contraindications (contraindications for Hiberix™ added) 
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The Hiberix™ vaccine should not be administered to subjects with known 
hypersensitivity to any component of the vaccine, or to subjects having shown 
signs of hypersensitivity after previous administration of Hib vaccines. 
Section 5.1.3 (section heading changed as follows and throughout section DSMB 
changed to IDMC: 17 changes)  
5.1.3 Data Safety Monitoring Board (DSMB) Independent Data Monitoring 
Committee (IDMC) 
(Composition of IDMC: 2nd paragraph amended as shown) 
The Charter (terms of references) of the Terms of reference (operating 
procedures) of the IDMC will be written after the first meeting of the IDMC 
members, prior to study start. 
Role of the IDMC (2nd paragraph) 
The IDMC will confer before the initiation of the study (pre-initiation review), 
during the study proper and at the close out of the study to review any relevant 
safety data and to review and approve the Report and Analysis Plan (RAP), where 
applicable ; after study end, the IDMC will have a first assessment report… 
(Role of Local Safety Monitor: Second and last bullet point amended as shown) 
reviewing blinded reactogenicity data after each dose according to IDMC charter 
and discussing with IDMC if necessary 
Unblinding a subject if deemed necessary, upon request of the 
investigator/physician in charge of the subject, to allow for adequate treatment. 
Section 5.2 General study aspects (1st paragraph and 2nd, 4th and 5th sentences of 
last paragraph) 
The maximum distance between a subject’s compound and the nearest health 
facility will be 1 km 10 km. Each visit to the clinic for vaccination will last 
approximately 4 hours; each home visit by a field worker will last about 15 
minutes. 
PATH and GSK Biologicals are not sponsor of this ancillary study but the 
protocol of this ancillary study is attached as an Appendix to this protocol (refer 
Appendix H for further details) for operational reasons (only one subject 
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information sheet will be written and only one informed consent will be submitted 
to the approval of the parents/guardians of the child, however, any 
parent/guardian accompanying the child at visits subsequent to the first visit 
who has not already signed an Informed Consent for this study will also have to 
sign an Informed Consent prior to providing any throat swab or saliva sample). 
This ancillary study will be reported separately by the investigators of the 
ancillary study. This ancillary study requires collection of throat swabs and saliva 
samples from the mothers parent/guardian and infants prior to the first dose (6-8 
weeks) and at 10 weeks, 18 weeks, 9 months and 12 months of age. The collection 
of throat swab and saliva samples will be detailed in the study procedures 
(section 5. 3) and the subject information sheet. 
Section 5.3 Outline of study procedures  
In Table 5-1, as mother’s blood sampling replaced by child’s blood sampling at 
Visit 1, corresponding footnote amended to refer to serology section:  
* from the mother only a minimum of 2 ml may be taken at prevaccination timepoint. See 
section 5.5.2; 
3rd footnote amended by addition of underlined text as follows : 
# any parent/guardian accompanying the child instead of the mother at visits subsequent to the 
first visit who has not already signed an Informed Consent for this study will have has to sign 
an Informed Consent prior to providing any throat swab or saliva sample.  
Note at end of footnotes (2nd sentence amended): 
OPV vaccine can be administered to the subjects at 6, 10 and 14 weeks of age concomitantly with 
the study vaccines or at any time during the study, whichever is more appropriate. 
Section 5.4 Detailed description of study stages/visits  
(Visit 1 change of the following 2 bullet points, regarding informed consent and 
blood sampling) 
Written informed consent from the subject’s mother parent/guardian. 
Collection of 3.5 ml of whole blood from the mother.  
Collection of blood for serology: a minimum of 3.5 ml of whole blood to 
provide a minimum of 1.5 ml of serum according to instructions in Appendix 
D. 
Collection of blood for serology: it is understood that collection of blood in 
infants aged 6 weeks may be technically difficult. Therefore a minimum of 
2.0 ml of whole blood, which is the minimum volume of blood that will allow 
the essential serology to be undertaken, has to be taken according to 
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instructions in Appendix D. However, whenever possible a 3.5 ml sample 
should be collected to provide the 1.5 ml sample of serum that is needed for 
full serological assessment of the response to the vaccine and for validation 
assays. Section 5.5.2. 
Technically skilled and trained individuals will draw blood to avoid 
unnecessary pain and technical failure as much as possible. 
(Visits 1, 2, 3 and 6: Amendment of the following bullet point) 
The field worker will be given a diary card and will visit the subjects at their 
home to record, on the day of vaccine injection (day 0) and during the 3 
subsequent days (days 1-3) or up to resolution of the symptoms, whichever is 
longer, the subject’s body temperature and any local (at the injection site) or 
general adverse events occurring on the day of vaccination (day 0) and during 
the 3 subsequent days (days 1-3) (see section 8.5.1). 
 
(Visits 1, 2, 3, 4 and 6: Amendment of the last bullet point) 
The subjects’ parents/guardians will be instructed to contact the investigator/study 
contact person at the health centre immediately should the subject manifest 
any signs or symptoms they perceive as serious. 
(Visit 2 amendment of 1st bullet point and N.B.) 
Provision of definitive study ID card (plastified ID card including picture of 
parent/guardian (mother) and infant). 
N.B. The parent/guardian (mother) of the study subject will be asked to present 
the study ID card every time they attend the hospital / health centers. 
(Visits 2, 4, 5, and 6: amendment of Note by deletions and addition of underlined 
text) 
Note: Any parent/guardian accompanying the child instead of the mother at 
visits subsequent to the first visit who has not already signed an Informed 
Consent for this study will have has to sign an Informed Consent prior to 
providing any saliva sample. 
(Visit 7: amendment of last bullet point) 
After study end, one dose Mencevax™ ACWY will be offered to the Tritanrix™-
HepB/Hiberix™ control group to protect them against meningococcal diseases 
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of these serogroups: The Mencevax™ ACWY will be given when the child is 
two years of age or, if a meningitis epidemic occurs, already earlier in the 
second year of life. 
(Visit 4, 6 and 7: amendment of following bullet point) 
Collection of blood for serology: a minimum of 3.5 ml of whole blood to provide 
a minimum of 1.5 ml of serum according to instructions in Appendix B. 
Technically skilled and trained individuals will draw blood to avoid 
unnecessary pain and technical failure as much as possible.. 
Section 5.5.2 Laboratory assays (2nd paragraph, points 1 and 4 and Table 5-3) 
2nd paragraph amended as follows: 
For all subjects, a 3.5 ml sample of whole venous blood will be collected at visits 
1, 4, 6 and 7 using tubes with serum separator. Since the investigator has 
suggested that the collection of this amount of blood at Visit 1 may be 
technically difficult in such small infants, the quantity collected at this visit can 
be reduced to 2.0 ml, as a strict minimum, however this will not allow for any 
validation/retesting etc that may be required when the testing is performed. In 
addition, in all mothers, a 3.5 ml of whole venous blood will be collected at Visit 
1. 
The following was added to the end of point 1: 
More recently, efficacy data from postlicensure surveillance has been shown to 
validate the SBA-MenC 1:8 cut-off as a serological correlate of protection for 
meningococcal serogroup C conjugate vaccines 29. 
The following was added to the end of point 4: 
Post-vaccination serum samples with ELISA anti-D antibody concentrations 
<0.1 IU/ml will be re-tested using a VERO-cell neutralization assay 33, 34. The 
cut-off of the VERO-cell assay is 0.016 IU/mL. 
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Table 5-3: Laboratory Assays amended as follows: 
 Antigen Assay 
method 
Test Kit/ 
Manufacturer
Assay 
unit 
Assay
cut-off 
Laboratory  
 SBA-MenA Bactericidal 
assay 
in house dilution for 
50% killing
1:8 Rixensart  
 SBA-MenC Bactericidal 
assay 
in house dilution for 
50% killing
1:8 Rixensart  
 PRP  ELISA in-house µg/ml 0.15 Rixensart*  
 PSA ELISA in-house µg/ml 0.3 Rixensart  
 PSC ELISA in-house µg/ml 0.3 Rixensart  
 Diphtheria  ELISA in-house IU/ml 0.1 Rixensart*  
 Tetanus ELISA in-house IU/ml 0.1 Rixensart*  
 BP ELISA commercial EL.U/ml 15 Rixensart*  
 HBs  ELISA commercial mIU/ml 10 Rixensart*  
 Diphtheria Vero-cell in house IU/ml 0.016 Rixensart  
 *or in a validated laboratory designated by GlaxoSmithKline Biologicals  
Section 5.5.3 Serology plan (1st, 2nd and 3rd paragraphs amended) 
Pre-vaccination (Day 0) serum samples will be tested in all subjects for 
antibodies against SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, diphtheria 
toxoid, pertussis antigen and recombinant DNA hepatitis B surface antigen (no 
pre-vaccination testing of anti-TT and anti-PRP is foreseen as immunogenicity 
results of the previous clinical study were highest for these two antibodies). 
Post-vaccination III and pre-booster serum samples will be tested in all subjects 
for antibodies against all vaccine antigens (SBA-MenA, SBA-MenC, anti-PRP, 
anti-PSA, anti-PSC, diphtheria and tetanus toxoids, pertussis antigen and 
recombinant DNA hepatitis B surface antigen). 
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The post-booster serum sample taken from all children and the prevaccination 
serum sample taken from their mothers will be tested for SBA-MenA and SBA 
MenC, anti-PSA and anti-PSC antibodies. 
In case of insufficient blood sample volume to perform assays for all antibodies, 
they will be analyzed according to the following priority ranking: 
• SBA-MenA 
• SBA-MenC 
• anti-PRP (only for Post vacc III and pre-booster) 
• anti-PSA 
• anti-PSC 
• anti-diphtheria, anti-tetanus, anti-BP, anti-HBs 
• anti-diphtheria (Vero-cell assay only when required for Post vacc III and 
Pre-booster) 
• anti-HBs 
• anti-tetanus, (only for Post vacc III and pre-booster) 
• anti-BP 
• anti-PSA 
• anti-PSC 
Section 5.5.4 Endpoints for suboptimal response (suboptimal response for anti-
diphtheria concentration changed to Vero-cell cut-off and last sentence amended) 
   anti-diphtheria concentration  <0.1IU/ml < 0.016 IU/ml (Vero-cell assay) 
The Mencevax™ ACWY will be given when the child is two years of age or, if a 
meningitis epidemic occurs, already earlier in the second year of life. 
Section 6.1.1 GSK Biologicals’ Haemophilus influenzae type b meningococcal 
AC-TT (Hib-MenAC) conjugate vaccine (section amended as follows) 
One lot of the vaccine will be used. The vaccine will be supplied as a white freeze 
dried pellet in monodose vials to be reconstituted with Tritanrix™-HepB before 
use. Each vial of the Hib-MenAC (5/5/5) vaccine needs to be reconstituted with 
2 vials of the Tritanrix™-HepB before use (0.5 ml per vial). Only half of the 
dose (i.e. 0.5 ml will be administered. For details of the dose dilution see Section 
6.1.7. One dose (0.5 ml) of the reconstituted vaccine contains the following 
components: 
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 Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid 
: TBD 2.5 µg  
 Neisseria meningitidis A capsular polysaccharide conjugated to tetanus toxoid 
: TBD2.5 µg  
 Neisseria meningitidis C capsular polysaccharide conjugated to tetanus toxoid 
: TBD2.5 µg  
Note: The dose of each component (2.5 µg or 5 µg for each polysaccharide) will 
be determined in a separate dose-range study, results of which will be available 
prior to study start. 
Section 6.1.3: GSK Biologicals’ Haemophilus influenzae type b conjugate 
vaccine: Hiberix (1st sentence) 
The vaccine will be supplied as a white freeze-dried pellet in monodose vials 
to be reconstituted with one 0.5 ml vial of Tritanrix-HepB before use. 
Section 6.1.7 Extemporaneous mixing of Tritanrix™-HepB and Hib-MenAC 
vaccines or Hiberix™  
New subheading “Tritanrix™-HepB and Hiberix™” added and 2nd sentence 
amended: 
The full content of the Tritanrix™-HepB vaccine vial should be extracted and 
injected into the vial containing the lyophilized Hib-MenAC or Hiberix™ 
vaccines. 
 
Additional subsection with subheading added as follows:  
Tritanrix™-HepB and Hib-MenAC : dose dilution to provide Hib-MenAC 
(2.5/2.5/5.5) 
The Hib-MenAC (2.5/2.5/2.5) formulation containing 2.5 µg of each 
polysaccharide will be used in this study. This will be obtained by dilution of the 
supplied Hib-MenAC (5/5/5) vaccine that contains 5µg of each polysaccharide. 
Each vial of the Hib-MenAC (5/5/5) vaccine needs to be reconstituted with 2 
vials of the Tritanrix™-HepB before use. 
The liquid Tritanrix™-HepB vaccine should always be shaken before use. The 
full content of two monodose vials of Tritanrix™-HepB vaccine should be 
extracted and injected into the vial containing the lyophilized Hib-MenAC 
(5/5/5) vaccine. The vial should be agitated until the lyophilized vaccine pellet 
has completely dissolved. The mixed vaccines will appear white. The 
reconstituted mixed vaccines should be used promptly after reconstitution 
(within 30 minutes): 
 
759346/009 (DTPwHB/HIBMenACTT009) GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009)   
Amendment 7: 12 April 2006 Confidential and Proprietary Information 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
Amendment 2 xiv
• withdraw one dose of 0.5 ml of the mixed vaccines from the vial; 
• a new needle should be used for injection; 
One dose (0.5 ml) of the mixed vaccines should be administered by 
intramuscular injection into the anterolateral quadrant of the left thigh. 
Note: The reconstituted vaccine remaining in the vial after 1 dose (0.5 ml) has 
been withdrawn is to be retained by the investigator for purposes of vaccine 
accountability and should not be reused. See Appendix G for more details. 
Section 6.3 Treatment allocation and randomization (1st sentence) 
The target sample size is 260 280 enrolled subjects (220 evaluable for 
immunogenicity analysis, with 110 subjects in each group). 
Section 6.4 Method of blinding and breaking the study blind (1st paragraph) 
The study will be double blind. The study vaccine and the control vaccine will 
have the same whitish appearance after reconstitution. However, since the 
vaccines used in this study are different in their packaging volumes 
(Tritanrix™-HepB and Hiberix™ = 1 vial of 0.5ml of each vaccine, 
Tritanrix™-HepB and Hib-MenAC = 2 vials of 0.5 ml of Tritanrix™-HepB and 
1 vial of 0.5 ml of Hib-MenAC), special precautions will be taken to ensure 
blinding. For each vaccination during the course of the study, a Syringe Filler 
and Vaccinator will work as a vaccination team: the Syringe Filler will prepare 
the vaccine for administration to a specific subject and the Vaccinator will 
administer the vaccine to each subject, according to the investigator’s SOP. To 
ensure blinding, a vaccination team will perform no other function in the study. 
The subject’s parent/guardian as well as those responsible for the evaluation of 
safety or immunogenicity study parameters will all be unaware which vaccine 
preparation was administered to a particular subject. The subject’s 
parents/guardians, the investigator and the study personnel will be blinded to the 
vaccines to be administered. 
 
Section 6.5 Replacement of unusable vaccine doses (addition of underlined text to 
1st sentence of 2nd paragraph 
In addition to the vaccine doses provided for the planned number of subjects, at 
least 5% additional doses of Tritanrix™-HepB and Hiberix™ will be supplied. 
Section 8 Adverse Events, and Serious Adverse Events and vaccine failure 
Section 8.3 Lack of efficacy (Last sentence amended) 
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Any case of diphtheria, tetanus, pertussis, hepatitis B, invasive diseases due to 
Haemophilus influenzae type b, measles, yellow fever or Neisseria meningitidis 
of serogroup A and C will be reported to the Data and Safety Monitoring 
Board (DSMB) Independent Data Monitoring Committee (IDMC). 
Section 8.7 Follow-up of adverse events and serious adverse events and 
assessment of outcome (Penultimate paragraph) 
All SAEs will be reported within 24 hours by the investigator to GSK 
Biologicals, to the PATH Focal Point, to the local safety monitor and to the 
WHO monitor study contact for SAE reporting. The local safety monitor will 
transmit the information to the DSMB IDMC according to the operating 
procedures of the DSMB IDMC. In addition, the local safety monitor will 
also provide a listing of all systemic grade 3 symptoms suspected to be related 
to vaccination and any case of diphtheria, tetanus, pertussis, hepatitis B, 
invasive diseases due to Haemophilus influenzae type b, measles, yellow fever 
or Neisseria meningitidis of serogroup A and C to the DSMB IDMC on a bi-
monthly regular basis according to the Charter for the IDMC. 
Section 8.8 
Since reporting will be to the local safety monitor (who will transmit reports to 
WHO and IDMC) as well as to GSK Biologicals, PATH, the headings and 
subheadings and text have changed as follows: 
8.8 Prompt reporting of serious adverse events to GSK 
Biologicals, WHO, and PATH and the local safety monitor 
8.8.1 Time frames for submitting serious adverse events to GSK Biologicals, 
WHO, and PATH and the local safety monitor 
Section 8.8.1 (1st and 2nd paragraphs) 
SAEs will be reported promptly to GSK Biologicals, WHO, and PATH once the 
investigator determines that the event meets the protocol definition of an SAE. 
The investigator or designate will fax transmit the SAE reports to GSK 
Biologicals’ Study Contact for Serious Adverse Event Reporting, to the WHO 
study contact for SAE reporting, and to PATH Focal Point within 24 hours of 
his/her becoming aware of these events. Additional or follow-up information 
relating to the initial SAE report is also to be reported to the GSK Biologicals’ 
Study Contact for Serious Adverse Event Reporting, to the WHO study contact 
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for SAE reporting, and to PATH Focal Point within 24 hours. 
In addition to the direct reporting of any SAE and any subsequent information by 
the investigator or its designate to GSK Biologicals and PATH, the investigator 
will also report the SAE and subsequent information to the local safety monitor 
for transmission to the IDMC (see section 5.1.3) and to the WHO monitor. 
8.8.2 Completion and transmission of serious adverse events to GSK 
Biologicals, WHO, and PATH and the local safety monitor 
Section 8.8.2 (1st paragraph and WHO study contact for reporting SAEs amended 
as follows) 
Once an investigator becomes aware that a SAE has occurred in a study subject, 
she/he will report the information to GSK Biologicals, WHO and PATH within 24 
hours as outlined in Section 8.8.1. The SAE Report Form will always be 
completed as thoroughly as possible with all available details of the event, signed 
by the investigator (or designee), and forwarded to GSK Biologicals, WHO and 
PATH within the designated time frames. If the investigator does not have all 
information regarding an SAE, he/she will not wait to receive additional 
information before notifying GSK Biologicals, WHO and PATH of the event and 
completing the form. The form will be updated when additional information is 
received and forwarded to GSK Biologicals, WHO and PATH within 24 hours as 
outlined in Section 8.8.1. 
Yuppaporn Wattanagoon 
M121 WHO/HTP/IVR/POP 
Avenue Appia 20 
CH-1211 GENEVE 27 
Switzerland 
Tel. +41 22 791 15 01 
Email: wattanagoony@who.int  
Dr. Zarifah Reed 
WHO/VAB/IVR/POP 
20 Avenue Appia 
CH-1211 GENEVE 27 
Switzerland 
Tel.  +41 22 791 4760 
Fax. +41 22 791 4860 
Email: reedz@who.int 
 
Section 10.1 Co-primary endpoints and Synopsis (6th bullet point amended by 
addition of bold italic text) 
Anti-diphtheria concentration ≥ 0.1 IU/ml by Elisa and, if negative, 
≥ 0.016 IU/ml by Vero-cell (seroprotection) 
Section 10.2 Secondary endpoints and Synopsis  
Pre-primary vaccination endpoints added, 11th bullet point of Antibody 
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persistence endpoints amended and Indirect pre vaccination status endpoints 
deleted as follows: 
Pre-primary vaccination 
In all subjects, just prior to the administration of the 1st dose of the primary 
vaccination 
• SBA-MenA titer ≥ 1:8 (seropositivity) 
• SBA-MenC titer ≥ 1:8 (seropositivity) 
• Anti-PSA concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSC concentration ≥ 0.3 µg/ml (seropositivity) 
• Anti-PSA concentration ≥ 2 µg/ml 
• Anti-PSC concentration ≥ 2 µg/ml 
• Anti-diphtheria concentration ≥ 0.1 IU/ml (seroprotection) 
• Anti-HBs concentration ≥10 mIU/ml (seroprotection) 
• Anti-BP concentration ≥ 15 EL.U/ml (seropositivity) 
Concentration/titers of SBA-MenA, SBA-MenC, anti-PSA, anti-PSC, anti-HBs, 
anti-diphtheria and anti-BP antibodies 
Antibody persistence (11th bullet point amended) 
• Anti-diphtheria concentration ≥ 0.1 IU/ml by ELISA and, if negative, ≥ 0.016 
IU/ml by Vero-cell (seroprotection) 
Indirect pre vaccination status through assessment of the mother: 
Just prior to the administration of the first vaccine dose, in each mother. 
• SBA-MenA titer ≥ 1:8 and titer 
• SBA-MenC titer ≥ 1:8 and titer 
• Anti-PSA and anti-PSC seropositivity and concentration 
Section 10.3 Estimated sample size (1st sentence, Table 10-1 and Table 10-2) 
The target sample size is 260 280 enrolled subjects to reach 220 evaluable 
subjects in the ATP cohort for immunogenicity (110 evaluable subjects in each 
group). 
Table 10.1: Power for criterion 1… Missing cut-off for SBA-MenC and SBA-
MenA added in bold italics in Endpoint column as follows: 
  SBA-MenC = 1:8 
  SBA-MenA = 1:8 
Table 10.2: Power for criterion 2… Cut-off for anti-diphtheria in Endpoint 
column and footnote amended in bold italics as follows: 
  Anti-diphtheria = 0.1 IU/ml by ELISA and, 
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   if negative, ≥ 0.016 IU/ml by Vero-cell 
References: MenAC-Hib-001 for % of anti-PRP, Hib-065 for % of anti-tetanus, anti-diphtheria (by 
ELISA only) and anti-HBs, DTPw-HBV-033 for s.d. of log10 (concentration) for anti-BP. 
Section 10.4 Study cohorts to be evaluated  
This section was updated to reflect GSK Biologicals change of use of the Total 
cohort to the Total vaccinated cohort. 
Changes were as follows with new text in bold italics: 
A total of 6 cohorts are defined for the purpose of analysis.  
• Three cohorts that will be used for the analysis of the primary vaccination 
course: 
! the Primary Total vaccinated cohort 
! the Primary ATP cohort for safety 
! the Primary ATP cohort for immunogenicity (used for the analysis of the 
co-primary objectives of immunogenicity) 
 
• Three cohorts that will be used for the analysis of the booster phase: 
! the Booster Total vaccinated cohort 
! the Booster ATP cohort for safety 
! the ATP cohort for immune memory 
 
The Primary Total vaccinated cohort (Primary vaccination) 
The primary total cohort will include all subjects vaccinated in the primary phase 
of the study. The analysis of an endpoint based on the primary total cohort will 
include all subjects vaccinated in the primary phase for whom data for the 
endpoint are available. 
The Total vaccinated cohort will include all subjects vaccinated in the primary 
phase of the study. For the Total analysis of safety, this will include all subjects 
vaccinated in the primary phase of the study with at least one vaccine 
administration documented in the primary phase. For the Total analysis of 
immunogenicity / efficacy, this will include subjects vaccinated in the primary 
phase of the study for whom data concerning immunogenicity/efficacy endpoint 
measures are available. The Total vaccinated cohort analysis will be performed 
per treatment actually administered. 
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Primary According to protocol (ATP) cohort for safety (Primary vaccination) 
The Primary According to protocol (ATP) cohort for safety will include all 
subjects: 
 
Primary According to protocol (ATP) cohort for immunogenicity (Primary 
vaccination) 
The Primary According to protocol (ATP) cohort for immunogenicity will include 
all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the 
procedures defined in the protocol, and with no elimination criteria during the 
study) from the Primary ATP cohort for safety for whom assay results are 
available for antibodies against at least one study vaccine antigen component at 
Visit 4. 
The Booster Total vaccinated Cohort cohort (Booster vaccination) 
The Booster total cohort will include all subjects vaccinated in the booster phase 
of the study. The analysis of an endpoint based on the Booster total cohort will 
include all subjects vaccinated in the booster phase for whom data for the 
endpoint are available. 
The Total vaccinated cohort will include all subjects vaccinated in the booster 
phase of the study. For the Total analysis of safety, this will include all subjects 
vaccinated in the booster phase of the study with at least one vaccine 
administration documented in the booster phase. For the Total analysis of 
immunogenicity/efficacity, this will include subjects vaccinated in the booster 
phase of the study for whom data concerning immunogenicity / efficacy 
endpoint measures are available. The Total vaccinated cohort analysis will be 
performed per treatment actually administered. 
Booster According To Protocol (ATP) cohort for safety (Booster vaccination) 
The Booster ATP cohort for safety will include all subjects from the Primary ATP 
cohort (primary vaccination) for safety 
 
Section 10.5 Derived and transformed data (whole section amended) 
For a given subject and cohort and the analysis of a given measurement, missing 
or non-evaluable measurements will not be replaced. Therefore, an analysis will 
exclude subjects with missing or non-evaluable measurements. 
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For immunogenicity data, the antibody concentrations/titers below the cut-off of 
the assay will be given an arbitrary value of half the cut-off for the purpose of the 
GMC/GMT calculation. 
Immunogenicity 
For a given subject cohort and the analysis of a given measurement, missing or 
unevaluable measurements will not be replaced. Therefore an analysis will 
exclude subjects with missing or unevaluable measurements. 
• The cut-off value is defined by the laboratory before the analysis and is 
described in Section 5.5.2. 
• A seronegative subject is a subject whose titer or concentration is below the 
cut-off value. 
• A seropositive subject is a subject whose titer or concentration is greater 
than or equal to the cut-off value. 
• Antibody concentrations or titers below the cut-off of the assay will be given 
an arbitrary value of half the cut-off for the purpose of GMC or GMT 
calculation.  
Other 
Subjects who missed reporting symptoms (solicited or unsolicited or 
concomitant medications) will be treated as subjects without symptoms 
(solicited or unsolicited or concomitant medications, respectively). 
Section 10.6.2 Analysis of Immunogenicity (1st paragraph) 
The analysis of immunogenicity will be based on the Primary ATP cohort for 
immunogenicity. If, for any vaccine group, the percentage of enrolled subjects 
with serological results excluded from this ATP cohort is more than 5%, a second 
analysis based on the Primary Total vaccinated cohort will be performed to 
complement the ATP analysis. 
Section 10.6.3 Analysis of safety (1st paragraph) 
The primary analysis will be based on the Primary Total vaccinated cohort. If the 
percentage of enrolled subjects excluded from the Primary ATP cohort for safety 
is more than 5%, a second analysis based on this ATP cohort will be performed to 
complement the Primary Total vaccinated cohort analysis. 
Section 10.7.1 Analysis of immunogenicity (1st paragraph) 
The analysis of antibody persistence and the analysis of immune memory will be 
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respectively based on the Booster ATP cohort for safety and the ATP cohort for 
immune memory. If, for any vaccine group, the percentage of enrolled subjects 
with serological results excluded from an ATP cohort is more than 5%, a second 
analysis based on the Booster Total vaccinated cohort will be performed to 
complement the ATP analysis. 
Section 10.7.2 Analysis of safety (1st paragraph) 
All analyses will be based on the Booster Total vaccinated cohort. If the 
percentage of enrolled subjects excluded from the Booster ATP cohort for safety 
is more than 5%, a second analysis based on this ATP cohort will be performed to 
complement the Booster Total vaccinated cohort analysis. 
Section 10.8 Reporting of final analyses (2nd paragraph) 
A final analysis for the booster vaccination will be carried out based on all data 
collected up to one month after the administration of one fifth of a dose of 
Mencevax™ AC. An annex report based on the final analysis for the booster 
vaccination will be provided. 
References (number 26 was amended and three additional references added) 
26 Enos K. Cerebrospinal meningitis in northern Ghana: the experience of the 
War Memorial Hospital, Navrongo [Report]. Ghana: Ministry of Health. 
1997. 
29 Andrews N, Borrow R, Miller E. Validation of serological correlate of 
protection for meningococcal C conjugate vaccine by using efficacy 
estimates from post licensure surveillance in England. Clin Diagn Lab 
Immunol 2003;10:780-786. 
33 Miyamura K, Nisho, S Ito A, Murata R, Kono R. Micro cell culture method 
for determination of diphtheria toxin and antitoxin concentrations using 
VERO cells: I. Studies on factors affecting the toxin and antitoxin titration. 
J Biol Stand 1974;2:189-201. 
34 Miyamura K, Nisho ,S Ito A, Murata R, Kono R. Micro cell culture method 
for determination of diphtheria toxin and antitoxin concentrations using 
VERO cells: II. Comparison with rabbit skin method and practical 
application for seroepidemiological studies. J. Biol Stand 1974;2:203-209. 
 
Appendix C Overview of the recruitment plan (5th and 6th paragraphs amended and 
2 bullet points) 
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On the day of immunization, prior to any study procedure, the parent information 
sheet and informed consent forms are read and explained to the subject’s 
parents/guardians (mothers) in the local language and according to the local 
custom and questions can be answered. Literate parents/guardians (mothers) are 
given the information sheet and IC form to read. 
When agreement is given by the parent/guardian (mother), the IC is signed or 
thumbprinted (illiterates) by the parents/guardians (mothers) of the subject, 
witnessed by an independent person. 
 
Anticipated recruitment rate is approximately 52 56 subjects per month. Subjects 
will be recruited when they present themselves at the immunization clinics. 
• Enrolment will be terminated when 260 280 subjects are enrolled. 
Appendix G: Vaccine supplies, packaging and accountability (Points 1, 2 and 3) 
1. Vaccine supplies 
• 390 420 doses of Hib-MenAC vaccine in monodose vials  
• 390 420 doses of Hiberix™ vaccine in monodose vials  
• 780 1260 doses of Tritanrix™-HepB vaccine in monodose vials 
• 260 280 doses of Mencevax™ AC 
• 520 560 doses of 0.5 ml diluent for the Mencevax™ AC vaccine 
2. Vaccine packaging 
The vaccines will be packed in labelled boxes. In order to ensure the double 
blind of the study, all vaccine boxes will be identical (size and appearance), 
despite the different number of vials needed for reconstitution of the vaccines. 
Only the vaccination team will open the boxes for reconstitution and 
administration of the vaccine so only the vaccination team will know which 
vaccine is contained in the individual boxes (see section 6.4). The box label will 
contain, as a minimum, the following information: study number, subject number, 
lot number (or numbers, when double-blind), instructions for vaccine 
administration. 
3 Vaccine accountability 
The investigator or pharmacist must sign a statement that he/she has received the 
clinical supplies for the study. At all times the figures on supplied, used and 
remaining vaccine doses should match. All used vials should be placed in sealed 
envelopes by the vaccination team in order to maintain the blinding of the 
study. At After the end of the study and unblinding, it must be possible to 
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reconcile delivery records with those of used and unused stocks.  An explanation 
must be given of any discrepancies. 
In addition, minor typographical errors have also been corrected throughout the 
protocol. The abbreviation list has been amended to include IDMC and Vero 
(African monkey kidney cells) and DSMB has been deleted. DSMB has also been 
changed to IDMC in definition of Local Safety Monitor in the Glossary of Terms. 
PARENT INFORMATION SHEET AND INFORMED CONSENT 
This document has also been amended so that it is consistent with the protocol. In 
addition, throughout the document, [your] child has been changed to [your] 
child/ward. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
5 June 2003 and 02 October 2003) 
Protocol Title: A phase II, double blind, randomized, controlled study to evaluate 
the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) 
Biologicals’ Hib-MenAC vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, as compared to GSK Biologicals’ Hiberix™ 
vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, 
when administered intramuscularly in infants at 6, 10 and 14 weeks of age. 
Amendment 3 
05 January 2004 
Coordinating Author: Nikola Bülow 
Rationale/background for changes: 
As the collaboration with MVP on this study was cancelled, PATH does not 
longer act as sponsor for this study. 
For the results of study 759346/001 (DTPwHB/HibMenACTT001) we refer to the 
new IB for Tritanrix™-HepB/Hib-MenAC (combined Diphtheria-Tetanus-whole 
cell Pertussis-Hepatitis B, Haemophilus Influenzae type B and Neisseria 
meningitidis serogroup A and C-Tetanus toxoid conjugate vaccine Investigator 
Brochure, 1st Edition, January 2004). 
The following items were amended on 05 January 2004: 
Reference to PATH and MVP was deleted from the entire protocol. 
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Section 1.2 GSK Biologicals’ combined H. influenzae type b - N. meningitidis 
polysaccharide A, C (Hib-MenAC) conjugated vaccine (paragraph 4: last sentence 
was deleted, wording of paragraph 5 was changed) 
See Appendix I for a summary of clinical data of this study, including a 
preliminary report on the Serious Adverse Events reported during that study. 
Pre-clinical and clinical data generated with GSK Biologicals’ meningococcal 
conjugate vaccines are available in the Neisseria meningitidis conjugate vaccines 
Investigator Brochure (Neisseria meningitidis A, C and Y conjugate vaccines, 3rd 
edition, September 2001). An updated edition of this Investigator Brochure 
(which will include the data presented in AppendixI) is under preparation. 
Tritanrix™-HepB/Hib-MenAC vaccine are available in the combined 
Diphtheria-Tetanus-whole cell Pertussis-Hepatitis B, Haemophilus Influenzae 
type B and Neisseria meningitidis serogroup A and C-Tetanus toxoid conjugate 
vaccine Investigator Brochure (DTPw-HBV-Hib-MenAC, 1st Edition, January 
2004). 
Section 4.1 Number of subjects (last sentence of 1st paragraph) 
The study will be conducted at the Navrongo Health Research Center in Ghana 
(War Memorial Hospital and 2 health centres of Navrongo health district). 
Section 8.8.2 Completion and transmission of serious adverse event reports to 
GSK Biologicals, WHO and the local safety monitor (1st sentence of 1st 
paragraph) 
Once an investigator becomes aware that a SAE has occurred in a study subject, 
she/he will report the information to GSK Biologicals and WHO within 24 hours 
and to the local safety monitor as outlined in Section 8.8.1. 
Appendix I: Summary of Clinical Results from Study 759346/001 
(DTPwHB/HibMenACTT001) 
The entire section was removed from the protocol as we now refer to the new IB 
for DTPw-HBV/Hib-MenAC. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
5 June 2003, 02 October 2003  
05 January 2004 and  27 January 2004) 
 
Protocol Title: Protocol Title: A phase II, double blind, randomized, controlled 
study to evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously 
mixed with GSK Biologicals’ Tritanrix™-HepB, as compared to GSK 
Biologicals’ Hiberix™ vaccine, extemporaneously mixed with GSK Biologicals’ 
Tritanrix™-HepB, when administered intramuscularly in infants at 6, 10 and 14 
weeks of age. 
Amendment 4 
27 January 2004 
Coordinating Author: Catherine Murphy 
Rationale/background for changes:   
Due to a lack of funding, the mucosal study component of the ancillary study was 
removed . 
The following items were amended on 27 January 2004: 
The following names and items have been deleted from the entire protocol:  
The School of Medical Sciences at the University of Bristol, United Kingdom 
(page 2, Section 5.1, Section 5.2 fourth paragraph and Appendix H); the Co- 
Investigator Dr Robert Heyderman (page 2 and Appendix H); and collection of 
saliva sample (Section 5.3 Outline of study procedures Table 1 and footnotes; 
Section 5.4 visits 1, 2, 4, 5 and 6; Section 5.5.1 See Appendix H; Section 5.5.2 
last sentence; and Appendix D last sentence). 
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Section 5.3, Table 5-1 (Informed consent) and Section 5.4 (Detailed description of 
study stages/visits – Collection of throat swabs…): At Visit 2, 4, 5, and 6 added:  
# any parent/guardian accompanying the child at visits subsequent to the first 
visit who has not already signed an Informed Consent for this study will have to 
sign an Informed Consent prior to providing any throat swab 
 
Study Contact for SAE reporting at WHO, abbreviation VAB changed to IVB 
(Fourth page and Pages 4 and 78  Main Protocol): 
From: WHO/VAB /IVR/POP  To: WHO/IVB/IVR/POP  
 
Appendices D and E 
The following changes and/or additions were made to each appendix: 
Attention changed from Mr. Emmanuel Dael/Mr. Philippe Hoebregts to 
Biospecimen Reception.  
An e-mail address and additional telephone numbers have been added  and a 
new fax number  provided. 
From: Attention Mr. Emmanuel Dael/Mr. Philippe Hoebregts 
Clinical Immunology 
R & D Department/Building 44 
Rue de l'Institut, 89 
B-1330 Rixensart – Belgium 
Telephone: +32-2-656 8949/+32-2-656 9718 
Fax: +32-2-656 9144 (Amended 05 June 2003) 
To:   
Attention: Biospecimen Reception 
R & D Department/Building 44 
Rue de l'Institut, 89 
B-1330 Rixensart – Belgium 
Telephone: +32-2-656 8949 or +32-2-656 6130  
or +32-2-656 8549 or +32-2-656 6108 
Fax: +32-2-656 6052 
E-mail: rix.ugbiospecimen-reception@gskbio.com  
 
759346/009 (DTPwHB/HIBMenACTT009) GlaxoSmithKline Biologicals 
104430 (DTPwHB/HIBMenACTT023 BST:009)   
Amendment 7: 12 April 2006 Confidential and Proprietary Information 
CARS Id : CLIN_200604_519/ Version : 1.2,Admin. QC/ Modify Date : 27/04/2006 
Amendment 4 iii
Appendix H 
The Ancillary Study Protocol has been amended. 
The title of this Appendix H and the Ancillary Study Protocol (within) are 
changed: 
From: Meningococcal carriage and mucosal immunity to Neisseria meningitidis in 
the African meningitis belt  
To Meningococcal carriage in the African meningitis belt.  
 
Please Note: Appendix I was deleted following the approval/availability of the IB, 
therefore, Appendix J sequentially became Appendix I. 
 
The Parent Information Sheet/IC: 
(Title page and Approval Section): The School of Medical Sciences, University of 
Bristol was deleted. 
The Amendment date, 27 January 2004, was added : Introduction (page1); Study 
Participation, seventh bullet; Confidential and source document review (page 7); 
Compensation (page 10, above signature); and Informed Consent pages 11 and 12, 
and Informed Consent page 13). 
In the Study Overview,  paragraph 5, the following sentence was changed  
From:  The blood samples taken during the study will help to see whether the 
vaccine has induced antibodies (antibodies are particles acting as soldiers to 
protect against diseases) in the blood of your child/ward but it is important that 
the vaccine also induces antibodies that will be present in your child’s/ward’s 
nose/throat  
To: The blood samples taken during the study will help to see whether the vaccine 
has induced antibodies (antibodies are particles acting as soldiers to protect 
against diseases) in the blood of your child/ward but it is important that the 
vaccine also prevents the bacteria from staying in the throat. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
5 June 2003, 02 October 2003, 05 January 2004, 
27 January 2004 and 2 April 2004)  
Protocol Title: Protocol Title: A phase II, double blind, randomized, controlled 
study to evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously 
mixed with GSK Biologicals’ Tritanrix™-HepB, as compared to GSK 
Biologicals’ Hiberix™ vaccine, extemporaneously mixed with GSK Biologicals’ 
Tritanrix™-HepB, when administered intramuscularly in infants at 6, 10 and 14 
weeks of age. 
Amendment 5 
2 April 2004 
Coordinating Author: Sheila Woods 
Rationale/background for changes:  
The 1st meeting of the IDMC recommended the following changes to the protocol:
• Considering the problem of assessment of birth weight in the field (birth 
weight is taken in less than 1/2 of the babies), amend eligibility criteria to 
exclude babies with low birth-weight/malnutrition  
• Include the use of verbal autopsy questionnaires to improve the mortality 
investigations in case of death 
• Clarify/improve the flow of communication for SAEs and non serious AEs 
suggesting lack of efficacy and non-serious vaccine-related grade 3 AEs; 
The following items were amended on 2 April 2004: 
The back-up study contact for reporting SAEs at GSK Biologicals is changed 
from Marc Ceuppens to the GSK Biologicals Clinical Safety Physician; the 
protocol has been amended accordingly. 
The email address of the study monitor Cornelia Bevilacqua has changed from 
cornelia_bevilacqua@yahoo.fr to corneliabevilacqua@usa.net and the fax 
number of the study monitor Valérie Marichal has changed from +32 2 656.9072 
to +32 2 656.8133; the protocol has been amended accordingly. 
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Section 1.4: the ‘Coordination with the EPI’ section was amended as follows:  
The vaccine trial will be conducted at three several EPI clinics in the Kassena-
Nankana district where routine immunization is taking place.:  
- KNE-Health Centre (serving the East sub district) 
- Biu Health Centre (serving the South sub district) 
- War Memorial Hospital (serving Navrongo central) 
Section 4.1: 2nd sentence amended as follows: 
The study will be conducted at the Navrongo Health Research Center in Ghana 
(War Memorial Hospital and 2 several health centres of Navrongo health district). 
Section 4.2: the following inclusion criterion deleted: 
• Birth weight > 2 kg. 
Section 4.3: exclusion criteria amended as follows: 
• Major congenital defects, malnutrition or serious chronic illness. 
• Babies for which birth weight is <2 kg (if known), and/or malnutrition at 
visit 1. 
Section 5.1.3: Role of the IDMC section 
3rd paragraph, 2nd bullet changed as follows: 
• systemic grade 3 adverse events (AEs) related to vaccination, serious adverse 
events and adverse events suggesting a lack of efficacy of the vaccine 
occurring during the study (transmitted through GSK Biologicals for SAEs 
and through the Local safety Monitor for the other adverse events) 
4th paragraph: 2nd and 3rd sentences changed as follows: 
All SAEs, including death, will be reported by the Principal Investigator to the 
IDMC (via the local safety monitor), to the Manager of Clinical Safety Vaccines 
at GSK Biologicals, to WHO and to the WHO safety monitor. All SAEs will be 
provided on an “as received” basis to the Board. local safety monitor, to the 
Manager of Clinical Safety Vaccines at GSK Biologicals, to WHO and to the 
WHO safety monitor. GSK Biologicals will be responsible to provide all 
information related to the SAEs to the IDMC according to the IDMC Charter. 
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Section 5.1.3: Role of Local Safety Monitor section. 
Heading and first paragraph changed as follows: 
Reporting to IDMC – Role of Local Safety Monitor 
A Local Safety Monitor (LSM) will act independently from the investigational 
team. The overall role of the Local Safety Monitor (LSM), who will be an 
experienced clinician based in-country, will be to support the clinical investigators 
and to act as a link between the investigators and the IDMC. All systemic grade 3 
AEs probably or suspected to be related to vaccination, all SAEs and all AEs 
suggesting a lack of efficacy of the vaccine will be reported to him/her in his/her 
capacity as a liaison to the IDMC. His/her involvement… 
 
Following added as 2nd bullet to bulleted list under “The LSM’s role will 
include:” 
• provide the IDMC and the medical monitor of GSK Biologicals with a 
blinded listing of non-serious systemic grade 3 symptoms (solicited and 
unsolicited) that are related with vaccination, and of non-serious adverse 
events suggesting a lack of efficacy of the vaccine, this according to the 
IDMC Charter (note: GSK Biologicals will send all information related to 
serious adverse events to the IDMC according to the IDMC Charter).  
Section 8.7: 
5th paragraph: Addition of following sentence at end of: 
In the case of a death, supplementary information will be gained using the 
verbal autopsy technique. This will be conducted according to previously 
published methods and detailed in the SOPs on file with the investigators. The 
Verbal Autopsy Questionnaire will be completed and transmitted by the 
investigator to GSK Biologicals, WHO and the Local Safety Monitor, in 
addition to the SAE report, irrespective of relationship to vaccination and 
whether a written autopsy was performed or not. The Standard Verbal Autopsy 
Questionnaire will not replace a written autopsy. 
7th Paragraph: Amended (including dividing into 2 paragraphs) as follows: 
All SAEs will be reported within 24 hours by the investigator to GSK Biologicals 
safety department, to the local safety monitor and to the WHO study contact for 
SAE reporting. The local safety monitor  GSK Biologicals will transmit the 
information to the IDMC according to the operating procedures of the IDMC. 
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In addition, the local safety monitor investigator will also provide a listing of all 
systemic grade 3 symptoms suspected to be related to vaccination and any case of 
diphtheria, tetanus, pertussis, hepatitis B, invasive diseases due to Haemophilus 
influenzae type b, measles, yellow fever or Neisseria meningitidis of serogroup A 
and C to the LSM. The Local Safety Monitor will send the listing and 
information related to the non-serious grade 3 systemic symptoms related with 
vaccination and non-serious adverse events suggesting a lack of efficacy of the 
vaccine to the IDMC and the GSK medical monitor (the GSK medical monitor 
will forward the information to the other members of the Steering Committee) 
on a regular basis according to the Charter for the IDMC. 
Section 8.8.1: 
1st paragraph: 1st sentence amended as follows: 
SAEs will be reported promptly to the LSM, GSK Biologicals and WHO once the 
investigator determines that the event meets the protocol definition of an SAE. 
1st paragraph: 3rd sentence amended as follows: 
Additional or follow-up information relating to the initial SAE report, including 
completed verbal autopsy questionnaire in case of death, is also to be reported to 
the GSK Biologicals’ Study Contact for Serious Adverse Event Reporting and to 
the WHO study contact for SAE reporting within 24 hours., 
2nd paragraph: Amended as follows: 
In addition to the direct reporting of any SAE and any subsequent information by 
the investigator or its designate to GSK Biologicals and WHO, the investigator 
will also report the SAE and subsequent information to the local safety monitor 
for transmission  will transmit the SAEs to the IDMC on a regular basis 
according to the Charter for the IDMC (see section 5.1.3). 
Appendix H; protocol for ancillary study 
Section II 1. 3rd paragraph amended in line with the main protocol. 
Section II 2. and 3.Inclusion and exclusion criteria have been amended in line 
with the main protocol. 
Section III 3.2 and 3.3 amended in line with the main protocol. 
Section IV 2. Amended in line with main protocol 
The Parent Information Sheet/IC: There were no changes to this document for 
this amendment. 
Various typographical errors were also corrected. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
Protocol Modification Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
5 June 2003, 02 October 2003, 05 January 2004, 
27 January 2004 and 2 April 2004, modified 07 July 2004)  
Protocol Title: Protocol Title: A phase II, double blind, randomized, controlled 
study to evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously 
mixed with GSK Biologicals’ Tritanrix™-HepB, as compared to GSK 
Biologicals’ Hiberix™ vaccine, extemporaneously mixed with GSK Biologicals’ 
Tritanrix™-HepB, when administered intramuscularly in infants at 6, 10 and 14 
weeks of age. 
Modification 1 
07 July 2004 
Coordinating Author: Nikola Bulow 
Rationale/background for changes:  
Change in study personnel: The back-up of the local safety monitor, Dr Rita 
Baiden, was replaced by Dr. Frank Baiden. 
The following items were modified throughout the protocol on 07 July 2004: 
Back-up Local Safety Monitor 
Dr. Rita Baiden Dr. Frank Baiden 
Navrongo Health Research Center, 
Ministry of Health, PO Box 114, Navrongo, Ghana 
Tel: + 233 742 22310/ 22380 
Fax: + 233 742 22320 
e-mail: radomako-bamfi@navrongo.mimcom.netfbaiden@navrongo.mimcom.net
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Number 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
5 June 2003, 02 October 2003, 05 January 2004, 
27 January 2004 and 2 April 2004, modified 07 July 2004, amended 14 January 
2005)  
Protocol Title: Protocol Title: A phase II, double blind, randomized, controlled 
study to evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, extemporaneously 
mixed with GSK Biologicals’ Tritanrix™-HepB, as compared to GSK 
Biologicals’ Hiberix™ vaccine, extemporaneously mixed with GSK Biologicals’ 
Tritanrix™-HepB, when administered intramuscularly in infants at 6, 10 and 14 
weeks of age. 
Amendment 6 
14 January 2005 
Coordinatin Author: Nikola Bulow 
Rationale/background for changes:  
To allow the analysis of the primary phase (up to Visit 4) on cleaned data, the 
database will be divided into two separate parts and therefore a new e-track study 
number and abbreviated title have been allocated for the booster phase of the 
study; the conclusion of the primary phase has been fixed at the end of Visit 4 
(additional page on the CRF). Recording of concomitant medication/vaccination 
will be done according to the initial protocol (see Section 6.8, i.e. throughout the 
study, from Visit 1 to Visit 7), but due to the separation of the data base in two 
parts, clarification on how this will be handled has been added to the protocol. It 
has to be noted that the informed consent signed by the subject’s parents/ 
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guardians is referring to the e-Track study number 759346/009; parents/guardians 
of the subjects will not be asked to re-consent for adding the second e-Track 
number and abbreviated title 104430 (DTPwHB/HIBMenACTT023 BST:009) as 
this change will not affect any aspect of the safety of the subject, nor the study 
procedures the subject is involved in or the objectives of the study. 
 
The following items were amended on 14 January 2005: 
Throughout the protocol the new e-Track number and abbreviated title 104430 
(DTPwHB/HIBMenACTT023 BST:009) for the booster phase of the study was 
added. 
Section 4.1 Number of subjects (one paragraph was added at the end of the 
section) 
If at the time of the initiation of the booster phase any parent/guardian declines 
participation of his/her child, refusal will be documented as instructed in the 
“subject tracking document” provided by GSK Biologicals. A copy of the 
completed tracking document will be forwarded to GSK Biologicals’ Study 
Monitor. The information will be entered in the GSK Biologicals’ clinical 
database for use in identification of any safety issue that may have prevented a 
subject’s participation. 
Section 5.3 Outline of study procedures (Table 5-1) 
The heading “Primary Phase (759346/009)” was added for Visits 1 to 4 and the 
heading “Booster Phase (104430)” was added for Visits 5 to 7. A double-line 
border was added between Visit 4 and Visit 5 to indicate the conclusion of the 
Primary Phase of the study. A row for the “Study Conclusion of the Primary 
Phase” was added and will be checked at Visit 4. A row for “Retrospective 
recording of relevant concomitant medication/vaccination since Visit 4###” was 
added and will be checked at Visit 5. The last row “Study conclusion” was 
changed to “Study conclusion of Booster Phase”. 
###Relevant medication/treatment will include meningococcal vaccine, any 
investigational or non-registered product (drug or vaccine), any 
immunosuppressant(s) or other immune-modifying drug(s), immunoglobulins 
and/or any blood product(s). 
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Section 5.4 Detailed description of study stages/visits 
Visit 4: The following bullet point was added: 
• Study conclusion of the primary phase 
Visit 5: The following bullet points were added: 
• If at the time of the initiation of the booster phase any parent/guardian 
declines participation of his/her child, refusal will be documented as 
instructed in the “subject tracking document” provided by GSK Biologicals. 
A copy of the completed tracking document will be forwarded to GSK 
Biologicals’ Study Monitor. The information will be entered in the GSK 
Biologicals’ clinical database for use in identification of any safety issue 
that may have prevented a subject’s participation. 
• Retrospective recording of any relevant concomitant medication/ 
vaccination since the last visit according to instructions provided in Section 
6.8. Relevant vaccines will include meningococcal vaccines and 
investigational or non registered vaccines and will be recorded with trade 
name, route of administration and date(s) of administration. Relevant 
medications/treatments will include any investigational or non-registered 
product(s), any immunosuppressant(s) or other immun-modifying drug(s), 
immunoglobulins and/or any blood products. All such medication/treatment 
is to be recorded with generic name of the medication (trade names are 
allowed for combination drugs, i.e. multi-component drugs), medical 
indication, total daily dose, route of administration, start and end dates of 
treatment. 
Section 6.8.1 Recording of concomitant medication/treatment during the 
primary phase of the study 
This sub-heading was added to differentiate the record of medication/treatment 
during the primary and booster phases. 
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Section 6.8.2 Recording of concomitant medication/treatment during the 
booster phase of the study 
The entire section was added: 
At Visit 5, the investigator will question the parents/guardians in a 
RETROSPECTIVE manner if the subject received any relevant 
medication/treatment or vaccine in the time period since the last study visit of 
the primary phase of the study (Visit 4). Relevant vaccines will include 
meningococcal vaccines and investigational or non registered vaccines and will 
be recorded with trade name, route of administration and date(s) of 
administration. Relevant medications/ treatments will include any 
investigational or non-registered product(s), any immunosuppressant(s) or 
other immune-modifying drug(s), immunoglobulins and/or any blood products. 
All such medication/treatment is to be recorded with generic name of the 
medication (trade named are allowed for combination drugs, i.e. multi-
component drugs), medical indication, total daily dose, route of administration, 
start and end dates of treatment. 
In addition, all concomitant medication, with the exception of vitamins and/or 
dietary supplements, administered at ANY time during the period starting with 
administration of each dose and ending one month (minimum 30 days) after 
each dose are to be recorded with generic name of the medication (trade names 
are allowed for combination drugs, i.e., multi-component drugs), medical 
indication, total daily dose, route of administration, start and end dates of 
treatment. 
Any treatments and/or medications specifically contraindicated, e.g., any 
immunoglobulins, other blood products and any immune modifying drugs 
administered at any time during the study period are to be recorded with 
generic name of the medication (trade names are allowed for combination 
drugs only), medical indication, total daily dose, route of administration, start 
and end dates of treatment. Refer to Section 4.4. 
Any vaccine not foreseen in the study protocol administered throughout the 
study period are to be recorded with trade name, route of administration and 
date(s) of administration, with the exception of OPV that can be given 
throughout the study. Refer to Section 4.4. 
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Any concomitant medication administered prophylactically in anticipation of 
reaction to the vaccination must be recorded in the CRF with generic name of 
the medication (trade names are allowed for combination drugs only), total 
daily dose, route of administration, start and end dates of treatment and coded 
as ‘Prophylactic’. 
Concomitant medication administered for the treatment of an AE or SAE must 
be recorded in the CRF with generic name of the medication (trade names are 
allowed for combination drugs only), medical indication (including which 
AE/SAE), total daily dose, route of administration, start and end dates of 
treatment. Refer to Section 8.2 for definition of SAE. 
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GlaxoSmithKline Biologicals  
Rue de l'Institut 89 
1330 Rixensart, Belgium 
Protocol Amendment Approval 
Study Drug 
Hib-MenAC 
Protocol Numbers 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Amended on: 05 June 2003, 02 October 2003, 05 January 2004, 
27 January 2004, 2 April 2004 and 14 January 2005 
Modified on: 7 July 2004  
Protocol Title: A phase II, double blind, randomized, controlled study to evaluate the 
immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Hib-
MenAC vaccine, extemporaneously mixed with GSK Biologicals’ Tritanrix™-HepB, as 
compared to GSK Biologicals’ Hiberix™ vaccine, extemporaneously mixed with GSK 
Biologicals’ Tritanrix™-HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment 7: 12 April 2006 
Co-ordinating Author: Chitra Nair, Scientific Writer 
Rationale/background for changes:  
In the primary vaccination phase of this study, serious adverse events were reported for 
11 subjects in the DTPw-HepB/Hib-MenAC group (including three deaths) and 2 
subjects in the DTPw-HepB/Hib control group; none of these SAEs were related to 
vaccination. The pattern of SAEs was varied and reflected the medical and health 
conditions in the district and there were no unusual causes of death. All 10 subjects with 
non-fatal serious adverse events had infectious diseases commonly reported in Navrongo 
Health District (malaria, bronchopneumonia, respiratory tract infection, typhoid fever, 
enteritis, gastroenteritis). The three fatal cases were dysentery and impetigo, aspiration 
pneumonia, and sudden infant death syndrome, all after the first vaccine dose. After 
review of these safety data, the Independent Data Monitoring Committee advised the 
sponsor (GSK Biologicals) to conduct a retrospective follow-up of SAEs for all subjects 
who participated in this study since the last study visit up to when subjects are aged at 
least 24 months. The protocol is being amended to reflect the addition of the extended 
safety follow-up phase. 
Additionally, contact details were updated in the relevant sections of the protocol. 
An addendum to the representative subject information sheet was prepared to detail the 
extended safety follow-up phase. 
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Amended text has been included in bold italics in the following sections: 
Title page of the protocol: 
 Coordinating Authors: Uma Swaminathan and Chitra Nair, Scientific 
Writers 
 
 Contributing Authors: Dr. Dominique Boutriau, Associate Director, 
Paediatric Vaccine Development Director, Clinical 
Research & Development, Meningitis vaccines 
Toufik Zahaf, Thierry Van-Effelterre and Christelle 
Durand, Statisticians 
 
Sponsor Information sheet: 
Study Contact for Reporting of a Serious Adverse Event at GSK Biologicals 
Dr. Dominique Boutriau,  
Associate Director Paediatric Vaccine Development  Director, Clinical Research & 
Development, Meningitis vaccines 
GlaxoSmithKline Biologicals,  
Rue de l'Institut 89, 1330 Rixensart, Belgium 
Tel: +32.2.656. 9120  
Fax: +32.2.656. 8133 8044 
e-mail: dominique.boutriau@gskbio.com 
 
Back-up Study Contact for Reporting SAEs at GSK Biologicals 
GSK Biologicals Clinical Safety Physician 
Tel: +32-2-656 88 50 
Fax: +32-2-656 80 09/5116 
Mobile phone for 7/7 day availability: +32 477 404 713 or 32-(0) 474 53 48 68 
24/24 hour and 7/7 day availability 
 
The above changes were made in all the relevant sections of the protocol. 
 
Study design in the Synopsis and in Section 3: Study Design Overview 
The following bullet points were updated and/or added: 
• Study duration per subject: approximately 12 months (from 6-8 weeks up to 13 
months of age). The total study duration will depend on recruitment 22.5 months 
to include the retrospective follow-up of SAE(s) up to the time that subjects are 
at least 24 months of age. 
• Retrospective follow-up of SAE(s). The parents/guardians of study subjects will 
be contacted by the local health staff when their child is at least 24 months of 
age for a follow-up of SAE(s) (i.e. any SAE(s) that occurred since the last study 
visit [Visit 7] up to the time that subjects are at least 24 months of age). 
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 The graphic schema of the study design in Section 3 was also updated to reflect the 
extended safety follow-up phase. 
Section 5.3: Outline of study procedures 
A table was added to describe the study procedures of the extended safety follow-up 
phase 
Table 5-2: List of study procedures for the extended safety follow-up phase 
 EXTENDED SAFETY 
FOLLOW-UP PHASE 
Age ±24 m 
Visit  
Timing Month 22.5 
Informed consent • 
Retrospective recording of SAE(s) since Visit 7 up 
to the time that subjects are aged at least 24 
months 
• 
Study conclusion  •  
 
Section 5.4: Detailed description of study stages/visits 
The following information was added to describe the details of the extended safety 
follow-up phase: 
 Extended Safety Follow-Up Phase: Retrospective recording of SAE(s)  
   
The parents/guardians of all study subjects will be contacted by the local health staff 
when their child is at least 24 months of age for a retrospective follow-up of SAE(s) 
(i.e. occurrence of any SAE(s) since the last study visit [Visit 7] up to the time that 
subjects are at least 24 months of age). Prior to initiating the study procedures for 
this safety follow-up phase, an informed consent will be obtained from the 
parents/guardians of the child after explaining the purpose of this contact. 
  
The study personnel will contact the parents/guardians of the subjects and will 
question them in a RETROSPECTIVE manner if the subject has suffered any 
unreported SAE(s) in the period between the last study visit (study conclusion of the 
booster phase) and this follow-up contact; the study personnel will also consult the 
child health card whenever available. If SAE(s) had occurred, further investigations 
will be performed on the subject’s hospital/health centre records (if available). 
Details of these SAE(s) will be reported on the SAE forms. If a death had occurred, 
a verbal autopsy report will be obtained whenever possible. 
 
As subjects will be at least two years of age at this safety follow-up visit, the study 
staff  will also remind parents/guardians that the children part of the control group 
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and those with sub-optimal response to the MenA and/or MenC component of the  
vaccines given to the  DTPw-HepB/Hib-MenAC group, will be offered a dose of 
Mencevax™ ACWY vaccine to protect them against meningococcal diseases 
(serogroups A, C, W and Y). 
 
This will be the study conclusion for the extended safety follow-up phase. 
 
Section 8.8.2: Completion and transmission of serious adverse event reports to 
GSK Biologicals, WHO and the local safety monitor 
 Study Contacts for Reporting SAEs  
 Medical Monitor at GSK Biologicals  
 Dr. Dominique Boutriau,  
Associate Director Paediatric Vaccine Development   
Director, Clinical Research & Development, Meningitis vaccines 
GlaxoSmithKline Biologicals,  
Rue de l'Institut 89, 1330 Rixensart, Belgium 
Tel: +32.2.656.9120 
Fax: +32.2.656. 8133 8044 
e-mail: dominique.boutriau@gskbio.com 
 
 Back-up Study Contact for Reporting SAEs at GSK Biologicals  
 Manager Clinical Safety Vaccines  
 GSK Biologicals Clinical Safety Physician  
 Tel: +32-2-656 87 98 88 50  
 Fax: +32-2-656 80 09/5116  
 Mobile phone for 7/7 day availability: +32 477 404 713 or 32-(0) 474 53 48 68
24/24 hour and 7/7 day availability 
 
Section 9.3: Extension study 
Not applicable. 
There will be a retrospective follow-up of SAE(s) that occurred since the last study 
visit [Visit 7] up to the time that subjects are at least 24 months of age. 
 
Section 8.5: Time period, frequency, and method of detecting adverse events and 
serious adverse events 
There will be a retrospective follow-up of SAE(s) (i.e. occurrence of any SAE(s) 
since the last study visit [Visit 7] up to the time that subjects are at least 24 months 
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of age). 
 
Section 10.8: Reporting of final analyses 
Serious adverse events reported during the extended follow-up period (i.e. from visit 
7 up to 24 months of age) will be reported in a separate annex report. 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by (Sponsor at GSK Biologicals):    
    
Director, Clinical Research 
& Development, Meningitis 
vaccines 
   
 Dr. Dominique Boutriau  dd-mm-yyyy 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by (Sponsor at GSK Biologicals):    
    
Associate Director, 
Statistical Manager 
   
 Brigitte Cheuvart  dd-mm-yyyy 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by:    
    
Collaborator (at WHO)    
 Dr. Marie-Paule Kieny  dd-mm-yyyy 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by:    
    
Collaborators (at the 
London  
   
School of Hygiene & 
Tropical Medicine) 
Prof. Brian Greenwood  dd-mm-yyyy 
    
    
    
 Dr. Daniel Chandramohan  dd-mm-yyyy 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by:    
    
Investigator    
 Dr. Abraham Victor Obeng 
Hodgson 
 dd-mm-yyyy 
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eTrack study 
number: 
759346/009 (DTPwHB/HIBMenACTT009) 
104430 (DTPwHB/HIBMenACTT023 BST:009) 
Protocol title: A phase II, double blind, randomized, controlled study to 
evaluate the immunogenicity, reactogenicity and safety of 
GlaxoSmithKline (GSK) Biologicals’ Hib-MenAC vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, as compared to GSK Biologicals’ Hiberix™ vaccine, 
extemporaneously mixed with GSK Biologicals’ Tritanrix™-
HepB, when administered intramuscularly in infants at 6, 10 
and 14 weeks of age. 
Amendment number: Amendment 7 
Amendment date: 12 April 2006 
    
Approved by:    
    
Investigator    
 Dr. Gerd Pluschke  dd-mm-yyyy 
    
    
 
 
